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ABSTRACT 
Background: Osteoarthritis (OA) is the most common form of arthritis and is a major 
cause of disability and impaired quality of life (QoL). The prevalence of OA is rapidly 
increasing affecting approximately 15% of the world’s population. Currently, there are 
no disease modifying treatments available. Non-steroidal anti-inflammatory drugs, the 
most widely prescribed medications for patients with knee OA (KOA), are associated 
with serious side effects, including bleeding and gastric ulceration. As a result, both 
patients and professional societies are looking for alternative therapies, with good 
effects, and less toxicity, to control pain sufficiently. Low-level laser therapy (LLLT) is 
a non-invasive treatment modality in the field of physiotherapy for pain management. 
Nonetheless, the effectiveness of LLLT in the treatment of OA is debatable.  
Objectives and Design: A randomised, double-blind, controlled trial was conducted to 
evaluate the efficacy of LLLT when it is applied on specific acupuncture points (APs) at 
the knee joint in combination with exercises and advice in patients with KOA.   
Participants: Forty-nine patients with KOA were randomly assigned into two groups; 
active laser group (n= 26) and placebo laser group (n= 23).  
Intervention: Using a gallium-aluminium-arsenide laser device, patients received either 
active or placebo LLLT treatment at five APs (ST 35, Xiyan, ST 36, SP9, and SP10) on 
the affected knee. All participants received a series of 9 treatment sessions over a period 
of three weeks by using LLLT (active or placebo) in addition to strengthening exercise 
and advice. 
Outcome Measures: Visual analogue scale (VAS), Saudi knee function scale (SKFS), 
active range of motion (ROM), knee circumference (KC), and patient satisfaction were 
   xxiii 
assessed at baseline, at the 5th treatment session, at the last (9th) treatment session, after 
six weeks and then six months after the last treatment session.  
Result: There was a statistically (but not clinically) significant improvement in the laser 
group compared to the placebo group in the primary outcome VAS after six weeks (P= 
0.014) and after six months of the last session of treatment (P= 0.003). There was a 
statistically (but not clinically) significant improvement in the laser group compared to 
the placebo group in the SKFS scores at the last treatment session (P= 0.035), and after 
six months (P= 0.006); in ROM only after six months (P= 0.019); in patient satisfaction 
at the 5th session (P= 0.033) and after six months. No significant difference between 
both groups was noted in the KC at any time. Within both groups there was statistically 
significant improvement in most outcomes.  
Conclusions: The results demonstrate that the short-period application of LLLT on 
specific APs associated with exercises and advice is effective in reducing pain and 
improving the QoL in patients with KOA. 
   1 
 
Chapter 1 INTRODUCTION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   2 
1.1 Problem definition 
Osteoarthritis (OA) is the most common form of arthritis, and is a major cause of 
disability and impaired quality of life (QoL) (Castaneda et al., 2012; Le et al., 2012). 
The direct cause of OA is unknown; however, it is a slowly progressive disease caused 
by various biological processes, such as wear and tear, inflammation, and enzymatic 
cartilage degradation on a joint (Breedveld 2004; Hellio Le Graverand-Gastineau 2009; 
Konttinen et al., 2012). OA is common in the elderly, especially in females, but, it also 
affects younger people, especially in the obese populations (Schuelert et al., 2011). 
The prevalence of OA is rapidly increasing; it affects approximately 15% of the world’s 
population (Egloff et al., 2012). This prevalence might be attributed to the ageing 
population and an increase in the prevalence of obesity worldwide, as a risk factor for 
OA (Al-Arfaj 2003; Felson et al., 2000; Le et al., 2012; Breedveld 2004), in addition to 
sedentary lifestyles and injuries. In the United States (USA), OA is affecting 
approximately 14% of adults aged 25 and older, and 33.6% over the age of 65 
(Lawrence et al., 2008). By the year 2020, almost 60 million (18.2% of the population) 
Americans will be affected by arthritis (Lawrence et al., 1998). Other estimates show 
that by 2030, 25% of the USA adults will suffer from arthritis (Hootman and Helmick, 
2006). In the UK, it has been estimated that 40% of the population over the age of 65 
have symptoms associated with knee or hip OA (Zhang et al., 2008). 
In Saudi Arabia, where the data collection of the current study was done, as in many 
other Arab countries, there are no accurate data to report the prevalence of OA. This 
does not imply that OA is less prevalent in these societies; Al-Arfaj and Al-Boukai 
(2002) concluded that radiographic evidence of knee OA (KOA) and its symptoms is 
more commonly found in the Saudi population than it is in western societies. 
Nevertheless, they reported that the incidence of KOA in Saudi Arabia is approaching 
60.6% in the 66–75 years age-group, in some regions. In recent years, in Saudi Arabia, 
   3 
and worldwide, the prevalence of OA is not limited to the elderly population, but it 
affects younger people also. Interestingly, in Saudi Arabia and other Gulf countries, 
adolescent overweight and obesity, as a prominent risk factor for OA, are among the 
highest in the world, while it reaches 8–9% in pre-school children (Ng et al., 2011). It 
has been reported that becoming overweight earlier in adult life increases the risks of 
KOA (Dawson et al., 2003; Holliday et al., 2011). Therefore, it may not be surprising to 
see patients with KOA in their thirties or even younger, which makes OA an increasing 
concern.   
Although OA may affect any synovial joint in the body, especially weight bearing 
joints, the knee is the most frequently affected joint (Coleman et al., 2012; Gupta et al., 
2005). Not only is the articular cartilage affected by this condition, but all joint 
structures are involved, including the subchondral bone, ligaments, capsule, synovial 
membrane, menisci, and extra-articular muscles (Brandt et al., 2006; Hellio Le 
Graverand-Gastineau, 2009). 
Currently, there are no disease-modifying treatments (DMTs) that have been approved 
by the Food and Drug Administration (FDA) or European Medicines Agency for 
treating OA (Egloff et al., 2012; Hellio Le Graverand-Gastineau, 2009; Schuelert et al., 
2011; Selvan et al., 2012). Notwithstanding, there are large numbers of non-
pharmacological therapies (physiotherapy, occupational therapy, weight loss, education, 
etc.), pharmacological therapies (e.g., simple analgesic, intra-articular injections, and 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)) and surgical therapies (e.g. total 
knee replacement (TKR) and osteotomies). These therapies are mostly symptomatic 
treatments. Therapeutic goals for treating patients with KOA focus on reducing joint 
pain, stiffness, and physical disability; improving joint mobility and health-related QoL; 
maintaining joints from further deterioration; and finally, educating patients regarding 
the nature of their problem and its management (Zhang et al., 2008).  
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Unfortunately, NSAIDs, the most widely prescribed medications for patients with KOA, 
are associated with serious side effects, including bleeding, gastric ulceration, and 
increased risk of cardiovascular disease, such as myocardial infarction (McDonald and 
Walsh, 2012; Moodley 2008; Schuelert et al., 2011). Furthermore, elderly patients 
suffering from OA are usually accompanied with several co-morbidities, including 
hypertension, cardiovascular disease, peripheral vascular disease, congestive heart 
failure, renal function impairment, diabetes, and respiratory disease, which increase the 
risk of drug-to-drug interactions (Breedveld, 2004; Hellio Le Graverand-Gastineau, 
2009; Le et al., 2012). Even more, these patients usually complain of moderate to 
severe pain which restricts their mobility, hastens disease progression, and exacerbates 
joint pain. 
 Moreover, surgery, as the last chance treatment, has its own side effects and 
limitations, such as infection, bleeding, and knee instability; in addition, many patients 
with co-morbidities are not fit to have surgery (Felson et al., 2000; Ronn et al., 2011). 
The socioeconomic impacts of OA are tremendous in terms of the costs associated with 
OA interventions and the management of its possible adverse effects. In addition there 
are the costs associated with surgery, long hospitalisation, clinical studies, and lost work 
productivity due to disability (Breedveld, 2004). Furthermore, according to Chen et al., 
(2012), it has been found that OA costs the USA, Canada, the UK, France, and 
Australia between 1–2.5% of the gross national product (GNP) for those countries. 
Last, but not least, it has been reported that older patients with OA may be more 
reluctant to seek medical help because of pessimism about the availability, effectiveness 
and risks of treatment (Sanders et al., 2004). 
 Consequently, both patients and professional bodies are looking for cost-effective, low-
toxicity alternative therapies to control pain. Non-pharmacological therapy as the first 
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line of treatment is often successful; although its beneficial effects may be limited in 
time, there are often little or no side effects, and patient satisfaction is usually relatively 
high (Pendleton et al., 2000; Zhang et al., 2008). Different modalities in physiotherapy, 
such as exercise, transcutaneous electrical nerve stimulation (TENS), acupuncture, and 
low-level laser therapy (LLLT) have been shown to help improve clinical symptoms 
and function of KOA, with fewer side effects than medical treatment (De Luigi, 2012).  
LLLT is increasingly recognised as a non-invasive and safe treatment for numerous 
chronic conditions, including OA (Gur et al., 2003a; Yurtkuran et al., 2007). It has been 
reported by Tascioglu et al. (2012) that several studies showed that LLLT has anti-
inﬂammatory, anti-oedema effects, and it has a role in pain reduction without any side 
effects. Although the results are conflicting, there is a large amount of research 
available on the subject of LLLT in treating acute and chronic painful conditions, such 
as fibromyalgia, rheumatoid arthritis, postoperative pain, low back pain, and OA (Gur et 
al., 2003a). Similarly, the results of using LLLT on patients with KOA are conflicting. 
Although many studies showed significant improvements (Alfredo et al., 2011; Fukuda 
et al., 2011; Hegedus et al., 2009; Rayegani et al., 2012; Shen et al., 2009; Stelian et al., 
1992), others did not (Bulow et al., 1994; Tascioglu et al., 2004; Trelles et al., 1991, 
Yurtkuran et al., 2007).  
Acupuncture is among the non-pharmacological interventions, which have been 
introduced as a safe and relatively cost-effective therapy for patients with KOA 
(Berman et al., 1999; Tillu et al., 2002; Witt et al., 2005). Berman et al., (1999) 
reported that in many Asian countries, as in western countries, acupuncture is a popular 
treatment for arthritis. Stimulation of acupuncture points (APs) has been shown to be 
effective in relieving pain in many chronic cases, such as in KOA (Lu et al., 2010; Tillu 
et al., 2002). Stump and Roberts-Retzlaff (2006) stated that it has been reported that 
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laser light can evoke specific effects in the periphery of the nervous system and in the 
brain by stimulating APs. 
 Stimulation of APs by LLLT (laser acupuncture) has been in use since 1968 (Mester et 
al., 1985). Despite that, the exact mechanism of pain reduction by both LLLT and 
acupuncture is not completely understood (Gur et al., 2003a; Ahsin et al., 2009). 
According to Baxter et al. (2008), LLLT has been recommended as an effective 
alternative to metal needles for stimulating APs. LLLT has some advantages over metal 
needles in acupuncture treatment, including that LLLT can be applied on anatomically 
dangerous areas (lung, heart, and neural and vascular structures) for relieving pain of 
surrounding tissues, while acupuncture can cause organ puncture or damage to these 
structures. LLLT can be applied to needle-phobic patients, burns or ulcerations, 
wounds, and implanted electrical device such as a pacemaker or medication pump. 
LLLT offers low cost, ease of application, and short time of application, and it is a non-
invasive and safe treatment (e.g. in cases of human immunodeﬁciency virus infection 
(HIV) infection and hepatitis). Furthermore, LLLT has no heat or vibration, and is 
invisible above 770 nanometres (nm); hence, patients have difficulty knowing if they 
have received real treatment or not; in this respect, LLLT is superior to needles in 
studies using a blinding technique in randomised clinical trials (RCTs) (Baxter et al., 
2008; Relf et al., 2008).  
Recent studies have clearly shown that laser light can be successfully used for effective 
acupuncture treatment (Litscher and Opitz, 2012; Stump and Roberts-Retzlaff, 2006). 
Despite several studies that have been carried out to determine the efficacy of LLLT for 
treating KOA when it is applied at and around the knee joint (Alfredo et al., 2011; 
Bulow et al., 1994; Fukuda et al., 2011; Gur et al., 2003a; Hegedus et al., 2009; Stelian 
et al., 1992; Tascioglu et al., 2004; Trelles et al., 1991), studies concerning laser 
acupuncture are rare. To the best of the author’s knowledge, to date, only two studies 
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have been published for testing the efficacy of LLLT when applied on APs in patients 
with KOA, and only one AP has been stimulated in each study (Shen et al., 2009; 
Yurtkuran et al., 2007).  
The LLLT studies have been criticised because the laser devices, experimental designs, 
parameters, and techniques described in the literature are highly variable. Therefore, it 
is important to be careful when reviewing and comparing these studies. One more 
criticism has been noted by Brosseau et al., (2004) in their systematic review, which is 
the lack of data on how LLLT effectiveness is affected by 4 important factors: 
wavelength, treatment duration, dosage, and site of application over nerves instead of 
joints. They recommended a need to investigate the effects of those 4 factors on the 
LLLT effectiveness for OA in RCTs.  
1.2 Aim and hypothesis of the study 
The aim of the current study is to assess the effects of LLLT as a non-invasive 
intervention for treating KOA, when applied in APs around the knee. 
The null hypothesis of the study is that LLLT, applied to five APs around the knee in 
the treatment of KOA and in combination with a specific regimen of advice and 
exercise is not better than a placebo, applied with the same co-adjuvant therapeutic 
regimen. 
1.3 Objectives of the study 
In order to clarify the research question of the study, a randomised double-blind 
controlled trial (RDBCT) has been designed and executed to compare the two 
interventions. 
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The primary outcome of the RDBCT was pain relief at the 5th session, and 9th (final 
treatment session), at 6 weeks and at 6 months following the end of the intervention and 
as measured by VAS. 
Secondary outcomes of the study were: 
1. To evaluate QoL as measured by the Saudi Knee Function Scale (SKFS), a 
specific questionnaire designed to assess knee function, taking into account 
cultural characteristics. 
2. To evaluate the effects of the LLLT treatment on the range of motion (ROM) of 
patients treated. 
3. To evaluate the effects of the LLLT on swelling as determined by knee 
circumference. 
4. To evaluate patient satisfaction with the LLLT treatment. 
The secondary outcomes were measured at the same time points as the primary 
outcome. 
1.4 Thesis structure 
The current thesis consists of 8 chapters. Chapter 1 provides the background to the 
thesis, including the problem definition, aim, hypothesis and the objective of the study. 
Chapter 2 provides a background and literature review of OA and KOA in particular, as 
treatment of this pathology is the central objective of the project and the condition being 
addressed. Also, this chapter discusses definitions of the condition, main existing 
treatments, demographics and burden of disease. 
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Chapter 3 discusses the principles of LLLT, explaining its history, development and 
supporting basic science. It discusses issues such as laser physics, relevant parameters 
for clinical treatment and different types of laser currently available for medical 
treatments, with particular focus in the chosen technique of LLLT.  
Chapter 4 discusses the principles and practice in acupuncture, how it has emerged from 
an ancient Chinese medicine, to current evidence of its efficacy, and different 
techniques, including the use of needles and Electro- Acupuncture (EA), which have 
been gaining increasing acceptance and which may help in the control of pain in 
patients with chronic diseases including KOA. 
Chapter 5 explains in detail the methodology of the current study as a RDBCT, how the 
participants were recruited to the study, inclusion and exclusion criteria, study design, 
randomisation and blinding techniques used.  In addition the measurement tools used 
are discussed, including evidence from the literature of their validity, reliability and 
repeatability. Furthermore, this chapter gives details about instruments used in the study 
such as the laser unit and its parameters, APs used in the current study, how they were 
located, how they were irradiated, and the reasons behind being chosen are discussed in 
details in this chapter. Also, treatment procedure and data collection are discussed in 
detail. At the end of this chapter, there is a clarification of statistical tests that were used 
to analyse the data derived from each variable, and also how the current study was 
powered.   
 Chapter 6 presents the results of analysed data derived from each variable. The first 
section presents baseline and demographic data, in addition to their between-group 
analysis. The second and third sections present the within and between group analysis 
of data derived from each variable of the study. Lastly, possible correlation and 
relationships of different variables of the study were analysed.  
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Chapter 7 discusses the results of the study and then compares this with other findings 
of related and similar studies; followed by chapter 8, which presents the conclusion of 
the current study in addition to a summary and implications for current and future 
research.  
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Chapter 2 Review of the literature of 
knee osteoarthritis (KOA) 
   12 
2.1 Background of OA 
As the most common type of arthritis, OA is a major cause of disability and impaired 
QoL (Castaneda et al., 2012; Le et al., 2012). It is classified as one of the oldest known 
diseases on the planet, with evidence derived from paleopathological studies. It has been 
found in the skeletal remains of dinosaurs, in the spine of a 200 million year old 
Dimetrodon Permian reptile (Buchanan et al., 2003), in Neanderthal and Cro-Magnon 
man (Dequeker and Luyten, 2008), in Saxons in England (Rogers et al., 1981), in 
Egyptian mummies (Braunstein et al., 1988), and in Icelandic Vikings (Byock et al., 
2005). 
OA is characterised primarily by the degradation of the superficial cartilage layer. As 
the disease progresses, it spreads to the deeper layers of the cartilage, subchondral bone, 
and synovial membrane leading to increased friction between bones inducing pain and a 
progressing disability (Breedveld, 2004; Konttinen et al., 2012). The direct cause of OA 
is unknown, particularly during the early phases of the disease (Breedveld 2004; 
Konttinen et al., 2012). It was thought to be a result of simple wear and tear, but this 
idea was rejected, and a current model states that OA affects the whole joint as an 
organ, including cartilage, bone, synovium, muscles, and ligaments (Hellio Le 
Graverand-Gastineau, 2009; Pottie et al., 2006). However, OA is a slowly progressive 
disease caused by various biological processes, such as wear and tear, inflammation, 
and enzymatic cartilage degradation on a joint (Breedveld 2004; Hellio Le Graverand-
Gastineau, 2009; Konttinen et al., 2012). OA is mainly characterised by different 
symptoms, such as joint pain, tenderness, stiffness, functional disability, joint 
instability, crepitus, occasional effusion, and limitation of movement.  
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2.2 Risk factors of OA 
OA is a multifactorial disease associated with several risk factors, such as trauma, age, 
obesity, gender, overuse, and genetics. According to Felson (2013), these factors do not 
work alone to cause disease. For example, being an older overweight female when 
combined with a major injury presents a very high risk of KOA, whereas a younger 
overweight male person with a major injury has less risk of KOA. 
Sarzi-Puttini et al., (2005) divided the risk factors of OA into systemic (e.g. age, gender, 
ethnicity, and genetic), local biomechanical factors (e.g. joint injury, malalignment, 
overweight, and muscle weakness), metabolic and nutritional factors (e.g. vitamin D 
deficiency and hyperglycaemia). Another system classified the risk factors of KOA into 
nonmodiﬁable factors (e.g. age, gender, and genetic susceptibility/family history) and 
potentially modiﬁable factors (e.g. body mass index (BMI), occupational risk, joint 
injury, quadriceps weakness, nutrients, bone mineral density, and oestrogen deficiency). 
Zhang (2010) and Felson (2013) stated that recent reviews showed that major risk 
factors for KOA are older age, female gender, obesity, knee injury, and occupational 
overuse.  
2.2.1 Age  
OA has been found to be age-related (Felson 2004; Lawrence et al., 2008). It affects the 
middle-aged and elderly, although it may be seen earlier in the younger population. 
Lawrence et al. (2008) estimated that 27 million US adults age 25 and older have 
clinical OA. However, the age of 45 is the most common age of onset of KOA 
(Buckwalter et al., 2004). Therefore, it has been known to be a disease of middle age 
but its prevalence increases dramatically after this age. Woolf and Pfleger (2003) 
reported that radiographic studies of the USA and European countries showed that 
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populations aged ≥ 45 years have high prevalence rates of KOA. Furthermore, Felson 
(2004) stated that KOA is seen radiographically in 33% of the population older than 60 
years of age. According to Chen et al. (2012), it has been shown that 15% of all 
musculoskeletal consultations were related to OA in those aged 45 and over, rising to 
25% in those aged 75 and over.  
With increasing age, the progress of OA starts with the failure of the cartilage collagen 
network, which ultimately becomes stiff, resulting in a decreased resistance of this 
network to mechanical failure (Verzijl et al., 2002). Furthermore, with ageing, changes 
in articular cartilage accompanied with a decrease in joint proprioception and muscle 
strength or unstable articulation is likely to play a role in the progress of OA 
(Bosomworth, 2009; Felson et al., 2000; Sharma et al., 2003). 
2.2.2 Gender and sex hormones  
There is growing evidence that gender, especially combined with ageing, is a major 
predisposing factor of KOA in women (Chen et al., 2012; Cho et al., 2010; Coleman et 
al., 2012; Egloff et al., 2012; Lohmander et al., 2004; Nishimura et al., 2011). In their 
meta-analysis, Srikanth et al. (2005) found that females, particularly postmenopausal, 
tend to have a more severe KOA, which could be attributed to many factors. It could be 
attributed to the fact that the knee joint is controlled locally and systemically by 
different hormones, including sex hormones (oestrogens, androgens, and progesterone) 
(Boyan et al., 2013). Moreover, there is increasing evidence that the oestrogen hormone 
has a role in maintaining the homeostasis of joint components including articular tissues 
(Roman-Blas et al., 2009). Hence, hormonal changes in women around the time of 
menopause or postmenopause could contribute to KOA development and progression 
(Boyan et al., 2013; Roman-Blas et al., 2009). Interestingly, Carbone and his colleague 
   15 
(2004) found that elderly women being treated with oestrogen had a significantly 
decreased prevalence of KOA. Furthermore, they stated that the majority of reports 
suggest a beneficial effect of oestrogen on OA.  
Boyan et al. (2013), on the other hand, stated that OA is an inflammatory disease and 
older women tend to have more robust inflammatory and immune responses than men, 
therefore making them more likely to be affected by KOA, this may be due to 
development and persistence of inflammatory cytokines in the knee, which may be 
secondary to the influence of hormones. Furthermore, it has been suggested that men 
have mainly larger joint surfaces and hence higher cartilage volume than women, where 
a high volume of cartilage may be protective against OA (Cicuttini et al., 2003; 
Eckstein and Wirth 2011). However, according to Eckstein and Wirth (2011), cartilage 
volume should not be directly compared according to gender. 
2.2.3 Obesity and BMI 
Numerous observational studies have identified obesity as a prominent risk factor for 
KOA (Dawson et al., 2003; Manek et al., 2003; Marks 2007; Toivanen et al., 2010). 
The prevalence of obesity is increasing markedly worldwide, in the UK the percentage 
of prevalence of obesity increased between 1986 and 1993 from 6% to13% in men and 
from 8% to16% in women. Similar results have been noted in the USA; national 
population surveys obtained since 1960 until 1994 have reported that the prevalence of 
obesity has more than doubled from 12.8% to 27%, and nearly 61% of adults are 
overweight or obese. In Saudi Arabia, studies conducted from 1990 to 1993, have 
shown an overall prevalence of obesity of 22.1% and approximately 53% of Saudi 
adults are either overweight or obese (Al-Nozha et al., 2005).  
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Individuals who were overweight earlier in adult life increase the risks of KOA 
(Dawson et al., 2003; Holliday et al., 2011). According to Rosemann et al. (2008), 3 to 
6 times body weight is transferred across the knee joint during each step. In obese 
individuals, it would increase the stresses and strains in the knee joint, which increase 
joint loading and alterations in gait mechanics. However, increased joint loading and 
gait alternations may cause damage to the knee cartilage and the menesci. According to 
Grazio and Balen (2009), 69% of total knee arthroplasty (TKA) may be attributed to 
obesity.  
Manek et al. (2003) stated that there are two major theories that could explain the 
association between obesity and KOA: biomechanical and systemic/metabolic 
mechanisms, where OA was also found in the hands of obese individuals. Furthermore, 
excess fat may have a direct metabolic effect on cartilage over and above the effects of 
stress, which acts indirectly to increase the risk of KOA. Sellam and Berenbaum (2013), 
on the other hand, stated that OA may have a systemic metabolic component and 
evidence from the literature supports the concept of metabolic OA. Furthermore, studies 
have demonstrated associations linking OA to several components of the metabolic 
syndrome, such as hypertension and diabetes or insulin resistance, independently from 
obesity or any of the other known risk factors for OA. Interestingly, it has been reported 
that, in women, the presence of obesity with at least two other metabolic syndrome 
components is associated with a higher risk of KOA compared to obesity alone. 
According to Carman et al. (1994), obesity has been found to be a risk factor for non-
weight-bearing joints, such as those in the hand. It has been reported that obese women 
with high BMI seem to have a higher risk factor for KOA than do non-obese women 
(Grazio and Balen 2009; Spector et al., 1994). However, it has been concluded that 
BMI is a substantial and independent risk factor for KOA (Nicolella et al., 2012). 
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Similar to obesity, BMI could have a biomechanical or metabolic effect on the knee 
joint (Wilson et al., 2011). 
2.2.4 Joint injury, deformity, and physical activity 
Joint injuries, including anterior cruciate ligament (ACL), collateral ligament, and 
meniscal injuries as well as joint fracture and dislocation increase the risk of subsequent 
KOA (Englund et al., 2009; Felson, 2013; Gelber et al., 2000). In their systematic 
review and meta-analysis study, Blagojevic et al. (2010) reported that previous knee 
trauma is one of the main risk factors consistently associated with KOA, and, moreover, 
it increases the risk 3.86 times. 
It has been hypothesised that OA is caused by increased forces across a local area of a 
joint, either from abnormal anatomy, excess overall load such as injury during sports or 
due to obesity, or a combination of anatomy and excess load. Injured meniscus and 
meniscectomies increase joint cartilage contact stress through altered load transmission, 
decreased shock absorption, and decreased joint stability. The greater the meniscus area 
removed, the worse the KOA progression is. ACL tears when accompanied with 
meniscal tears are more likely to lead to KOA (Englund et al., 2009). However, Keays 
et al. (2010) reported that the incidence of KOA after ACL reconstruction is relatively 
high, reaching 50% six years after surgery. Meniscal tears and meniscectomies as a 
major risk factor provide evidence that abnormal mechanics cause OA (Felson 2013). 
However, varus (bow-legged) and valgus (knock-kneed) malalignment of the knee joint 
is a substantial risk factor for progression of KOA. Varus alignment increases risk of 
subsequent medial KOA progression, whereas valgus alignment increases risk of 
subsequent lateral KOA progression (Sharma et al., 2001). Sharma et al. (2010) found 
that varus malalignment increases the risk of the initial development of KOA. 
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Despite that physical activities, including physical activity during leisure and moderate 
exercise, have been linked with reductions in pain and improvements in cartilage health 
(Hanna et al., 2005; Manninen et al., 2001; Roos and Dahlberg 2005; Toivanen et al., 
2010), there is evidence that heavy physical activities are positively related to the 
incident risk of radiographic KOA (McAlindon et al., 1999; Michaelsson et al., 2011). 
2.2.5 Occupation  
Occupational activities requiring repetitive use can be associated with a higher 
prevalence of KOA. Occupations involving kneeling, squatting, or lifting heavy objects 
such farmer, jackhammer operator, construction worker, miner, housekeeper, and truck 
driver, may increase the risk for KOA (Felson, 2013; Manninen et al., 2002; 
McWilliams et al., 2011; Palmer, 2012; Rossignol et al., 2003). Coggon et al., (2000) 
found that subjects who reported frequent kneeling, squatting, and heavy lifting at work 
were at risk of developing KOA. 
In their systematic review, Maetzel et al. (1997) studied the relationship of KOA and 
mechanical occupational exposure. They found that there is evidence of a strong 
positive relationship between work-related knee bending exposure and KOA in men, 
but, in women, this relationship was inconclusive. Andersen et al. (2012) reported that 
male floor-layers and bricklayers in addition to health care assistants of both genders 
had the highest risks of KOA. 
2.2.6 Ethnicity and genetics  
It has been reported that ethnicity has a role in developing OA based on variations 
among racial and ethnic groups. In their comparative study, Zhang et al. (2001) found 
that older Chinese women have a higher prevalence of KOA than did women in 
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Framingham, Massachusetts (USA). They stated that these differences could be 
attributed to genetic differences and heavy physical activity among the Chinese. They 
also found that the prevalence of KOA among Chinese men is roughly similar to that 
among white men. Interestingly, despite that men in China work at manual labouring 
jobs for many years and also spent significant amounts of time in a squatting position, 
which can create stress on the knees, severe radiographic OA was more prevalent 
among the subjects in the Framingham Study compared with those in Beijing. Possible 
explanation of this is that high body weight predisposes to more severe structural 
change and not physical activity alone. However, it has been found that older people in 
a rural farming region of northern China have a high prevalence of symptomatic and 
severe radiographic KOA compared with their ethnic peers living in urban region, 
Beijing (Kang et al., 2009). 
Felson et al. (2002) conducted a study to compare characteristics of OA in different 
racial groups. They found that Chinese subjects have a much more lateral KOA than do 
Caucasian subjects in the Framingham group despite the fact that those Chinese women 
and men from Beijing have a prevalence of medial KOA similar to that in Caucasian 
men and women of the same age from Framingham. 
OA has been known to have a strong genetic predisposition. Numerous family and twin 
studies showed increased prevalence of OA among relatives (Spector and MacGregor, 
2004; Spector et al., 1996; Valdes and Spector, 2008). Spector et al. (1996) investigated 
the genetic influences on OA in twin women and they found a clear genetic impact of 
KOA in radiographs of hands. 
According to Das and Faroogi (2008), the fact that OA is multifactorial in origin may 
explain why OA behaves differently worldwide. They attributed these differences to 
genetic makeup, lifestyles, and nutrition. Furthermore, by citing from previous studies, 
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they stated that polymorphisms of many genes have been associated with OA in some 
geo-ethnic populations, for example the cartilage oligomeric matrix protein gene 
polymorphisms have been found to be associated with OA in Caucasian but not in 
Japanese populations. There are additional factors which can increase the risk of 
developing KOA; for example, nutritional factors (McAlindon et al., 1996), weather 
(Wilder et al., 2003), and educational status (Verbrugge et al., 1991). 
2.3 Definition and diagnosis of KOA 
Different definitions and tools have been used to define OA. However, the definitions 
can be categorised into clinical or radiological definitions or both (Blagojevic et al., 
2010). The clinical presentation of OA is based on symptoms (patient’s self-report) 
alone or with radiographic changes. Clinical features accompanied with radiographic 
investigation could provide a crucial diagnosis of KOA (Bosomworth 2009). 
Nonetheless, diagnostic tools for evaluating KOA are various and include patient 
history, physical examinations, radiology, and laboratory findings. 
Pain is the primary symptom of KOA (Schuelert et al., 2011). At the onset of the 
disease, the pain is initiated on movement and alleviated at rest. Later, as the disease 
progresses, this pain may become more persistent, and it may restrict mobility and 
disturb sleep (Michael et al., 2010; Sakalauskiene and Jauniskiene, 2010). KOA is a 
disease which is characterised by loss of hyaline articular cartilage, which contains no 
pain fibres (aneural) and no blood vessels (avascular). This implies that the pain might 
arise from the surrounding structures after being affected; this can be a sign of advanced 
KOA (Bosomworth 2009; Dieppe and Lohmander, 2005; Michael et al., 2010; 
Sakalauskiene and Jauniskiene, 2010). Felson et al. (2001) found that bone marrow 
lesions on Magnetic Resonance Imaging (MRI) are strongly associated with the 
presence of pain in KOA. 
   21 
Stiffness, especially during early morning, is a common complaint of KOA. Loss of 
function of the affected joint is also one of the important symptoms of KOA, which may 
be exaggerated by the pain. Pain has the ability to restrict mobility and the ability to 
undertake physical activities, which can hasten disease progression, exacerbate joint 
pain, and ultimately inhibit daily activities and then lead to disability (Castaneda et al., 
2012; Schuelert et al., 2011).  
Signs that may be found by clinical examination include ROM reduction, which may be 
caused by the presence of osteophyte formation, pain avoidance, and capsular 
thickening (Reid and McNair, 2010). Crepitus is also one of the important signs related 
to KOA, and it may be caused by irregularities in the joint surface. Additional signs that 
may be noted include bony enlargement, muscle weakness, joint instability, and 
tenderness (Sarzi-Puttiniet et al., 2005; Zhang et al., 2011). 
For clinical definitions and outcomes, the severity of KOA is often assessed using 
different patient self-reporting and scoring systems, such as the Western  Ontario  and  
McMaster Universities (WOMAC)  osteoarthritis  index  and  the  visual  analogue scale  
(VAS) (Lu et al., 2010; Michaeal et al., 2010). The progress of KOA can be defined 
radiographically according to four main radiographic features (Figure 2.1). The first 
feature is joint space narrowing, which begins at the point of maximal loading within 
the joint. The second feature is osteophyte formation, which may be formed in an 
attempt to self-repair. Subchondral sclerosis is the third feature, which may be caused 
by deposition of new bone in an attempt to self-repair. The last feature is subchondral 
cysts, which appear between thickened subchondral trabecular (Buckland-Wright 2004; 
Gupta et al., 2005; Heidari, 2011; Jacobson et al., 2008). 
For a radiographic definition of KOA, the most commonly accepted grading system is 
the Kellgren and Lawrence (KL) grading scale, which was established more than 40 
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years ago and still stands. The KL grading system assigns one of five grades (grades 0–
4, with 0 being normal and 4 severe OA) (Kellgren and Lawrence, 1957). Another 
definition used is minimal joint space, which is a measurement of the shortest or 
narrowest distance between the two bones of the joint; for example, the femur and the 
tibia for the knee joint (Jacobson et al., 2008; Swagerty and Hellinger, 2001). 
 
Figure  2-1 Main radiographic features of KOA. (A) Left knee shows medial joint space 
narrowing (arrow). (B) Left knee shows sclerosis with marked osteophyte formation (arrows). 
(C) Osteoarthritic changes with medial joint space narrowing (white arrow) (D) Subchondral 
cysts (solid arrowhead) (adapted from Swagerty and Hellinger, 2001) 
 
Clinical symptoms, such as pain, stiffness, and loss of function, are not necessarily 
relevant to the level of joint pathological degeneration and vice versa (Bedson and 
Croft, 2008; Hannan et al., 2000). However, it has been reported that a large proportion 
of those diagnosed with radiographic changes of OA are asymptomatic (Srikanth et al., 
2005). Altman et al. (1986) cited from a previous study, stated that 40% of those 
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diagnosed with degenerative OA based on radiographic assessment have no symptoms. 
Hannan et al. (2000) found in their study that only about 15% of patients with KOA and 
who were diagnosed via radiography complain of knee pain. They reported that there is 
a lack of correlation between the clinical definition and the radiographic definition. 
However, the preferred definition for KOA includes x-ray findings accompanied by 
symptoms such as joint pain to confirm diagnosis and exclude other possible conditions 
(Bosomworth, 2009). 
Despite criticisms, plain radiographs have conventionally been used as the diagnostic 
tool to note, identify, and define KOA progression. It has been criticised for its 
unavailability in many parts of the world; which made the World Health Organization 
(WHO) (2003) recommend that a definition of OA based on a staging system based on 
symptoms or physical findings would be preferable.  Another criticism is the difficulty 
in measuring changes over time. Furthermore, soft-tissue structures such as cartilage 
cannot be seen on x-ray. Radiographic technique, patient positioning, scoring features 
(bias), are all subject to criticism for using normal x-ray (Boulos et al., 2003). However, 
where MRI technology is available it produces excellent images of the joint and its soft-
tissue structures, and does not expose the patient to ionising radiation.  
Ultrasonography is another way to demonstrate the soft tissues and fluid-filled spaces of 
joints. Previous technology is highly examiner-dependent and hence requires much 
experience for proper assessment (Michael et al., 2010). Arthroscopy is one of the 
modalities that can be used to directly visualize cartilage and some of the soft-tissue 
structures for assessing the affected joint with OA. Another tool for evaluating OA is 
biomarkers. Biomarkers can be measured in serum, urine, or synovial fluid (Boulos et 
al., 2003).  
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2.4 Treatment of KOA 
The effects of OA, which today are already serious, are rapidly increasing to affect 
approximately 15% of the world’s population; despite that, currently, there are no 
DMTs available for OA (Egloff et al., 2012; Hellio Le Graverand-Gastineau, 2009; 
Schuelert et al., 2011; Selvan et al., 2012). Unfortunately, despite a wide variety of 
therapeutic options for the treatment of OA, including non-pharmacological, 
pharmacological, and surgical choices, currently there is no ability to stop the progress 
of the disease. Current treatment is for symptomatic relief, focusing on reducing 
symptoms, such as pain, which is the main reason for seeking health care; about 55% of 
patients with OA report pain as the worst feature of the disease.  
The Osteoarthritis Research Society International (OARSI) recommendations 
emphasised that the treatment of KOA should be directed towards educating patients 
about OA, reducing joint pain and stiffness, maintaining and improving joint mobility, 
reducing physical disability and handicap, improving QoL, and minimising the 
progression of joint damage (Zhang et al., 2008). Previous recommendations are similar 
to other guidelines for the treatment of KOA and hip OA, such as the American 
Academy of Orthopedic Surgeons (AAOS) and National Institute of Health and Clinical 
Excellence (NICE) (Zhang et al., 2008). Figure 2.2 presents a sequential, pyramidal 
approach to the management of OA. 
2.4.1 Non-pharmacological treatment 
Non-pharmacological interventions such as education, physiotherapy, and occupational 
therapy are currently the first line of treatment and often are successful (Hunter and 
Felson 2006; Zhang et al., 2007). 
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Figure  2-2 Principles of the management of OA (adapted from Dieppe and Lohmander, 2005) 
 
2.4.1.1 Prevention, education and behavioural modification   
According to Michael et al. (2010), prevention is an important treatment for KOA. Joint 
protection plays a major role in preventing further damage of the joint structures. By 
eliminating the influences that can potentially affect or damage the joint components, 
development of OA can be prevented or at least slowed down. To achieve this goal, it is 
important for practitioners to educate their patients and make them aware of the extent 
of their condition and the importance of having an active role in its management.  
Barlow et al. (2000) found that a self-management program for OA offers a number of 
important benefits, and it could be used as a useful adjunct to medical care. According 
to Pendleton et al. (2000), there is good evidence that education plays a role in reducing 
pain in patients with KOA. Furthermore, Hirano et al. (1994) reported that educational 
aspects can offer an additional 15–30% improvement over the effects of medication 
alone.  
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Patient education should include advice about weight reduction. Interestingly, a loss of 
5 Kg may be associated with a 50% reduction in the possibility of developing 
symptomatic KOA as well as a reduction in the severity of joint pain (Grainger and 
Cicuttini, 2004; McGoey et al., 1990). Furthermore, Christensen et al. (2007), in their 
meta-analysis, reported that a reduction of 5% of body weight within 20 weeks was 
related to symptomatic relief in patients with KOA. Moreover, it has been reported that 
for each 1 Kg of body weight lost, there is a 4 Kg reduction in the load on the knee joint 
per step (4800 Kg reduction for each Km walked) (Messier et al., 2005). 
Psycho-education, including patient education and self-management programmes, has a 
role in the management of patients with KOA (Jamtvedt et al., 2008). Psychological 
support and coping strategies are very important for patients with chronic pain, such as 
KOA. Through the provision of information by explaining to patients the possible 
causes of their pain and that the symptoms they are experiencing are normal for their 
condition, their anxiety about their condition can be reduced (Adams et al., 2006).  
2.4.1.2 Physiotherapy and occupational therapy 
Pain and disability are the main reason for patients with KOA to seek health care, 
including physiotherapy (Peat et al., 2001). Chronic pain patients, including patients 
with KOA, have a significant reduction in their physical activities as a result of their 
tendency to avoid pain, which leads, in turn, to a reduction and limitations in 
cardiovascular fitness, strength, endurance, coordination, and range of motion. These 
limitations can affect their ability to perform self-care and ultimately impair QoL 
(Strong 2002; Watson 2000).  
Physiotherapy plays an essential role in managing KOA by helping to increase patient 
activity levels (Hawkeswood and Reebye, 2010). Exercise is a core recommendation in 
all international guidelines as a first-line management strategy for patients suffering 
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from KOA (Stemberger and Kerschan-Schindl, 2013). Patients with KOA have a 
significant decrease in knee muscle strength, especially the quadriceps muscle, the 
weakness of which is an early and common clinical feature of KOA. However, there is 
strong evidence that exercises can reduce pain and improve function in patients with 
OA (Alfredo et al., 2011; Conroy et al., 2012; Iwamoto et al., 2011). 
A wide range of different modalities are used by physiotherapists to control pain. For 
instance, TENS, which is a well-known pain-relieving modality, is used widely in 
physiotherapy clinics as a treatment to reduce chronic pain (Baxter and Barlas, 2002; 
Hawkeswood and Reebye, 2010). Other modalities are used for the same reason, but 
using a different form of energy, including shortwave, microwave, and shock-waves. 
Thermal heat or cold (e.g. hot pack, ice pack) and ultrasound are among the modalities 
used in physiotherapy clinics for controlling pain. 
Acupuncture has been shown to be an effective treatment for KOA, which now could be 
applied by physiotherapists, either in the clinic as a member of a multidisciplinary team 
or patients could be referred from pain clinics for individual treatment (Hawkeswood 
and Reebye, 2010; Sweet, 1998). Within the field of electrotherapy, LLLT has been 
introduced by physiotherapists recently as a pain management therapy for localised and 
painful musculoskeletal conditions, including KOA (Abrisham et al., 2011; de Carvalho 
et al., 2012; Gur et al., 2003a). Furthermore, it has been reported that LLLT stimulates 
reparative properties in human cartilage (Fukuda et al., 2011). More details are 
presented in Section (3.8.2) on page 53.  
Manual therapy, such as mobilization, manipulation, and soft-tissue massage that uses 
manual force is widely used in physiotherapy clinics. It can improve the mobility and 
extensibility of restricted joints and their connective tissues, resulting in decreases in the 
intra-articular pressure (Hoeksma et al., 2005). It has been shown that manual therapy 
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reduces pain and improves function in KOA patients (Bialosky et al., 2009; Pollard et 
al., 2008). Furthermore, manual therapy can delay the need for TKA in patients with 
KOA (Deyle et al., 2000; Zeni et al., 2010). 
Occupational therapy plays a major role in joint protection by providing patients with 
assistive devices, such as canes, braces and insoles, which have great benefit when used 
properly. Using these devices is recommended by the American College of 
Rheumatology (ACR) 2012. In addition, wedged insoles, can be used to realign the 
limb, which reduces the load on joints and ultimately reduces pain and improves 
function (Hochberg et al., 2012; Recommendation for the medical management of 
osteoarthritis of the hip and knee 2000; Stemberger and Kerschan-Schindl, 2013). 
2.4.2 Pharmacological treatment 
In many cases of patients with KOA, non-pharmacological treatment is not adequate to 
control pain or improve functional status; even those who undergo surgery 6-30% still 
have persistent knee pain. Therefore, the logical next step is the use of pharmacological 
treatment (Cheng and Visco, 2012; Le Loet et al., 2005; Zhang et al., 2011). 
2.4.2.1 Analgesics, NSAIDs  
NSAIDs are the most widely prescribed medications for patients with KOA, although 
they are associated with serious side effects, including bleeding and gastric ulceration. 
Unfortunately, it has been reported that 20–30% of deaths from peptic ulcer disease in 
elderly people may be related to the use of NSAIDs (Griffin et al., 1988). Therefore, 
treatment of KOA should be tailored to the individual patient, and many factors need to 
be taken into account prior to any treatment, such as age, co-morbidity, and the presence 
of inflammation. For mild to moderate pain without inflammation, paracetamol 
(acetaminophen) is commonly used as self-medication because of its relative safety. For 
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those unresponsive to paracetamol, particularly in the presence of persistent pain and 
inflammation, NSAIDs would appear to be the logical next step (Cheng and Visco, 
2012; Pendleton et al., 2000). Topical analgesics, such as capsaicin cream or topical 
NSAIDs could be used as monotherapy or adjunctive treatment (Sarzi-Puttini et al., 
2005). 
2.4.2.2 Intra-articular therapy  
Intra-articular joint injection of glucocorticoids may be used for treating KOA, 
especially in the presence of effusion and local inflammation. Intra-articular injection of 
hyaluronan is currently available for the treatment of KOA. It is thought to help replace 
the synovial ﬂuid and facilitate shock absorption and lubrication (Sarzi-Puttini et al., 
2005; Walker-Bone et al., 2000). 
2.4.3 Surgery  
Initial treatment for patients with KOA should be conservative (pharmacological and 
non-pharmacological), but if it fails and symptoms persist, surgery could then be 
considered (Ronn et al., 2011). There are many kinds of surgical procedures carried out, 
and the options depend on factors such as the patient’s age, sex, the location, and stage 
of OA, level of activity, co-morbidities and weight (Ronn et al., 2011). Arthroscopic 
lavage and debridement of the knee (e.g. shaving of rough cartilage or smoothing of the 
degenerated meniscus) is a successful option for younger and middle-aged patients with 
KOA accompanied by evident lesions of the meniscus or cartilage ﬂaps (Felson et al., 
2000; Ronn et al., 2011).  
Osteotomies (realignment surgery) around the affected knee are another surgical option, 
performed for unicompartmental OA associated with varus or valgus deformity, 
especially in young and active patients with early OA. The efficacy of this surgery is to 
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realign osteoarthritic joints with the intent of relieving joint pain and improving 
function (Egloff et al., 2012; Ronn et al., 2011). 
TKA, by all measures, is a well-accepted method for treatment of advanced KOA. 
Durability of prosthetic components is limited to about 15–20 years, therefore, 
whenever possible, use on patients younger than 60 years should be avoided. By TKA 
surgery, the pain and disability of end-stage OA can be eliminated, restoring patients to 
near normal function and improving their QoL. Despite its safety and efficacy, it suffers 
from several problems and complications, such as persisting pain, femoropatellar 
problems, loosening of components, infections, and stiffness of the knee (Felson et al., 
2000; Ronn et al., 2011). 
Arthrodesis, or joint fusion, successfully relieves pain and is commonly performed on 
the spine and in small joints, but not in the major proximal joints (Felson et al., 2000). 
Indication for knee arthrodesis in patients with KOA is severe pain and instability of the 
knee joint following an infection at a previous TKA. Patients with this surgery will have 
some functional difficulties with climbing stairs and with sitting, in addition to some 
complications such as an arthrodesis of the contralateral hip or knee, significant OA in 
the ipsilateral hip or ankle, or shortening of the leg (Zhang et al., 2008). 
2.5 Search strategy 
Search strategy used for the current study to identify studies and relative information 
from electronic databases is presented in Appendix I. 
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Chapter 3 Review of the literature of low 
level laser therapy (LLLT) 
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3.1  History and Background of Laser 
LASER is an acronym for Light Ampliﬁcation by Stimulated Emission of Radiation. 
The applications of lasers are associated with many fields, which range from the use of 
very high-power lasers in military and medical applications to the very low power laser 
used in supermarket barcode systems, lecture pointers, and compact discs (Baxter, 
1994). 
 Interestingly, the sun was the first source of medicinal light, which was classically 
referred to as heliotherapy (Bloch, 1990). Heliotherapy has been practiced for thousands 
of years and was employed in the treatment of several conditions, including epilepsy, 
asthma, scurvy, rickets, rheumatoid arthritis, and depression (Rosenshein, 1997). 
At the turn of the 20th century, an artificial source of therapeutic ultraviolet (UV) was 
developed by Dr Niels Finsen, who won the Nobel Prize for medicine in 1903 for his 
work with UV in the treatment of dermal tuberculosis. In the 1950s, Schawlow and 
Townes amplified a beam of microwaves producing Microwave Amplification by 
Stimulated Emission of Radiation (MASER), putting into practice what had been 
conceived earlier by Albert Einstein, who in 1917, showed that the existence of 
equilibrium between electromagnetic radiation and its interactions with matter required 
a previously undiscovered radiation process called stimulated emission. Later, in 1960, 
Theodore Maiman amplified light using a ruby crystal as a lasing medium emitted light 
in the red part of the visible spectrum at a wavelength of 694.3 nm. As a result, the birth 
of laser was declared (Baxter 1994; Jackson et al., 2001).  
In 1961, Javan and his colleagues developed the first gas laser using a mixture of two 
gases, helium (He) and neon (Ne), which emitted red and infrared light. In the same 
year, Johnson developed a laser emitting in the invisible infrared spectrum using an 
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yttrium aluminium garnet (YAG) doped neodymium (Nd: YAG) laser. Not long 
afterwards, in 1962, the argon laser (a gas laser giving a blue-green visible beam) was 
discovered by Bennett and his associates (1962). Two years later, in 1964, Patel 
developed the carbon dioxide (CO2) laser, which emits in the invisible infrared portion 
of the spectrum (Jackson et al., 2001; Peng et al., 2008). 
In 1967, a few years after the first laser was created, Professor Endre Mester conducted 
a study to investigate if laser radiation might cause cancer in mice. He shaved the hair 
of their backs and divided them into two groups, and then he irradiated the shaved area 
of one group with a low-powered ruby laser (694nm). The irradiated mice did not get 
cancer; instead, he noted that the hair grew back quicker at the irradiated area than it did 
in the untreated group. This was how ‘laser bio-stimulation’ was discovered (Baxter and 
Barlas 2002; Huang et al., 2009). 
Clinical laser use is based upon the photo-thermal and photo-ablative interactions with 
tissue at relatively high-power and energy densities (Peng et al., 2008). In surgery, 
lasers are used to cut (as alternatives to metal scalpels), weld, and even destroy tissue, 
such as in tumour ablation and tattoo removal. Ophthalmic surgeons were the first to 
use the pulsed ruby laser for the treatment of detached retina in humans (Baxter and 
Barlas, 2002).  
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3.2  Laser physics 
3.2.1 Principal components of a laser device 
The laser device, in order to produce laser radiation, must consist of three basic 
components, namely a lasing medium, a power source, and resonating cavity (Figure 
3.1).  
 
Figure  3-1 Principal components of a laser device 
 
3.2.1.1 Lasing medium 
A laser medium can be gaseous, liquid, solid, crystal or semiconductor. These media 
should have the property of absorbing energy generated by an external power source 
and ultimately giving off energy as photons of light. A photon (quantum) is a particle of 
energy that travels at a speed of 3×108 ms; where the brightness of light is the number 
of photons and the colour of the light is the energy contained in each photon (Rojas and 
Gonzalez-Lima, 2011). 
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3.2.1.2 The power source 
The power source might be electrical, chemical, or optical energy, and it is used to 
excite or ‘pump’ the laser medium to higher energy level laser radiations (photons). 
3.2.1.3 Resonating cavity 
The resonating cavity consists of the lasing medium within a central chamber, which is 
located between two parallel mirrors at either end. The two mirrors are positioned at 
right angles to the longitudinal axis of the medium and also placed a fixed distance 
apart, allowing excited atoms of the laser medium (photons) to move back and forwards 
across the chamber. The rear mirror is 100% reflective, and the front one allows a small 
percentage of the laser beam to be transmitted as the output signal (output coupler) 
(Baxter, 1994).  
The vast majority of the atoms of the lasing medium are at the lowest energy level prior 
to the activation of the power source in the medium. This phase is termed the ground 
state. When the energy source is supplied from the power source and is directed into the 
resonating cavity, the energy is absorbed by the electrons of the medium which are then 
excited, and they store an exact quantum of energy. At this stage, the atoms in the 
excited state are unstable, and their electrons spontaneously return to their ground level, 
releasing their temporarily stored extra energy as a photon of light. Radiated photons 
have a wavelength specific to the atoms of the lasing medium. This process is called 
spontaneous emission of radiation (Figure 3.2 a).  
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Figure  3-2 Spontaneous and stimulated emission of radiation (adapted from 
http://cnx.org/content/m39557/1.1/) 
The releasing photon must have the same characteristics as the energy and wavelength 
that will be released when the electron returns to the ground phase. This process is 
referred to as stimulated emission of radiation (Figure 3.2 b). Ultimately, the intensity 
of the intra-cavity energy is amplified using the two parallel mirrors, permitting a 
portion of the energy to leak out through the partially transmissive front mirror (Baxter 
1994; Tuner and Hode, 2002). 
3.2.2 Characteristics of laser radiation 
Laser radiation has important characteristics over the ordinary light source (Figure 3.3). 
3.2.2.1 Monochromatic 
Laser light is of a single and defined wavelength, which gives a single pure colour, such 
as the He-Ne laser that produces a red laser beam. A laser light is, consequently, said to 
be highly monochromatic (single coloured). In contrast, ordinary light consists of all 
colours of the spectrum (polychromatic) (Baxter, 1994; Tuner and Hode, 2002) (Figure 
3.3). 
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3.2.2.2 Coherent 
All energy waves of the laser light travel in phase (synchronicity), and the light emitted 
from ordinary light is described as incoherent. Laser light has the ability to stay in phase 
for very long distances, with a relatively little beam spread (Baxter, 1994) (Figure 3.3). 
3.2.2.3 Collimation 
This refers to the minimal divergence of the laser beam, and there is little intensity loss 
as distance increases. This allows a concentrated beam to be focused on a relatively 
small area. The He-Ne laser is the most highly collimated low-power laser used in 
therapeutic applications (Baxter 1994) (Figure 3.3). 
Previous characteristics might play an important role in the clinical application of a 
laser. It has been reported that the mechanism of LLLT at the cellular level has been 
attributed to the absorption of monochromatic visible and near infrared (NIR) radiation 
by components of the cellular respiratory chain (Huang et al., 2009). Furthermore, it has 
been found that coherent light has a positive effect on an injured nerve; whereas non-
coherent light has been known to affect the injured nerve adversely (Smith, 2010).  
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Figure  3-3 Characteristics of laser radiation versus ordinary light 
3.3 Laser types  
Laser type is wavelength dependant, as well as the lasing medium (Figure 3.4). A 
variety of therapeutic laser systems are currently available for clinical applications, 
including gas laser medium, dye (liquid) lasers, and semiconductor lasers. Gas lasers, 
such as the carbon dioxide, argon, and Nd: YAG are commonly used in the surgical 
field, with subsequent ability to vaporize and coagulate tissue (de Paula Eduardo et al., 
2010; Peng et al., 2008).  
Dye lasers, which are usually liquid solutions, can be turned to a much wider range of 
wavelengths by changing the chemical composition of the lasing medium. In medicine, 
these lasers are applied in several areas, including blood vessel disorders, kidney stones, 
and dermatology, such as in scars and for tattoo removal (Peng et al., 2008; Shankarling 
and Jarag, 2010).  
According to da Silva et al. (2010), the most frequently used types of lasers in the field 
of LLLT are helium-neon (He-Ne) lasers and diode lasers. Diode lasers (semiconductor 
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lasers) include gallium-aluminium-arsenium (GaAlAs), arsenium-gallium (AsGa), and 
indium-gallium-aluminium-phosphide (InGaAlP) lasers. Unlike lasers used in surgery, 
the effects of LLLT are photochemical rather than thermal (Tuner and Hode 2002).  
 
Figure  3-4 Wavelength of common medical lasers (adapted from Peng et al., 2008) 
 
Laser light can also be described according to its beam as continuous-wave (CW), 
pulsed, or quality switched (Q-switched). CW lasers consist of a consistent beam of 
relatively low steady output power. The beam of the pulsed lasers is emitted in bursts, 
output power with peak powers higher than CW lasers. This operation is controlled by 
mechanical shutters or electrical switches; however, the pulsed light can be set typically 
in millisecond (ms) with regards to surgical lasers, and it is measured by the number of 
pulses per second or Hertz (Hz) (Acland and Barlow, 2000). Quality switching is a 
technique used to produce a pulsed output beam with extremely high peak power 
(Wohlmuth et al., 2009). It has been reported that Q-switched lasers are used clinically 
to remove tattoos (Kilmer and Anderson 1993).  
3.4 Laser parameters 
The laser system could be described through its parameters, which include the laser 
wavelength, power output, power density (intensity), and energy density (fluence, or 
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dose). It has been reported that parameters such as wavelength and fluence play a major 
role in cellular metabolism during therapeutic application. Furthermore, LLLT at certain 
wavelengths and fluencies can stimulate cell proliferation (AlGhamdi et al., 2011; Yu et 
al., 1997). Huang et al. (2009) indicated that LLLT can be likened to other forms of 
medication, and that LLLT has its active ingredients or ‘medicine’ (irradiation 
parameters) and a ‘dose’ (the irradiation time). Table 3.1 shows major parameters of 
LLLT. 
3.4.1 Wavelength 
Light is a type of electromagnetic radiation and a form of energy called luminous 
energy. Electromagnetic waves have crests and troughs. The wavelength is the distance 
between successive crests or troughs of the same phase measured in nanometres (nm). 
The number of oscillations per second is called frequency; whereas the difference 
between crests and troughs is called amplitude (Rojas and Gonzalez-Lima, 2011). Each 
laser has distinct uses depending on the wavelength and power output; moreover, 
penetration of the laser beam into the target tissue is wavelength dependent (Figure 3.5). 
Furthermore, laser with wavelengths ranging from 600 to 700 mm is used for treating 
superficial tissues, whereas wavelengths between 780 and 950 nm are used for deeper 
tissues (Chung et al., 2012; Hamblin and Demidova, 2006).  
3.4.2 Power output 
A laser’s power output (radiant power) is the amount of energy it produces, and it is 
measured in Watts (W). However, because the laser radiation in therapeutic application, 
especially in LLLT is below 1W, it is expressed in milliwatts (mW) (Baxter, 1994). The 
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stronger the laser radiant power (mW) is the shorter the required treatment time is 
(Hawkins and Abrahamse, 2007). 
3.4.3 Power density 
Power density (irradiance) or the light intensity of the beam on the area of irradiation is 
expressed in mW per square centimetre, mW/cm2, which is defined by the power output 
divided by the area of the target tissue being irradiated by the laser light, with the area 
being defined by the beam spot size (r2) at the tissue surface (Baxter, 1994). Then, 
power density measures the amount of power per unit area leaving the laser probe. The 
larger the area irradiated the greater the reduction in power density. 
3.4.4 Energy density 
Energy density (fluence, or dose) measures the amount of energy received by a given 
target tissue. It is expressed in joules per square centimetre (J/cm2) as a product of 
power (mW) and time (s) per spot size (cm2). The fluence (dose) of the laser required 
depends upon  the laser wavelength, type of tissue, condition and depth of the target 
tissue, chronic or acute problem, pigmentation, and treatment technique (contact versus 
non-contact), whereas the laser fluence administration is influenced by the power (mW), 
irradiance (mW/cm2), time (s), and treatment intervals (Hawkins and Abrahams, 2007). 
Furthermore, it has been stated that there is evidence suggesting that energy density as 
well as power density are key biological parameters for the effectiveness of laser 
therapy (Sommer et al., 2001). 
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Table  3-1 Major parameters of LLLT (adapted and modified from Rojas and Gonzalez-
Lima 2011) 
Parameter  Unit  Explanation 
Wavelength nm  Wavelength is the distance between wave peaks. Light is 
a form of energy with wave behaviour. Photo-acceptors 
exhibit different sensitivities to different wavelengths. 
The most effective LLLT wavelength range is 600–1100 
nm. Light visible to the human eye is 400–700 nm. The 
higher the wavelength, the lower the energy. 
Energy J  Energy (E) is the frequency (v) of radiation by Planck’s 
constant (h) of 6.626 × 10-34 Js (E = hv). Energy of a 
photon depends on the frequency of radiation (Ephoton = 
hv). A photon is a particle of electromagnetic radiation 
with zero mass and a quantum of energy (minimum E 
gained or lost by atom). Energy (J) = Power (W) × Time 
(s). 
Power W  Amount of energy (J) transferred or flowing per unit of 
time (W = J/s). 
Irradiance W/cm2 Power (W) per surface area (cm2). Also called power 
density or light “intensity”. Irradiance = Power (W) / 
Area (cm2). 
Radiant exposure J/cm2 Energy (J) per surface area (cm2). Equivalent to power 
density per unit of time (s). Also called fluence, energy 
density, or light “dose.” Thus, “dose” can be easily varied 
by changes in exposure time. However, at the same 
energy density (J/cm2) variations in either irradiance 
(W/cm2) or time may cause different LLLT effects on 
tissues. 
Exposure time s Time during which the target tissue is exposed to light. 
Wave type Continuous 
versus pulsed 
Continuous waves may be advantageous for transcranial 
applications. Pulse waves may decrease thermal effects. 
Pulse Average Power = Peak Power (w) × Pulse width (s) 
× Pulse Frequency (Hz). 
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3.5 Laser classification and hazard 
The laser produces an intense beam of light which could be directed, reflected, or 
focussed upon an object. Laser light will be partially absorbed, raising the temperature 
of the surface, causing an alteration or deformation of the material. Under certain 
circumstances (laser power, wavelength, and exposure duration) exposure to laser light 
can result in tissue damage to the eye and skin. 
According to the American National Standards Institute (ANSI) as specified in the 
ANSI Standards Z136.1-2007, ‘‘The Safe Use of Lasers’’, the laser light is classified 
into 7 classes (1, 1M, 2, 2M, 3R, 3B and 4) to indicate the level of laser beam hazard 
and maximum Accessible Emission Levels (AELs), which is the maximum accessible 
level of laser radiation permitted within a particular laser class. 
A class1 laser system produces laser that is considered being safe during operation and 
is exempted from any control measures or other forms of surveillance. The class 1M 
laser system produces laser that is considered being safe during normal operation unless 
the beam is viewed with an optical instrument such as an eye-loupe (diverging beam) or 
a telescope (collimated beam). It is also exempt from any control measures or other 
forms of surveillance during normal operation. A class 2 laser system produces laser 
light that only emits visible radiation in the wavelength range from 400 nm to 700 nm 
with output less than the appropriate AEL. It is considered to be safe for accidental 
viewing as eye protection is afforded by aversion responses. A class 2M laser system is 
the same as class 2, however, total output is in excess of that normally permitted for 
class 2 and potentially hazardous if viewed with certain optical aids. 
A class 3R laser system produces laser light that is in the wavelength range from 302.5 
nm to 1mm where the AEL can be exceeded, but with a low risk of injury. The class 3R 
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laser is normally not a diffuse reflection or fire hazard. A class 3B laser system 
produces laser that is hazardous if the eye is exposed directly. Protective eyewear is 
required for direct viewing of the class 3B laser and laser units must be equipped with a 
key switch and a safety interlock. The laser unit used in the current study falls in this 
range. A class 4 laser system produces high-power lasers that exceed the AELs of other 
classes and are capable of producing hazardous diffuse reflections and causes skin and 
eye injuries. Its use requires extreme caution (American National Standard for Safe Use 
of Laser; ANSI Z136.1, 2007). Table 3.2 shows 4 major hazard classes (I to IV) of 
lasers recognised by the FDA. 
Table  3-2 major hazard classes (I to IV) of lasers recognised by the FDA (adapted 
from:http://www.fda.gov/radiationemitting 
productss/radiationemittingproductsandprocedures/homebusinessandentertainment/las
erproductsandinstruments/default.htm) 
Class, FDA Class IEC Laser Product Hazard Product Examples 
I 1, 1M Considered non-hazardous. Hazard 
increases if viewed with optical aids, 
including magnifiers, binoculars, or 
telescopes. 
-Laser print 
-CD player 
-DVD players 
IIa, II 2,2M Hazard increases when viewed 
directly for long periods of time. 
Hazard increases if viewed with 
optical aids. 
-Bar code scanners 
IIIa 3R Depending on power and beam area, 
can be momentarily hazardous when 
directly viewed or when staring 
directly at the beam with an unaided 
eye. Risk of injury increases when 
viewed with optical aids. 
-Laser pointers 
IIIb 3B Immediate skin hazard from direct 
beam and immediate eye hazard 
when viewed directly. 
-Laser light show 
projectors  
-Industrial lasers 
-Research lasers 
IV 4 Immediate skin hazard and eye 
hazard from exposure to either the 
direct or reflected beam; may also 
present a fire hazard. 
-Laser light show 
projectors 
-Industrial lasers 
-Research lasers 
-Lasers used to perform 
LASIK eye surgery 
IEC, International Electro-technical Commission 
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3.6 Laser penetration  
Penetration depth of the laser beam is a wavelength dependent (Litscher and Opitz, 
2012; Rojas and Gonzalez-Lima, 2011) (Figure 3.5). Laser light with a longer 
wavelength penetrates deeper, whereas, laser light with a shorter wavelength penetrates 
superficially. Furthermore, it has been stated that the penetration depth of laser light 
depends on the type of tissue being irradiated and the frequency of laser light (Ezzati et 
al., 2009; Rojas and Gonzalez-Lima, 2011). Blue-green light yields poor penetration as 
it is absorbed in biologic pigments, whereas, red and NIR wavelengths (700 to 1200 
nm) penetrate considerably deeper (Houreld, 2006). Laser beam continues to penetrate 
deeper until water absorption becomes relatively high, causing the penetration depth to 
decrease rapidly (Welch et al., 1989). A CO2 laser beam is completely absorbed in 
water, making the penetration rate in the tissue to be weak. Nd: YAG laser beam is 
absorbed by protein, making its penetration quite high. He-Ne laser beam (red light) is 
absorbed less by blood, so its penetration rate is relatively high. A Laser beam from the 
diode laser, particularly the GaAlAs (830nm) has the highest penetration rate (Houreld, 
2006). The GaAlAs (830nm) is identical to the one used in the current study.  
   46 
 
Figure  3-5 Penetration depth of some common medical lasers in human skin tissue (adapted 
from Houreld, 2006) 
3.7 Medical laser 
Despite that laser is used today by a large variety of professions (see Section 3.1), its 
use in medicine is one of the most meaningful applications of laser technology. The 
clinical use of laser therapy is based upon the photo-thermal and photo-ablative 
interactions of laser with tissue at relatively high-power and energy densities (Peng et 
al., 2008). 
Lasers are used in most medical disciplines as a surgical tool, as well as diagnostically, 
and as a therapeutic modality. The laser can cauterize deeply (alternatives to metal 
scalpels) as it cuts, and reducing the surgical trauma caused by a scalpel. It can vaporize 
the surface of a tissue as in tattoo removal. Also, it can weld and even destroy tissues 
such as in tumour ablation. Ophthalmic surgeons were the first who administrated the 
laser in surgery using the pulsed ruby laser for the treatment of detached retina in 
humans (Baxter and Barlas, 2002; Peng et al., 2008). Furthermore, light energy (optical 
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biopsy or optical diagnostics) is used to obtain information on the structure and function 
of tissue without disrupting it, as in early diagnosis of lung cancer (Peng et al., 2008). 
When the laser beam is directed towards tissue, it may be reflected, transmitted, 
scattered and/or absorbed and the optical properties of substances are characterised by 
coefficients for each of these events (Chung et al., 2012). Only about 3% of the directed 
light beam is reflected while the remaining light goes into the tissue where absorption 
and scattering take place.  
Both the absorption and scattering of light in tissue are wavelength dependent. The laser 
photons that enter tissue are scattered once or multiple times until they either escape or 
are absorbed. A scattering of laser photons occurs after it has entered the tissue 
spreading out within the tissue resulting in irradiation of the surrounding area. 
Depending on the rate of laser photons absorbed within the tissue; the energy (heat 
oscillations) is delivered. As a result, depending on the degree of generating energy, 
target tissue may be carbonized, vaporized or coagulated, or the tissue proteins may be 
degraded or denatured (Houreld 2006; Peng et al., 2008). The absorption and scattering 
of light in tissue form the basis of techniques using laser in medicine. The current study 
mainly focuses on the LLLT used in physiotherapy and rehabilitation, and it is beyond 
the scope of this research to discuss the laser technique used in surgery. 
3.8 Low-level laser therapy (LLLT) 
Shortly after Endre Mester, in 1967, discovered the ability of the He-Ne laser to 
increase hair growth and stimulate wound healing in mice, he began to use lasers on 
humans to treat patients with non-healing skin ulcers. Since then, LLLT has gained 
attention for treating a variety of medical conditions that require tissue repair, pain 
relief, inflammation reduction, preventing cell death and tissue damage. LLLT was 
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mainly employed as a treatment for wound healing and pain relief of musculoskeletal 
and soft-tissue injuries. In recent years, it has been broadened to treat serious diseases 
such as stroke, myocardial infarction, spinal cord injury, degenerative or traumatic brain 
disorders, and retinal disease (Chung et al., 2012; Hashmi et al., 2010; Rojas and 
Gonzalez-Lima, 2011).  
According to Rojas and Gonzalez-Lima (2011), LLLT can be defined as the use of low 
power and high-fluence monochromatic or quasi-monochromatic light from lasers or 
light-emitting diodes (LEDs) in the red to NIR wavelengths (600–1100 nm) to modulate 
a biological function or induce a therapeutic effect in a non-destructive and non-thermal 
manner.  
This treatment modality is termed LLLT because the optimum levels of energy density 
delivered are low compared with the high-power laser as practiced for ablation, cutting, 
and thermally coagulating tissue (Chung et al., 2012). The effects of LLLT are 
photochemical rather than thermal such as the one used in surgery (Tuner and Hode, 
2002). Furthermore, it can be referred to as photobiology or bio-stimulation. LLLT is 
variously known as low-power lasers, low-intensity laser irradiation, low energy laser 
therapy, cold laser therapy, photon therapy, phototherapy, photobiomodulation. Red and 
NIR lasers, usually in the range of 1mW to 500mW, are widely used in the field of 
LLLT and includes He-Ne lasers with a wavelength of 633nm and semiconductor lasers 
emitting light in the range of 780 to 950nm such as GaAlAs laser (Huang et al., 2009; 
Kreisler et al., 2003). It has been reported that lasers with wavelengths ranging from 
600 to 700 nm are used for treating superficial tissues, while wavelengths between 780 
and 950 nm are used for deeper tissues (Chung et al., 2012; Hamblin and Demidova, 
2006). Bjordal et al. (2003) reported that when the laser light hit the skin, its energy loss 
due to the skin barrier for continuous He-Ne (632nm) laser is 90%, for continuous 
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GaAlAs (820 nm) is 80%, and finally for GaAs (904 nm) infrared pulse laser the loss is 
50%. 
LLLT has become an increasingly mainstream modality and is practiced as a part of 
physiotherapy, physical medicine and rehabilitation (Baratto et al., 2011; Chung et al., 
2012; de Carvalho et al., 2012; Gur et al., 2003a; Hashmi et al., 2010; Vladimirov et 
al., 2004). Moreover, it is used in a wide range of clinical settings ranging from 
dentistry, to dermatology and rheumatology (Chung et al., 2012; Vladimirov et al., 
2003). According to Alfredo et al. (2011) the European League against Rheumatism 
(EULAR) suggests that LLLT should be considered when planning optimal treatment 
for OA.  
Guidelines by the USA FDA stated that laser devices used for treating human and 
animals must meet Mandatory Performance Standards, which include ‘‘safety features 
and labelling to provide adequate safety to users and patients’. Therefore, FDA 
clearance for using laser devices means that it has ‘‘passed a quality assurance test and 
that it complies with the performance standard”. Although the use of LLLT is not new 
and has been practiced in clinical settings since the 1960s, the first cleared by US FDA 
was as late as 2002. The FDA granted 510 (k) approval for several companies to market 
lasers that provide LLLT. A 510(k) is a premarketing submission made to FDA to 
demonstrate that the device to be marketed is as safe and effective. For example, in 
2002, the FDA cleared the MicroLight 830-NM diode laser for treatment of carpal 
tunnel syndrome (FDA laser information, 2009). 
3.8.1 Mechanism of LLLT 
The light applied in laser therapy is usually red or NIR in the range of 600nm to 
1000nm, known as the ‘optical window’, where the effective tissue penetration of light 
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is maximised, with a power density of between 1mW-5W/cm2. In spite of its increasing 
use and application since discovery, LLLT as a therapeutic tool has been dogged by 
controversies because of its yet-to-be-understood biochemical mechanisms, making its 
application essentially empirical; also because of its lack of flexibility in terms of usage, 
since the following factors have to be chosen for each treatment: wavelength, fluence, 
power density, pulse structure, and timing of the applied light, a failure of which might 
affect the efficacy of treatment and possibly produce a negative therapeutic outcome 
(Chung et al., 2012; Huang et al., 2009). 
The exact biochemical mechanisms of the action responsible for the therapeutic effects 
of LLLT are poorly understood in spite of its increasing use. However, there have been 
several attempts to provide an explanation, with many of these proposals suggesting that 
the underlying mechanism of action of LLLT could be at the molecular, cellular, and 
tissue levels. There is consensus, as to the following modes of action, that LLLT 
stimulates the mitochondria to increase adenosine triphosphate (ATP) production and 
regulates the reactive oxygen species (ROS) and the induction of transcription factors 
(Chung et al., 2012; Hashmi et al., 2010; Huang et al., 2009). 
3.8.1.1 Cytochrome c oxidase and nitric oxide release 
The first explanation for LLLT is that it follows the first law of photobiology, which 
states that for low-power visible light to have any effect on a living biological system, 
the photons must be absorbed by electronic absorption bands belonging to some 
molecular photo-acceptors (Figure 3.6). Cytochrome c oxidase (Cox) is believed to be 
the principal photo-acceptor for the red-NIR range in mammalian cells. It has also been 
proposed that the mechanism for LLLT could possibly be by the photo-dissociation of 
nitric oxide (NO) from Cox, thereby enabling cellular respiration which would have 
been switched off by the excessive binding of NO to Cox inside the mitochondria. The 
association between NO and Cox is able to inhibit respiration in cells by totally 
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dislodging oxygen, particularly in stressed or hypoxic cells. LLLT reverses this 
association by the inhibiting oxygen dislodgment and thus stimulates unimpeded 
cellular respiration and increases cellular ATP thereby enhancing cellular energy levels 
and up-regulating the cyclic AMP molecule needed for several signalling pathways 
(Chung et al., 2012; Hawkins and Abrahamse, 2007; Huang et al., 2009).  
 
Figure  3-6 Diagrammatic illustration of the absorption of red and near infrared light (NIR) by 
specific cellular photo-acceptor inside the mitochondrial respiratory chain (Adapted from Huang 
et al., 2009) 
3.8.1.2 Reactive oxygen species and gene transcription 
Another suggested mechanism of action for LLLT is that it induces transcriptional 
changes in cells through the activation of several transcription factors (nuclear factor 
kappa B (NF-κB), p53 and hypoxia-inducible factor (HIF) -1 brought about by changes 
in cellular redox state (Figure 3.7). LLLT is able to stimulate such reaction in cells 
through the boosting of oxygen metabolism leading to the production of ROS, a natural 
by-product and a chemically active molecule that plays an important role in evoking 
cellular signalling, regulation of cell cycle progression, enzyme activation, and nucleic 
acid and protein synthesis (Hashimi et al., 2010; Huang et al., 2009). 
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Figure  3-7 Diagrammatic illustration of reactive oxygen species (ROS) created due to the 
effects of LLLT on mitochondria, which could trigger the redox-sensitive transcription factor 
NF-κB (relA-p50) through protein kinase D (PKD) (Adapted from Huang et al., 2009) 
3.8.1.3 Mitochondrial respiration and ATP 
There is strong evidence to suggest that LLLT acts on the mitochondria to increase ATP 
production. ATP is a form of cellular energy generated by oxidative phosphorylation of 
molecules by the mitochondria. When cells are exposed to a laser, the mitochondria and 
cell membrane traps the photon from the laser in the form of photonic energy, using the 
cytochromes inside the mitochondria. The photonic energy is transformed to chemical 
kinetic energy inside the cell, leading to alterations in membrane permeability as well as 
enhanced signalling between mitochondria, nucleus, and cytosol, thereby resulting in 
intensified oxidative metabolism to produce more ATP. The greater oxidative 
metabolism encourages cell metabolism and activation of signalling pathways necessary 
for significant cell migration, cell mitosis, and cell proliferation, which are required for 
normalisation of cell function, pain relief, and wound healing  (Chuang et al., 2012; 
Hashimi et al., 2010; Huang et al., 2009).  
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3.8.2 Evidence for effectiveness of LLLT in musculoskeletal 
conditions 
Several studies have been published regarding LLLT for musculoskeletal conditions. 
The first clinical trial testing LLLT in musculoskeletal pain to investigate the effects of 
LLLT on rheumatoid arthritis was published in 1980 by Goldman et al. (de Almeida et 
al., 2012; Gur et al., 2004). According to de Bie et al. (1998), the first RCTs were 
published in 1981 by Gallachi et al., who described the effects of laser therapy in the 
treatment of cervical and lumbar pain, and the study conducted by Lewith and Machin 
(1981), who evaluated the effects of infrared stimulation of local trigger points on the 
pain caused by cervical OA. 
Although LLLT has been available for nearly three decades, this modality remains 
controversial (Bjordal et al., 2008). A number of clinical trials have been performed 
with LLLT to treat a variety of musculoskeletal conditions, and they have reported 
positive effects in the treatment of conditions such as in rheumatoid arthritis (Johannsen 
et al., 1994, Juhl,  2006),  fibromyalgia (Gur et al., 2002a;  Gur et al., 2002b; Panton et 
al., 2012), low back pain (Gur et al., 2003b), neck pain (Chow et al., 2006; Gur et al., 
2004), and epicondylitis (Bjordal et al., 2008). Nevertheless, positive results have been 
countered by numerous negative clinical trial results such as in painful musculoskeletal 
pathologies; for example, epicondylitis (Krasheninnikoff et al., 1994), plantar fasciitis 
(Basford, 1998), and myofascial pain (Thorsen et al., 1992). Furthermore, a meta-
analysis conducted by Gam (1993) on the effect of LLLT on musculoskeletal pain 
showed that LLLT has no effect on musculoskeletal pain syndromes. 
Likewise, the clinical efficacy of LLLT in the treatment of KOA is still debatable in 
terms of conflicting results. Many clinical trials have reported signiﬁcant improvement 
(Alfredo et al., 2011; Gur et al., 2003a; Hegedus et al., 2009; Shen et al., 2009; Stelian 
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et al., 1992), whereas others have failed to show such an effect (Bulow et al., 1994; 
Tascioglu et al., 2004; Trelles et al., 1991; Yurtkuran et al., 2007). Brosseau et al. 
(2004) conducted a meta-analysis to determine the effectiveness of laser therapy for OA 
of the hand, knee, and hip. Of the 144 potential articles, 7 studies met the inclusion 
criteria. In those studies, 184 patients were randomised to laser and 161 patients to 
placebo laser. The analysis found no difference between the effects of the laser and the 
placebo on pain. 
Previous conflicting and negative results of published clinical trials regarding LLLT can 
be attributed to several factors and reasons. One of these reasons, the lack of 
standardization and the great variety of research methodologies used in terms of 
dosimetry, such as inadequate or excessive energy delivered, irradiation of an 
insufficient area of the pathology, inappropriate anatomical treatment location, 
treatment timing and repetition, pulsing, polarization, and concurrent patient medication 
(Alfredo et al., 2011; de Paula Eduardo et al., 2010; Hashmi et al., 2010; Huang et al., 
2009). An ideal dose is required to obtain an optimal response, whereas lower dose rates 
present no significant results, and high dose rates present inhibitory effects; the effect of 
LLLT is dose dependent (Almeida-Lopes et al., 2001; Bjordal et al., 2008). Another 
reason is that the mechanisms of action of LLLT found at the molecular, cellular, and 
tissue levels remain uncertain (Hashmi et al., 2010). Furthermore, lack of proper 
scientific training by the authors and lack of knowledge of photobiology could be 
another reason for conflicted results of published clinical trials regarding LLLT (Smith 
2010).  
It has been believed that LLLT represented by red or NIR light without any thermal 
effect produces the most significant responses in vivo and, consequently, is the best in 
terms of its photo-biological response (Rojas and Gonzalez-Lima, 2011). The main 
reason for using the red and NIR spectral region is the fact that haemoglobin, as photo-
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acceptor or chromophore, does not absorb in this region, and light can penetrate deep 
into living tissue. Despite the wide use of LLLT in clinical practice and research and 
despite the fact that various mechanisms of its effect have been proposed, its mechanism 
remains not fully understood (Fukuda et al., 2011; Gao and Xing 2009; Zhang et al., 
2009). 
At the cell membrane of target cells, light photons are absorbed by photo-acceptors, 
where photonic energy is converted to chemical energy within the cell. Mitochondrial 
respiratory chain components are thought to be the principal photoreceptors of red and 
NIR light, and they play an important role in energy generation and metabolism (Gao 
and Xing, 2009; Hashmi et al., 2010; Huang et al., 2009). When photons are absorbed 
by the mitochondria; they stimulate more ATP and ROS and increase ribonucleic acid 
(RNA), protein synthesis, reactive intracellular calcium and release of nitric oxide (NO) 
(Al Ghamdi et al., 2011; Gao and Xing 2009; Hashmi et al., 2010; Huang et al., 2009; 
Rojas and Gonzalez-Lima 2011). As a result of these reactions, the application of LLLT 
produces analgesic and anti-inﬂammatory effects and stimulates healing and the 
enhancing of ﬁbroblasts and bone cells (de Andrade et al., 2012).  
When human soft-tissue is injured or traumatized, it releases chemical mediators, 
including prostaglandins, serotonin, histamine, substance P, and other inflammatory 
chemicals, which ultimately promote pain (Lee et al., 2011). Although LLLT is 
clinically used to relieve pain, the mechanism by which it reduces pain is still not clear. 
Pain relief can occur as an inhibition of nociceptive signals at the peripheral nerves 
or/and as a result of anti-inflammatory, collagen proliferation, and circulation 
enhancement resulting from exposure to LLLT (Bjordal et al., 2006; Gur et al., 2004 
Tascioglu et al., 2012). Increase in ATP production as well as enhanced redox systems 
of the cell as a result of treating by LLLT have been shown to restore neuronal 
membranes and decrease pain transmission (de Paula Eduardo et al., 2010). It has also 
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been demonstrated that LLLT induces analgesia by modulating inhibition of  
cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2), modulating nerve 
transmission and increasing endorphin and serotonin release (Abrisham et al., 2011; 
Fulop et al., 2010).  
The anti-inflammatory effect of LLLT has been found in laboratory tests through the 
reduction of PGE2 and inhibition of COX-2 (Bjordal et al., 2006; Sakurai et al., 2000). 
Suppression of the activity of COX-2 enzyme reduces oedema formation and 
hyperalgesia (Pallotta et al., 2012). In a review undertaken by Lopes-Martins et al. 
(2007), the authors concluded that LLLT has an anti-inflammatory effect. Pallotta et al. 
(2012) found that LLLT operating at 810 nm markedly reduced the signs of 
inflammation. 
One of the important and interesting effects of using LLLT, is its ability to stimulate 
reparative properties in human cartilage. However, studies on the laser treatment of 
cartilage injury have produced divergent results (da Rosa et al., 2012). It has been 
reported that several in vitro studies have shown that LLLT at certain wavelengths and 
certain combinations may stimulate fibroblast proliferation (de Paula Eduardo et al., 
2010). Young et al. (1989) found that wavelengths from 660 nm to 870 nm encourage 
macrophages to release factors that stimulate ﬁbroblast proliferation, whereas an 880 
nm wavelength inhibits the release of these factors. Nevertheless, da Rosa et al. (2012) 
found in their study on experimental models of OA, an AsGaAl laser with a wavelength 
808 nm proved more effective in the repair of cartilage injury, leading to the stimulation 
of angiogenesis as well as a reduction in inﬂammatory exudate. The action of LLLT 
could have a direct bio-stimulatory effect on ﬁbroblasts and trigger the production of 
collagen (Ng et al., 2004). 
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It has been concluded that LLLT has a positive bio-modulator effect on the healing of 
bone defects and on bone regeneration (Kawasaki and Shimizu, 2000; Luger et al., 
1998; Merli et al., 2005). Several in vivo, in vitro, and clinical trial studies have 
demonstrated the positive effects of photobiostimulation on cell proliferation, increased 
microcirculation, vascular neo-formation, and the stimulation of collagen production by 
ﬁbroblasts and bone repair (de Andrade et al., 2012;  da Rosa et al., 2010). Stein et al. 
(2005) demonstrated that the He-Ne laser (632.8 nm) can promote signiﬁcant 
proliferation and differentiation of human osteoblasts (increasing the accumulation of 
calcium and promote bone repair) in vitro. Gerbi et al. (2008) demonstrated that the 
GaAlAs laser (830 nm) is effective in accelerating the healing process of bone injuries. 
Interestingly, the effect of LLLT and the response of the tissue in vivo are directly 
correlated to stress conditions, and thus it is lacking when applied to healthy tissue 
(Almeida-Lopes et al., 2001).  
3.8.3 Studies examining the efficacy and effect of LLLT  
3.8.3.1 Evidence-based in literature: 
In medicine and healthcare studies, finding and using research results to support 
researchers’ professional decisions is based on the principle of evidence-based medicine 
(EBM) (Makela and Witt, 2005). Sackett et al. (2000) defined EBM as ‘the explicit, 
judicious, and conscientious use of current best evidence from health care research in 
decisions about the care of individuals and populations’. Sackett (1996) proposed a 
standardized system of interpreting medical research, with Level I being the highest 
(prospective, randomised, blinded controlled trials) and Level V being the lowest (case 
reports). In another classification for EBM, presented in Barbier and Hoogmatens 
(2004) review article, the  lowest  level  of  evidence  (level  5) is  the expert opinion, 
whereas the  systematic  review and the  meta-analysis provides the highest (level 1 
   58 
evidence) (Figure 3.8). However, RCT, as in the current study, reaches a 1B level of 
evidence, especially blinded studies. Furthermore, there are many evidence databases 
that have been developed, such as the physiotherapy evidence database (PEDro), which 
was developed specifically for use in physiotherapy as a means of rating the quality of 
published RCTs (PEDro 2013). 
 
Figure  3-8 Level of Evidence Pyramid (adapted from http://gollum.lib.uic.edu/nursing/node/12) 
 
Moreover, consideration of the strengths and weaknesses of a research article is 
important when assessing the usefulness and validity of research findings. Therefore, 
clinicians must be able to select and appraise scientific literature that is relevant to their 
field (Young and Solomon, 2009). According to Young and Solomon (2009), critical 
appraisal has been defined as the ‘. . . application of rules of evidence to a study to 
assess the validity of the data, completeness of reporting, methods and procedures, 
conclusions, compliance with ethical standards, etc. The rules of evidence vary with 
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circumstances’. Finally, for the current study, the quality of included studies were 
assessed according to information and recommendations derived from evidence 
databases such as PEDro and level of evidence pyramid (Figure 3-8), in addition to a 
review done by Young and Solomon (2009), which were all mentioned in the current 
section.  
 
3.8.3.2 Studies examining the efficacy and effect of LLLT in the treatment 
of KOA when applied on APs 
Laser acupuncture or using LLLT as an alternative to metal needles for the stimulation 
of APs or musculoskeletal trigger points has been promoted for almost three decades. 
Recent studies have clearly shown that laser acupuncture can be successfully used as an 
alternative to metal needles for effective AP treatment. Furthermore, LLLT is safer and 
it requires less time than needle AP; with it, patients can avoid the pain and 
psychological fear of traditional AP (Baxter et al., 2008; Lin et al., 2012; Litscher and 
Opitz, 2012).  
In 1979, Zhou, a surgeon in China, used laser acupuncture as a type of controlled 
anaesthetic method for dental indications; the author performed more than 10,000 tooth 
extractions with this laser acupuncture anesthesia. In the western world, it was a 
Canadian, Friedrich Plog, who pointed out the usefulness of laser acupuncture, and 
tested lasers instead of needle acupuncture in 1973 in this context (Litscher and Opitz 
2012). Laser acupuncture is promoted as inherently safer than needle acupuncture and 
as a non-invasive treatment (see chapter 1). APs have been shown to play very 
important roles in acupuncture therapy, where they have lower electrical resistance than 
their surrounding tissues (Liu et al., 2008).  
Baxter et al. (2008) conducted a systematic review to evaluate RCTs used in laser 
acupuncture as a primary intervention. Relevant studies (n = 18) were identified; 9 
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studies were undertaken to investigate the effectiveness of laser acupuncture in the 
treatment of myofascial pain or musculoskeletal trigger points affecting the neck, 
shoulder, and thoracic or lumbar spine. Seven of these studies reported positive 
outcomes in favour of laser acupuncture. However, this systematic review included no 
studies conducted for treating OA. 
During this search via search engines, to find the studies in which LLLT was applied on 
APs, only two published studies were found. One was conducted by Yurtkuran et al. 
(2007), and the other one was a pilot study carried out by Shen et al. (2009).  
Shen et al. (2009) carried out a randomised, single-blind and placebo-controlled trial 
(RSBCT) to assess the efficacy and safety of combined 10.6 μm and 650 nm laser 
irradiation on patients with KOA. Forty patients were randomly assigned, via Excel 
2000 software-generated randomised numbers, either to a laser group or a placebo 
group. The laser group (20 patients, 18 women and 2 men) received a combined active 
laser therapy (semiconductor laser generates an ∼ 0. 65–0.66 μm red light transmitted by 
quartz-glass light fibres with an output power of 36 mW, and a CO2 laser, which 
generates a 10.6 μm light transmitted by a silver halide light fibre with an output power 
of 200 mW and set to pulse with a frequency of 40 Hz, with a single beam 2 mm in 
diameter and non-contacted with the skin, with 2 cm distance and 20 minutes of 
treatment time). Laser irradiation was applied to Dubi or Xiyan (ST35) AP, which is 
located in the depression on the lateral side of the patella and the patellar ligament; for 
more details of this AP see Figure 5.7 and Table 5.2. Participants in the placebo laser 
group received the same procedure, but the laser device was inactivated. Both groups 
were treated 3 times per week, for 4 weeks. The subjects were evaluated at baseline and 
week 2. 
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The primary outcomes of the study were pain, stiffness, and function by WOMAC. The 
4 week assessment could not be analysed because some patients dropped out (2 from 
the active laser group and 11 from the placebo group). Consequently, the authors of the 
study stated that they could not conclude that the positive result of the study was due to 
a therapeutic effect or a placebo effect, as a result of the high dropout rate of the placebo 
group. 
Yurtkuran et al. (2007) conducted a RDBCT to investigate the effects and minimum 
effective dose of laser acupuncture on patients with KOA. Fifty-five patients were 
randomly assigned either to a laser group or a placebo group. Laser group received 
active laser therapy (GaAs infrared laser 904 nm with 10 mW/cm2 power density, 4 mW 
output power, 0.4 cm2 spot size, 0.48 J dose per session, and 120 s treatment time on the 
median side of the knee to the Yinlingquan AP spleen 9 (SP9), which is located on the 
inferior border of the medial condyle of the tibia, in the depression between the 
posterior border of the tibia and the gastrocnemius muscle, for more details of this AP 
see Figure 5.7 and Table 5.2. The placebo group received a placebo laser therapy (0 
J/cm2, red light emitted). Patients in both groups received knee exercise and all 
treatments were applied once a day for 20 minutes, 5 days a week for a total of 2 weeks 
(10 treatment sessions).     
The subjects were evaluated at baseline, after the treatment, and at the 12th week. The 
main outcome measures were WOMAC and VAS to evaluate pain and function, 
Nottingham Health Profile (to evaluate QoL: perceived physical, social, and emotional 
health), 50 foot walking time (patients were asked to walk a standard distance as fast as 
possible, and then the duration was recorded in seconds), KC by standard tape measure 
(cm), medial tenderness score (MTS) by using a pressure algometry, a technique used to 
evaluate pressure pain threshold, the minimal amount of pressure that produces pain, 
where the most painful point was evaluated. The authors of the study concluded that 
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their application of LLLT was effective only in reducing the periarticular swelling when 
compared with the placebo treatment. 
Although the studies by Shen et al. (2009) and Yurtkuran et al. (2007) appear to be 
rigorous, as both were conducted RCBTs (level of evidence IB, according to 5-levels 
EBM (Barbier and Hoogmatens 2004); Shen et al.’s study appears to be less rigorous 
because it was conducted in a single-blind fashion rather than double-blind as in 
Yurtkuran et al. 
Both studies have a strong homogeneity of the subjects due to the rigorous inclusion 
and exclusion criteria; however, this homogeneity could be affected in terms of gender 
distribution (4 men and 36 women in Shen et al. and 2 men and 53 women in Yurtkuran 
et al.), in particular, because the discrepancies between studies still stand in who has a 
higher pain threshold and pain tolerance, women or men (Defrin et al., 2009). The 
consequence of this heterogeneity is that using pain as a main outcome measure for the 
majority of LLLT studies could be affected. Both studies used well-known validated 
and reliable outcome measurement tools; however, Yurtkuran et al.’s study is still more 
rigorous in terms of using a mixture of subjective (e.g. WOMAC and VAS) and 
objective (e.g. 50-foot walking time and MTS) tools, whereas Shen et al. used only 
subjective tools (WOMAC and patients’ global assessment).  
Both studies suffer from limitation because only one AP was irradiated, while in 
acupuncture and other laser acupuncture studies, researchers usually use more APs, as 
will be highlighted in the next chapter. Furthermore, in laser acupuncture trials more 
APs should be added to make the treatment more comparable to clinical acupuncture 
trials. Shen et al.’s study suffers from its short follow-up period (4 weeks), and a high 
dropout rate (13 of 40 participants), especially among participants in the placebo group, 
whereas Yurtkuran et al.’s study has a reasonable follow-up period (12 weeks) and a 
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reasonable sample size (55 participants). However, Shen et al.’s study is a pilot study, 
and the authors reported some of the aforementioned limitations. Likewise, Yurtkuran et 
al. reported that the applied doses were less than the doses recommended by the World 
Association for Laser Therapy (WALT) for musculoskeletal diseases. 
3.8.3.3 Studies examining the efficacy of LLLT in the treatment of KOA 
when applied on different site other than APs 
Several studies have been conducted to investigate the efficacy or the effect of using 
LLLT for treating patients with KOA. These studies are discussed in details in the 
following pages, and are summarized in Table (3.3) below, in order to facilitate 
comparison between them.  
Rayegani et al. (2012) conducted a RDBCT to assess the effects of LLLT on patients 
with KOA and compared LLLT to therapeutic ultrasound. Sixty-two patients were 
selected for the examinations, but only thirty-seven completed the study, patients were 
randomly assigned to receive either LLLT, placebo LLLT or ultrasound. Laser group 
(12 patients: 10 women and 2 men) received active laser therapy (diode laser with 880 
nm) (see Table 3.3), 8 points on the affected knee were irradiated with a total dose of 24 
J/cm2 per session; irradiation was done in contact with the skin). The placebo group (13 
patients: 12 women and 1 man) was treated with an ineffective laser probe (power 0 
mw) and with the same method. The ultrasound group (12 patients: 11 women and 1 
man) received ultrasound (given in a pulsed method, 1 MHz, with a dose of 1.5-2 
W/cm2, for 5 minutes per knee). All patients received a common treatment, including 
acetaminophen (up to 2 grams per day) and medical advice for lifestyle modification 
and exercise. 
All treatments were applied five times a week over a period of two weeks. The subjects 
were evaluated at baseline, 1 month, and 3 months after completing the therapy. The 
main measurements were pain, function, and disability, using VAS and WOMAC. The 
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result of the study showed that LLLT reduces pain, joint stiffness, and disability in 
KOA and is superior to placebo and ultrasound. Furthermore, the positive effects of 
active LLLT still persisted three months after treatment, except for joint stiffness.  
Alfredo et al. (2011) conducted a RDBCT to estimate the effects of LLLT on patients 
with KOA. Forty-six patients were randomly assigned either to a laser group or a 
placebo laser group. Forty patients completed the study, the laser group (20 patients: 15 
women and 5 men) received active laser therapy (GaAs infrared laser 904 nm) over the 
joint line onto five points of the synovial region of the medial side of the knee and in 4 
points at the lateral side, total dose per knee was 27 J per treatment), in addition to 
exercises. The placebo group (20 patients: 16 women and 4 men) received identical 
procedures as did the active laser group but without emission of energy. All treatments 
were applied 3 times per week for 3 weeks following initial assessment (9 treatment 
sessions by laser) and exercises were provided during 8 weeks, with 3 sessions a week,   
and each session lasted 45 minutes.   
The subjects were evaluated at baseline, after laser treatment (3 weeks), and after 11 
weeks following the end of exercise therapy. Main measures were pain via VAS, an 
activity using the WOMAC, functionality using the Lequesne questionnaire, range of 
motion with a universal goniometer, and muscular strength using a dynamometer. The 
authors of the study found a positive effect of LLLT, and they stated that the application 
of LLLT 3 times per week for 3 weeks can assist in the execution of exercises in 
patients with KOA, and that the combination of laser and exercise can improve the pain, 
function, and activities of those patients. 
Hegedus et al. (2009) conducted a RDBCT to investigate the effect of LLLT on pain 
and possible microcirculatory changes in patients with KOA. Thirty-five patients were 
randomly assigned to receive either active or placebo laser. Only 27 patients (22 women 
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and 5 men) completed the study (18 were in the laser group and 9 were in the placebo 
group). Treatments were delivered twice a week over a period of 4 weeks with a 
GaAlAs laser ( 830nm), 8 points at the affected knee were irradiated with a total dose of 
48 J/cm2 per session; irradiation was with contact with the skin). The same machine 
with a placebo probe (power 0.5mW) with the same appearance and display was used in 
the placebo group.  
Outcome measurements were subjective (pain via VAS), semi-objective (pressure 
sensitivity using the Ritchie index (facial expressions), and objective (joint flexion in 
degrees via Domjan-Balint mobimet, KC (cm), and microcirculatory changes via 
thermography by AGA infrared camera). Patients were evaluated at baseline, weekly 
after the second treatment at the same time each week, at 2 weeks and 2 months after 
completing the therapy. The result of the study showed that there was improvement in 
all outcome measures in the active laser group compared to baseline, but not in the 
placebo group. The authors of this study found the positive effect of active LLLT still 
persisted 2 months after treatment. They concluded that LLLT is an effective treatment 
for patients with painful KOA, at least for the short-term.  
Tascioglu et al. (2004) conducted a RSBCT to evaluate the analgesic effect of LLLT in 
patients with KOA. Sixty patients were randomly assigned to three groups, and the 
active laser was a GaAlAs diode laser (Endolaser 476, Enraf Nonius, Netherlands). The 
treatment was applied to five painful points at both sides of the affected knee. Group I 
(20 patients: 14 women and 6 men) received active laser therapy (2 minutes irradiation/ 
per point, dose 3 J/point, total dose per treatment 15 J/ point). Group II (20 patients: 15 
women and 5 men) received active laser therapy (1 minute irradiation/ per point, dose 
1.5 J/ point, total dose per treatment 7.5 J/ point). Group III (20 patients: 13 women and 
7 men) received the same procedures as the active laser groups did, but with an 
inactivated laser beam.  
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 Outcomes measurement tools were WOMAC and VAS. Patients were evaluated at 
baseline, 3 weeks, and 6 months. All treatments were applied once a day, 5 days a week, 
for a total of 10 days. The result of the study showed that no significant statistical 
difference was observed within the groups or between the groups at any time between 
the active laser treatments given at two different dosages and the placebo group at any 
time. 
Gur et al. (2003a) conducted a RDBCT that was designed to evaluate the efficacy of 
infrared LLLT in painful KOA and compared two different laser therapy regimes with 
regards to some parameters, such as power output, stimulation time, and pulsing 
frequency. Ninety patients (72 women and 18 men) were randomly assigned to 3 
treatment groups.  
The laser device used in this study was a GaAs infrared laser (904 nm). The same unit 
was used for the placebo treatment, which emitted no laser beam. The treatment was 
applied to two points at the antero-lateral and antero-medial portals of the affected knee. 
In group I, 30 subjects (25 women and 5 men) received active laser (GaAs infrared 
laser, 5 minutes irradiation, 3 J total energy, and 30 J accumulated dose; i.e. 15 J/point). 
In group II, 30 subjects (23 women and 7 men) received an active laser (2 J total energy, 
and 20 J accumulated dose; i.e. 10 J/point. In Group III, 30 subjects (24 women and 6 
men) received the placebo laser; the laser emitter was similar to the infrared emitter in 
appearance, but it did not emit light. In all groups, patients were given an exercise 
therapy programme over 14 weeks. All patients received a total of 10 treatments with 
active or placebo laser for 2 weeks, and exercise continued for 14 weeks.  
The outcome measurement tools used were VAS, WOMAC, goniometry, duration of 
morning stiffness in minutes, and painless walking distance in meters. Follow-up 
measures were assessed at baseline and at 4, 8, and 12 weeks after the last therapy. The 
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results of the study showed that the different regimes of LLLT which were applied on 
patients with KOA in the study were a safe and effective treatment. Furthermore, the 
authors of the study concluded that signiﬁcant improvements in some outcome 
measures starting from week 10 in the placebo laser group may have arisen from the 
exercise therapy applied rather than the placebo effect. 
Bulow et al. (1994) investigated the effect of LLLT on patients with chronic KOA with 
periarticular tender points by conducting a RDBCT. Twenty-nine patients (24 women 
and 5 men) were randomly assigned to treatment with either laser (14 patients) or 
placebo laser (15 patients). The study was divided into pre-treatment, treatment, post-
treatment periods, of 3 weeks each. Outcome measures were pain via fill in a 
questionnaire form based on the level of pain, palpation tenderness by using a pressure 
of approximately 4 Kg, and isokinetic quadriceps strength via a Kin-COM 
dynamometer.  
The active laser was a GaAlAs infrared laser with a wavelength of 830 nm. Each patient 
participated in the study for 9 weeks. Patients received a total of 9 treatments, which 
were started in weeks 4, 5, and 6 (period 2), each for 15 minutes and applied to 
periarticular tender points, for 2–4 treatments a week. Each tender point received 
between 1 and 3 minutes of irradiation, and the dose varied between 1.5 and 4.5 J each. 
The dose per treatment of active laser was 22.5 J, and the accumulated dose for all 9 
treatment sessions was 202.5 J. 
The result of the study showed that no significant differences were found between the 
two groups with respect to pain and muscle strength. A significant reduction was noted 
in the palpation tenderness in the laser group when it was compared before and after the 
treatment. Within each group, there was a small insignificant change in favour of pain. 
The authors concluded that the overall assessment showed no significant differences 
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between the participants who were treated with the active laser and those who were 
treated with the placebo laser.  
Stelian et al. (1992) investigated the efficacy of LLLT on pain and disability in elderly 
patients with degenerative KOA. The study was designed as a partially RDBCT 
comparing He-Ne red laser with a wavelength of 633 nm, a GaAlAs infrared laser with 
a wavelength of 830nm, and placebo laser light emitters. The study was conducted in a 
partially double-blinded design (double-blinded fashion for infrared and placebo 
emitters but not for the red emitter where light is visible). Fifty patients (34 women and 
16 men) were randomly assigned to 3 groups. Group I (n =15) received red laser), 
Group II (n =18) received infrared laser, and Group III (n =17) received placebo laser, 
which was the same as the infrared emitter in appearance but did not emit light. Each 
patient received 15 minutes of intervention applied at both sides of the knee twice a day 
for 10 days. Every treatment was composed of 7.5 minutes of continuous wave 
application and 7.5 minutes of pulse treatment. The outcome measures were pain level 
and functional disability, which were evaluated by a Short-Form McGill Pain 
questionnaire (SF-MPQ), Present Pain Intensity (PPI) questionnaire, and VAS, 
Disability Index questionnaire (DIQ). The follow-up measures were assessed at baseline 
and on the 10th day of therapy.   
The result of the study showed significant pain reduction and functional improvement in 
the red laser and infrared laser light groups, but not in the placebo laser group, in all 
three pain evaluation methods. The authors of the study concluded that the short-time 
application of LLLT is effective in pain relief and in improvement of functional ability 
in elderly patients with degenerative KOA.  
Trelles et al. (1991) conducted a non-randomised and uncontrolled study to investigate 
the efficacy of LLLT in patients with KOA. Forty patients (24 women and 16 men) 
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were treated by active GaAlAs laser with a wavelength of 830 nm at 4 points around the 
patella, which were irradiated for 60 s each, with the energy density of 18 J/cm2 per 
point, a total of 72 J/cm2 per session, and with light contact technique). Treatment was 
administrated 3 sessions per week for 4 weeks. Radiological changes, pain scores, and 
joint mobility were the outcome measurement tools of the study. Assessments were 
made at the baseline, immediately after last treatment, and at 4 months after the final 
LLLT session. The result of the study showed that 33 patients (82%) reported 
significant improvement of pain and recovery of articular joint mobility. The authors 
concluded that this treatment is a safe, effective, and non-invasive alternative to 
conventional surgical and medical treatment modalities for patients with KOA. 
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Table  3-3 Summary for some related studies examining LLLT for the treatment of KOA  
Study Design Patients 
 (n =) 
Laser type & 
(parameters) 
Endpoint 
assessment 
Mean baseline 
of primary 
outcome (VAS)   
Endpoint mean 
and/or mean 
difference 
between groups; p 
value 
Other 
outcomes 
Result of the end 
point assessment 
(between 
groups) 
Rayegani 
et al. 
(2012) 
RDBCT (n = 62), 
37completed 
(33 F, 4 M) 
Laser parameters:  
Diode 880 nm 
continuous wave 
Power output: 50 mW  
Spot size:  1 mm2 
Dose: 6J point X 8 
points X 10 sessions 
3 months Active group: 
mean= 6.3  
Control group: 
mean= 5.2 
 
 
 
Active group: 
mean= 4.8 
Control group: 
mean= 4.4 
 
 
WOMAC Pain reduced and 
the quality of life 
improved  
Alfredo et 
al. (2011) 
RDBCT (n =46), 
40 completed 
(31 F, 9 M) 
Laser parameters:  
GAAS  904 nm   
Pulsed: 700 Hz 
Power output: 60 mW 
Spot size:  0.5cm2 
Dose: 3J point/  50 s X 9 
points X 10 sessions 
11 weeks Active laser 
group: mean= 
5.32  
Control group: 
mean= 3.54 
 
Active  group: 
mean= 2.58 
Control group: 
mean= 2.30; 
p = 0.120 
WOMAC 
Lequesne 
questionnaire, 
goniometer, 
dynamometer 
(muscular 
strength) 
Pain reduced; 
function  and 
activities 
improved 
Hegedus 
et al. 
(2009) 
 
RDBCT  
(n = 27), 
(22 F, 5 M) 
 
Laser parameters:  
GaAlAs 830 nm  
Continuous wave 
Power output: 50 mW 
Spot size:  0.5cm2 
Dose: 6J point X8 points 
X 8 sessions 
2 months Active group: 
mean= 5.75 
Control group: 
mean= 5.62 
 
Active  group: 
mean= 1.18 
Control group: 
mean= 4.12 
 
Ritchie index 
(pressure 
sensitivity), 
Domjan-Balint 
mobimet 
(ROM), KC, 
AGA infrared 
camera 
Pain reduced and 
microcirculation 
improved 
(microcirculatory 
changes) 
n, patients number; F, female; M, Male;  p, p value  
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Study Design Patients 
(n =) 
Laser type & (parameters) Endpoint 
assessment 
Mean baseline of 
primary outcome 
(VAS)   
Endpoint mean 
and/or mean 
difference between 
groups; p value 
Other outcomes Result of the end 
point assessment 
(between 
groups) 
Shen et al. 
(2009) 
RSBCT (n = 40) 
(36 F, 4 M) 
Laser parameters:  
Combined 10.6 μ m Co2 
and semiconductor 650 
nm  
Power output: 200 mW 
Pulsed: 40 Hz 
Spot size: 2mm 
Dose: not specified – AP ( 
ST35) X 20 mins X 12 
sessions 
2 weeks _ _ WOMAC 
Patients’ global 
assessment; 
assessment of 
adverse effects; 
medication 
usage; masking 
effectiveness 
Pain reduced 
Yurtkuran 
et al. 
(2007) 
 
 
RDBCT 
(n = 55), 
(53 F, 2 M) 
Laser parameters:  GaAs 
904 nm 
Pulsed: 200 nanosecond 
Power output: 4 mW  
Spot size: 0.4 cm2  
Dose: 0.48J point X AP 
(SP9) X 120s X 10 sessions 
12 weeks 
 
Active group: 
mean= 6.47 
Control group: 
mean= 6.06 
 
Active group: 
mean= 5.58 
Control group: 
mean= 4.81; 
p = 0.50 
 
 
WOMAC, 
Nottingham  
Health  Profile  
(NHP), 50-foot 
walking, Medial 
Tenderness 
Score (MTS), KC, 
No significant 
differences 
between groups 
were observed, 
except regarding 
KC. 
 
 
Tascioglu 
et al. 
(2004) 
RSBCT (n =60), 
(42 F and  18M) 
 
Laser parameters:  
GalAlAs 830 nm  
Power output: 50 mW 
Spot size: 1 mm  
Dose: (AcƟve group I): 3J 
point X 5 points X  2 mins 
point X 10 sessions; 
  (AcƟve group II): 1.5J 
point X 1 min point X 10 
sessions; 
(Control group):  placebo 
6 months 
 
Active group I: 
mean= 6.80 
Active group II: 
mean= 6.57 
Control group: 
mean= 6.39 
 
Active group I: 
mean= 6.68 
Active group II: 
mean= 6.18 
Control group: 
mean= 6.20, 
p > 0.05 
 
 
WOMAC Regarding to VAS 
and WOMAC, there 
were no significant 
differences were 
observed between 
groups. 
 
 
n, patients number; F, female; M, Male;  p, p value; _ , VAS was not used in the relevant study. 
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Study Design Patients 
(n =) 
Laser type & (parameters) Endpoint 
assessment 
Mean baseline 
of primary 
outcome (VAS) 
Endpoint mean 
and/or mean 
difference 
between groups; p 
value 
Other outcomes Result of the end 
point assessment 
(between 
groups) 
Gur et al. 
(2003) 
RDBCT (n = 90), 
72 F, 18 M) 
Laser parameters:  GaAs 904 
nm 
Power output: 
Active group I : 10-mW 
average power, 
Active group II : 11.2-mW 
average power 
Spot size: 1-cm2 
Dose: ( Active group I): 3J 
point X 2 points X  5 mins 
point X 10 sessions; 
( Active group II ): 2J point X 3 
min point X 10 sessions; 
(Control group):  placebo 
12 weeks Active group I : 
mean= 7.32 
Active group II: 
mean= 7.44 
Control group : 
mean= 6.74 
 
Active group I : 
mean= 3.58 
Active group II: 
mean= 3.80 
Control group : 
mean= 4.30; 
p > 0.05 
 
  
 
WOMAC, a 
goniometry, 
duration of 
morning stiffness 
in minutes, 
painless walking 
distance in (m). 
Pain reduced and 
the quality of life 
improved. 
 
Bulow et 
al. (1994) 
RDBCT (n =29), 
(24 F, 5 M) 
Laser parameters:  GaAlAs 
830 nm 
Continuous beam 
Power output: 
25 mW 
Spot size: 0.28 cm2 
Dose: 1.5 - 4.5 J point X  5- 
15 points X 1-3 mins 
irradiaƟon X 9 sessions 
9 weeks _ _ Questionnaire 
form based on 
the level of pain, 
palpation 
tenderness by 
using a pressure 
of approximately 
4 kg. 
No significant 
difference was 
observed 
between groups. 
 
 
 
 
 
n, patients number; F, female; M, Male; p, p value; _ , VAS was not used in the relevant study.  
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Study Design Patients 
(n =) 
Laser type & (parameters) Endpoint 
assessment 
Mean baseline 
of primary 
outcome (VAS)   
Endpoint mean 
and/or mean 
difference 
between groups; p 
value 
Other 
outcomes 
Result of the end 
point assessment 
(between groups) 
Stelian 
et al. 
(1992) 
Partially 
RDBCT 
(n = 50), 
(34 F, 16 
M) 
 
Laser parameters:  red laser 
and pulsed near infrared 
laser. 
Continuous & pulsed 
Power output:  
18, 75, 25, and 270 mW 
Spot size: 2 cm2 
Dose: 7.5 mins of 
continuous wave & 7.5 
mins of pulse 
treatment X both sides of 
the knee X 10 sessions 
 
10 days Active group I : 
mean= 6.53 
Active group II : 
mean= 7.16 
Control group: 
mean= 6.23 
 
Active group I: 
mean= 3.33 
Active group II : 
mean= 3.22 
Control group : 
mean= 6.29; 
p < 0.05 
 
 
(SF-MPQ), DIQ, 
PPI  
 
The pain relief 
period was 
significantly longer 
for the two laser 
groups in 
comparison to the 
placebo group. 
 Pain reduced; 
function and 
activities 
improved. 
Trelles 
et al. 
(1991) 
Non 
randomised 
and non-
controlled  
(n =40), 
(24 F and 
16 M) 
Laser parameters:  GaAlAs 
830 nm  
Continuous beam  
Power output:  
 60 mW  
Spot size: 2 cm2 
Dose: 60 s of irradiaƟon X 4 
points X 8 sessions 
4 months _ _ Radiological 
changes, joint 
mobility and KC 
Pain and 
inflammation, 
reduced. 
n, patients number; F, female; M, Male; p, p value; -, VAS was not used in the relevant study. 
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Most of the previous studies discussed herein appear to be rigorous (level of evidence 
IB) in that they were conducted in a strong design RDBCT (Alfredo et al., 2011; Bulow 
et al., 1994; Gur et al., 2003a; Hegedus et al., 2009; Rayegani et al., 2012) except for 
those by Stelian et al. (1992), which was designed as a partially RDBCT; Tascioglu et 
al. (2004), which was conducted in a single blinded fashion; and Trelles et al. (1991), 
which was conducted in a non-randomised and uncontrolled fashion. Although RDBCT 
has been described as a gold standard technique which has been accepted by medicine 
as an objective scientific methodology when ideally performed produces knowledge 
untainted by bias, Relf et al. (2008) reported that the blinding techniques used in 
RDBCT of laser treatment rely on staff cooperation and hence are subject to bias or 
interference and indicate significant deficiencies in the laser trial methodology.  
The majority of the studies have a strong homogeneity of the participants due to their 
rigorous inclusion and exclusion criteria, although this homogeneity could be affected 
in terms of gender distribution. Most of these studies were on a sample of females rather 
with some balance between genders. As mentioned earlier, there are discrepancies with 
regards to pain threshold and pain tolerance between genders which could affect the 
pain measure as a main outcome measure in LLLT studies. All studies used at least one 
validated and reliable measurement tool; however, Alfredo et al. (2011), Hegedus et al. 
(2009), Bulow et al. (1994), and Gur et al. (2003a) used a mixture of subjective and 
objective outcome measurement tools, which made these studies more rigorous than 
others which used only subjective measurement tools, such as VAS and WOMAC (e.g. 
Rayegani et al. 2012 and Tascioglu et al. 2004). Lu et al. (2010) reported that subjective 
assessment tools are influenced by several factors, such as age and mental condition as 
in VAS, and/or influenced by some diseases other than OA, e.g. low back pain, 
depression, and fatigue as in WOMAC. Therefore, objective and precise assessment 
tools are required to fill this gap. 
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In all studies 4–8 points were irradiated at and around the knee joint except in the study 
by Gur et al. (2003a), in which only two points were irradiated, and in Stelian et al. 
(1992) where the laser irradiation was applied on both sides of the affected knee, but at 
no specific points. By using more irradiated points, the authors could add extra strength 
to their studies and make their treatment method more comparable to other similar 
clinical trials, especially those on acupuncture and other LLLT trials for treating KOA. 
Tascioglu et al.’s (2004) study has the longest follow-up period (6 months) among these 
studies, which might makes their results more rigorous. In contrast, Stalin et al. (1992) 
had the shortest follow-up period, which was on the 10th day (i.e. after the last 
treatment session). 
Furthermore, Brosseau et al. (2004) conducted a meta-analysis (level I of evidence) to 
determine the effectiveness of laser therapy for OA of the hand, knee, and hip. Of the 
144 potential articles, 7 studies met the inclusion criteria, and 184 patients were 
randomised to receive laser treatment, and 161 patients were randomised to undergo the 
placebo laser. The analysis found no difference between laser and placebo on pain.  
The main limitation of this systematic meta-analysis is the heterogeneity of the included 
studies, including different dosages, wavelengths, site of application, and types of 
LLLT, and the authors found statistically significant heterogeneity (p < 0.05). 
Nevertheless, it has been reported by the Cochrane Library that this systematic meta-
analysis was withdrawn from the library for two reasons. The first being that ‘comments 
received have suggested the presence of a substantial number of additional trials 
claiming positive results that need to be reviewed, and that, if eligible, could affect the 
conclusions’. The second reason was that ‘some errors made in the extraction of data 
from two trials were pointed out’. According to the Cochrane Library, these errors 
involved only 3 in over 100 figures and we note that replacing our calculations would 
not affect the conclusions of the review’. 
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On the contrary, Bjordal et al. (2003) conducted a systematic review (level 1 of 
evidence) of LLLT with location-specific doses for pain from chronic joint disorders. 
Eleven trials were included that involved 565 patients. LLLT within the suggested 
dosage range was administered to the knee joint in 4 studies. The result of this review 
indicated that LLLT with the suggested dose range significantly reduces pain and 
improves health status in chronic joint disorders in favour of the active LLLT group. 
The authors concluded that more and larger trials are needed to determine the optimal 
treatment procedures for LLLT and possible interaction with other therapies for chronic 
joint disorders.  
As in Brosseau et al. (2004), this review is suffers from some limitations. The weakest 
point of this review is the heterogeneity in treatment procedures within the patient 
sample. The differences in numbers and frequencies of the treatment sessions, dosages, 
wavelengths, site of application and types of LLLT in addition to trial design could 
increase heterogeneity in results. The use of prohibited co-intervention drugs is also a 
factor that could increase the heterogeneity in results. 
Two animal studies were conducted to investigate the effect of LLLT on knee arthritis. 
Pallotta et al. (2012) conducted a RCT to investigate the effect of LLLT (infrared, 810 
nm, 100 mW output power, 0.028 cm2 spot size area, power density of 5 W/cm2, and the 
irradiation was performed with skin contact) in experimentally induced rat knee 
inflammation. Thirty male Wistar rats were used for the study. According to the results 
of the study, the authors concluded that laser radiation could be acting to modulate the 
inflammatory process and possibly stimulating the production of anti-inflammatory 
mediators. 
The second study was conducted by da Rosa et al. (2012) to analyse the inﬂuence of 
LLLT in an experimental model of KOA. Thirty-six male adult Wistar rats were divided 
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into three groups. Group I received InGaAl LLLT (wavelength 660 nm, and 4 points at 
knee joint were irradiated). Group II received GaAlAs LLLT (wavelength 808nm at the 
same points used for group I). Group III received no treatment and served as the control 
group. The results of the study illustrated that the GaAlAs 808 nm laser proved to be 
more effective in the repair of cartilage injury in an experimental model of KOA as a 
consequence of the stimulation of angiogenesis as well as a reduction in inﬂammatory 
exudates. 
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Chapter 4 Review of the literature of 
acupuncture 
 
 
 
 
 
 
   79 
4.1 Background 
Although the history of acupuncture dates back in China for several millennia, it has not 
lost its popularity; instead, it has gained popularity (Cabyoglu et al., 2006). 
Acupuncture is an essential part of Traditional Chinese Medicine (TCM), which 
includes a variety of interventions such as moxibustion (burning herbs), herbal 
prescription, cupping, and Tai Chi exercise. Furthermore, it is among the best known 
forms of complementary and alternative medicine (CAM). Acupuncture is commonly 
practiced as a routine treatment in China, Japan, Korea, and Taiwan and, since the late 
1970s, has gained popularity in the USA and the rest of the western world (Sierpina and 
Frenkel, 2005). The term acupuncture consists of two words from the Latin: acus, or 
needle and puncture or insertion (Cabyoglu et al., 2006). Two different types of 
acupuncture therapy, manual acupuncture (MA) and electro-acupuncture (EA), are 
performed. EA uses an electrical current which is usually TENS (Lin and Chen, 2008). 
Moreover, Staud (2007) stated that APs can be manipulated in several different ways, 
including manual needling, electrical stimulation, heat (moxibustion), pressure 
(acupressure), and laser energy. 
Acupuncture is characterised by the insertion and manipulation of fine, solid, usually 
stainless steel needles (usually 32 to 36 gauge) into selected body locations (APs, n = 
365) along 12 meridians (channels of energy flow) located throughout the body, 
depending on the condition being treated (Sierpina and Frenkel, 2005; De Luigi, 2012). 
Although many references reported that the human body contains 365 APs and 12 
meridians, Liu et al. (2008) stated that there are more than 2000 APs, which are 
nonuniformly distributed on the human body. Whereas, Ahn et al. (2008) cited from 
some previous studies that about 361 points are located on 14 main meridians. APs are 
thought to be linked to each other by meridians and are located at sites that have a high 
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density of neurovascular structures and are generally between or at the edges of muscle 
groups; these sites are less painful than random needle sticks into a muscle group 
(Sierpina and Frenkel 2005).  
 
Figure  4-1 Simple body chart for acupuncture points (adapted from 
http://purenaturalhealing.com/use-acupressure-chart/)  
 
Main meridians are connected to various body organs as well as to each other. They 
serve as pathways for the ﬂow of ‘vital energy’ or Qi. Qi (pronounced ‘Chee’), or life 
energy is a key concept in TCM, and it is considered to be the essential element in the 
healing system. As a consequence, and according to the principle of TCM, imbalances 
in the flow of energy among the meridians, organs, and  five elements (fire, earth, metal, 
water, and wood) are the cause of disease, pain, and susceptibility to illness (Mayer,, 
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2000; Sierpina and Frenkel, 2005; Staud, 2007). Furthermore, pain or ill health happens 
when something occurs to cause meridian energy circulation to be blocked, inserting 
needles at APs unblock these obstructions, allowing energy to flow again (Manheimer 
et al., 2010; Suarez-Almazor et al., 2010).  
4.2 Evidence supporting Efficacy of acupuncture 
Acupuncture is one of the non-pharmacological interventions recommended by EULAR 
for treating KOA (Bjordal et al., 2007). In addition, its use for pain relief is supported 
by clinical trials, which facilitated its acceptance in pain clinics in most countries 
(Lundeberg, 2002). Chronic pain, especially musculoskeletal pain syndrome, is the most 
common reason patients try acupuncture (Kelly, 2009; Vickers et al., 2010). As 
acupuncture is one of the widely used CAM interventions for pain, a survey released in 
2004 by a nationwide study showed that 36% of US adults aged 18 years and over use 
some form of CAM. Furthermore, more than 20% of the UK population uses CAM each 
year, and 47% will try CAM at some point in their lifetime (Staud, 2007).  
According to Vickers et al. (2010), Medline listed over 1100 English language 
randomised trials of acupuncture in June 2010. However, Staud (2007) reported that 
Medline databases showed approximately 12,000 articles relating to acupuncture. A 
large number of systematic reviews on acupuncture for pain have been published, 
where, for example, the Cochrane Library for 2007 listed 12 Cochrane Collaboration 
reviews of acupuncture for pain, with over 50 additional non-Cochrane systematic 
reviews published on this topic (Vickers et al., 2010). Finally, Wang et al., (2013) 
found 3833 articles during their recent PubMed search of ‘acupuncture clinicaltrials’. 
Ezzo et al. (2001), in their systemic review, concluded that the evidence suggests that 
acupuncture may play a role in the treatment of KOA. There is convincing evidence 
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from RCTs of acupuncture in patients with various diseases, such as low back pain 
(Weidenhammer et al., 2007; Thomas et al., 2005; Witt et al., 2006a), neck pain (Witt 
et al., 2006b), shoulder pain (He et al., 2004), fibromyalgia (Martin et al., 2006), 
postoperative pain (Sun et al., 2008), and headache (Coeytaux et al., 2005; Linde et al., 
2009a; Linde et al., 2009b), in addition to many other diseases and complications. 
4.3 Studies examining the efficacy and effect of 
acupuncture in the treatment of KOA 
There are several reviews that were carried out to determine the efficacy of acupuncture 
for the treatment KOA. Cochrane reviews have been done by Lee and Ernst (2011) and 
by Manheimer et al. (2010), for numerous conditions including peripheral joint OA of 
the knee, hip, or hand. Both reviews showed statistically signiﬁcant benefits of 
acupuncture in sham-controlled trials. Kwon et al. (2006) carried out a systematic 
review and meta-analysis of acupuncture for peripheral joint OA, where 14 RCTs out of 
18 focused on KOA. The authors of the study concluded that acupuncture has a 
signiﬁcant effect compared with sham acupuncture, and it seems an option worthy of 
consideration, particularly for KOA.  
Another review was conducted by Selfe and Taylor (2008) to evaluate the effect of both 
needle and EA on KOA. Ten trials with 1456 participants were analysed, which then 
provided evidence that acupuncture is an effective treatment for pain and physical 
function of patients with KOA. A systemic review done by Ezzo et al. (2001) to 
evaluate trials of acupuncture for KOA, and which included 7 trials and 393 subjects, 
indicated that there was strong evidence for pain reduction using acupuncture compared 
with the sham treatment. However, there was insufficient evidence for function in such 
effect. 
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Overall, reviews on the efficacy of acupuncture have been criticised for signiﬁcant 
heterogeneity of acupuncture treatment regimens and inclusion criteria throughout the 
literature, which makes definitive conclusions difficult. Nevertheless, there was 
consistency in the literature that acupuncture shows statistically signiﬁcant benefits for 
pain and function when compared with sham acupuncture for the treatment of OA (De 
Luigi, 2012). 
Acupuncture for the treatment of KOA has been evaluated by several RCTs with a 
variety of treatment and sham acupuncture (Table 4-1). Suarez-Almazor et al. (2010) 
conducted a 3-month RCT in patients with KOA to compare the efficacy of traditional 
acupuncture with sham acupuncture and to examine the effects of acupuncturists’ 
communication styles. Four hundred and fifty-five patients with KOA were randomised 
into 1 of 3 groups (patients on a waiting list, those with high expectations of success by 
acupuncturist, or those with neutral expectations). Xi Yan, He Ding, Gb34, Sp6, Sp9, 
Ear-Knee, and1–2 tender Ashi point proximal to the knee APs were used in traditional 
acupuncture group.  
Primary outcome measures were Joint-Speciﬁc Multidimensional Assessment of Pain 
(J-MAP), WOMAC, and satisfaction scores. Outcome measures were collected at 
baseline, 4 weeks, 6 weeks (end of treatment), and 3 months. The result of the study 
showed that traditional acupuncture was not superior to sham acupuncture, and the 
needling of meridian points was not more effective than the use of sham points. 
Acupuncturists’ communication styles had a small but statistically significant effect on 
pain reduction and satisfaction. 
In a RSBCT carried out to investigate the effect of EA on pain intensity and plasma 
levels of endorphin and cortisol, Ahsin et al. (2009) allocated 84 patients into two 
groups who received either EA or sham acupuncture. St34, St35, St36, Liv8, Sp10, and 
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St44 APs were stimulated. Outcome measures were WOMAC and VAS, which were 
collected on the first day of the treatment session and after ten days of daily treatment. 
The study suggests that EA is effective for relieving pain, stiffness, and functional 
disability with an increase in plasma-endorphin and a decrease in plasma cortisol, by 
comparison with sham acupuncture in patients with primary KOA.  
Taechaarpornkul et al. (2009) conducted a comparative randomised trial to compare the 
effectiveness of 6 and 2 APs in the treatment of KOA using EA. Seventy patients were 
randomised into two groups. The 6-point group received treatment at 6 APs (St35, EX-
LE4, St36, Sp9, SP10 and St34) and the 2- point group received treatment at just the 1st 
pair of points, St35 and EX-LE4. A Thai language version of the WOMAC was a 
primary outcome, and patients were assessed at baseline, week 5, week 9, and week 13. 
Acupuncture at both 6 and 2 acupuncture points was associated with a significant 
improvement; however, there was a non-statistically signiﬁcant improvement in pain in 
subjects who received both 2 and 6 APs. Instead, the authors suggest that EA to two 
local points may be sufficient to treat KOA.  
EA and MA were compared with sham acupuncture in a RCT done by Jubb et al. 
(2008) on patients with KOA. Sixty-eight patients were allocated to two groups, to 
receive acupuncture or sham acupuncture treatment. Li 4, Sp10, Xiyan, Sp9, GB34, St 
36, Liv3, Bl40, and Bl57 APs were chosen for the study. WOMAC, VAS, Euro QoL, 
and plasma β-endorphin were the main outcomes of the study, and they were conducted 
at baseline, after the 10 sessions of the treatment and at 1 month after treatment. The 
primary end point was the change in pain after a course of 10 treatments as measured by 
the WOMAC pain subscale. The result of the study showed that acupuncture is 
significantly superior to non-penetrating sham acupuncture for patients with KOA. The 
authors of the study concluded that skin penetration of the needle is required to gain the 
beneficial effect. 
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A multicentre RCT has been carried out by Foster et al. (2007) to investigate the benefit 
of adding acupuncture to an exercise and advice program for pain reduction in patients 
with KOA in older adults. From 37 NHS physiotherapy centres, 352 patients were 
randomly assigned to three treatment groups. Group 1 received an advice and exercise 
program, while groups two and three received either true acupuncture or non-
penetrating acupuncture on selected acupuncture and trigger points (Sp9, Sp10, St 34, St 
35, St36, Xiyan, Gb34, LI4, TH5, Sp6, Liv3, St44, Ki3, Bi60, and Gb41) in addition to 
the advice and exercise program. WOMAC was the main outcome, and the secondary 
outcomes were functionality, pain intensity, and unpleasantness of pain at 2 weeks, 6 
weeks, 6 months, and 12 months. The results of the study clarified that the addition of 
acupuncture to a course of advice and exercise for KOA provided no additional 
improvement in pain scores.  
Berman et al. (2004) conducted a RCT to determine the efficacy of true acupuncture 
compared with sham acupuncture or education in patients with KOA. Five hundred and 
seventy patients were randomly assigned into three groups. Group1 received true 
acupuncture; group 2 received sham acupuncture; and group 3 received education. 
Patients received 23 true acupuncture sessions over 26 weeks. Controls received six 2-
hour sessions over 12 weeks or 23 sham acupuncture sessions over 26 weeks. Nine APs 
were stimulated at five local points (Gb34, Sp9, St36, St35, Xiyan point) and 4 distal 
points (Ub60, Gb39, Sp6, Ki3). WOMAC was the primary outcome and the secondary 
outcomes were patient global assessment, 6-minute walk distance, and physical health 
scores of the 36-Item Short-Form Health Survey (SF-36). Assessments were conducted 
at baseline and 4, 8, 14, and 26 weeks after randomisation. Although 25% of the 
participants in each of the true and sham acupuncture groups and 43% in the education 
group were not available for analysis at week 26, the authors concluded that 
acupuncture appears to provide improvement in function and pain relief as an adjunctive 
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therapy for KOA when compared with credible sham acupuncture and education control 
groups. 
A RSBCT has been done by Sangdee et al. (2002) to compare the efficacy of EA and 
diclofenac and their combination in the treatment of KOA. One hundred and ninety-
three patients with KOA were randomised into 4 groups: placebo, diclofenac, EA, and 
combined (diclofenac plus EA). VAS, WOMAC, Lequesne’s functional index, 50-feet 
walk time, and the orthopaedist’s and patient’s opinion of change were the outcomes of 
the study. Participants were evaluated at baseline and at the end of the study (week 4). 
The results of the study demonstrated a signiﬁcant improvement of pain and function 
with EA compared with the placebo and diclofenac. 
A prospective controlled trial comparing acupuncture with no treatment in patients with 
advanced KOA awaiting TKR has been conducted by Tillu et al. (2002). Seventy-five 
patients were allocated into two groups. Group A received acupuncture on Sp9, Sp10, 
St34, St36, and Li4 APs at weekly intervals for 6 weeks and group B acted as a control 
group receiving no treatment. The Hospital for Special Surgery score, time to walk 50 
meters, time to climb 20 steps, and degree of pain were assessed. Participants were 
assessed at baseline and at the end of two months. The result of the study showed that 
the acupuncture group improved in all parameters, whereas the control group 
deteriorated. 
Similar to LLLT, acupuncture studies have been criticised for several flaws. Although 
RDBCTs is the gold standard, in studies involving acupuncture, conducting a study in 
which both the researchers and the patients are unaware of the type of the treatment 
used would be virtually impossible. Furthermore, there are difficulties in acupuncture 
study designs because of the variability in recommendation of matching appropriate 
control group, randomisation, needling techniques, AP speciﬁcation, number, and 
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duration of treatment sessions (Ahsin et al., 2009). Foster et al. (2007), by the same 
token, stated that clinical studies of acupuncture have been criticised for small sample 
sizes, inadequate blinding, and lack of credible sham controls and long-term follow-up. 
Moreover, it is difficult to know if the positive effect of EA comes from the electrical 
current or as a result of needle insertion. Furthermore, Qi sensation, which is required 
for a successful acupuncture treatment, is difficult to apply in animal studies. All 
acupuncture studies aforementioned suffer one or more of previously discussed flaws.  
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Table  4-1 Summary for some studies examined acupuncture as a treatment for KOA  
Study Design Partici-
pants 
Intervention and 
Control 
APs Endpoint 
Assessment 
Baseline (Mean 
or Median) of 
primary 
outcome (VAS) 
Endpoint mean 
or Median 
and/or mean or 
Median 
difference 
between 
groups; p value 
Other 
outcomes 
Result of the 
end point 
assessment 
(between 
groups) 
Suarez-
Almazor 
et al. 
(2010) 
RCT 450 Active group: 
acupuncture 
 
Control group : 
Sham acupuncture 
Xi Yan, He 
Ding, GB34, 
Sp6, Sp9, Ear-
Knee 
3 months - 
 
- (J-MAP), 
WOMAC, 
and 
satisfaction 
scores 
Acupuncture 
was not 
superior to 
sham 
acupuncture 
Ahsin et 
al. (2009) 
Single-
blinded, 
sham-
controlled 
study 
84 Active group: 
 EA 
Control group: 
 Sham acupuncture 
ST34, ST35, 
ST36, LIV8, 
SP10, and 
ST44) 
10 days (VAS) 
No values 
available in the 
study 
(VAS) 
No values 
available in the 
study 
WOMAC EA is effective 
for relieving 
pain 
Taechaar
p-ornkul 
et al. 
(2009) 
Acomparative 
randomized 
trial 
70 Active group:  
6 points EA 
 
Control group:  
2 points EA 
ST35, EX-LE4, 
ST36, SP9, 
SP10 and 
ST34 
13 weeks _ _ WOMAC EA to 2 local 
points may be 
sufﬁcient to 
treat KOA 
Foster et 
al. (2007) 
Multicentre 
RCT 
352 Active group I: 
Exercise and advice 
Active group II: true 
acupuncture + 
exercise and advice 
Control group: Sham 
acupuncture + 
exercise and advice 
Sp9, Sp10, St 
34, St35, St 
36, Xiyan, Gb 
34, LI4, TH5, 
Sp6, Liv3, St 
44, Ki3, Bi60, 
and Gb41 
12 months _ _ WOMAC, 
function, 
pain 
intensity, 
and 
unpleasant
ness of pain 
No significant 
difference. 
_, VAS was not used in the relevant study. 
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Study Design Participants Intervention/ 
Control 
APs Endpoint 
Assessment 
Baseline 
(Mean or 
Median) of 
primary 
outcome 
(VAS) 
Endpoint mean or 
Median and/or 
mean or Median 
difference 
between groups; p 
value 
Other 
outcomes 
Result of the 
end point 
assessment 
(between 
groups) 
Berman 
et al. 
(2004) 
RCT 570 Active group: 
acupuncture 
 
Control group: 
Sham 
acupuncture or 
education 
Gb34, Sp9, 
St36, St35, 
Xiyan point, 
Ub60, Gb39, 
Sp6, Ki3 
26 weeks _ _ WOMAC, 
patient global 
assessment, 
6-minute 
walk 
distance, (SF-
36) 
Acupuncture 
seems to 
provide 
improvement 
in function and 
pain relief 
Sangdee 
et al. 
(2002) 
RSBCT 193 Control group: 
Placebo 
Active group I: 
diclofenac 
Active group II: EA 
Active group III: 
combined 
(diclofenac plus 
EA) 
ST35, Medial 
Xiyan,  Liv8 
and a trigger 
point 
4 weeks Mean: 
Control group: 
6.35 
Active group I: 
6.48 
Active group II: 
6.69 
Active group III: 
5.76 
Mean: 
Control group:  
-3.31 
Active group I: -4.90 
Active group II: -5.65 
Active group III:  
 -6.28; 
p < 0.05 
WOMAC, 
Lequesne 
functional 
index, 50-
foot walk 
time 
EA was 
significantly 
more effective 
than placebo 
regarding VAS 
and  Lequesne 
functional 
index 
Tillu et 
al. (2002) 
Prospecti
ve, non-
Randomi
sed CT 
57 Active group: 
acupuncture 
 
Control group: no 
treatment 
Sp9, Sp10, 
St34, St36, Li4  
2 months Median: 
Active group: 
5.1 
Control group: 
5.7 
 
Median: 
Active group: 1.0 
Control group: -0.2; 
p= 0. 0001 
Hospital for 
Special 
Surgery (HSS) 
score, time to 
walk 50m, 
time to climb 
20 steps 
Acupuncture is 
an effective 
treatment for 
KOA 
_, VAS was not used in the relevant study. 
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Chapter 5 Patients and Methods 
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5.1 Patient  recruitment 
The study was carried out at the Physiotherapy Department (PTD) of the Security 
Forces Hospital (SFH) in Riyadh, Saudi Arabia, from August 2010 to March 2011. 
Before the study was started, orthopaedic physicians, family medicine and 
rheumatology clinics were informed about the intention to conduct a study to 
investigate the efficacy of LLLT on patients with KOA. They were asked to refer any 
patient suffering with KOA who met the inclusion criteria of the study. Of a total 107 
patients who were referred to PTD by their physician for the initial assessment, 25 did 
not meet the inclusion criteria; 24 refused to participate; and 9 dropped out after they 
have been randomised, but had not attended the first treatment session including the 
baseline assessment without clear reasons. Eventually 49 patients completed the study. 
Figure 5.1 shows the flow of the study. 
5.2 Inclusion and exclusion criteria of the study 
The inclusion criteria for this study were male or female patients who had KOA 
according to the ACR criteria (Hochberg et al., 1995) (Table 5.1), had an average pain 
intensity of 3 or more on a 10 cm VAS for the last month before baseline assessment, 
had an ability to practise all movements included in the evaluation forms, had the ability 
to read or understand patient information sheets and the ability to sign a consent form. 
Patients with bilateral KOA had the most painful knee assessed. 
Table  5-1 The ACR criteria for KOA 
 
Knee pain and radiographic osteophytes and at least 1 of the following items: 
Age > 50 years   
Morning stiffness  ≤ 30 minutes in duration  
Crepitus on motion  
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Figure  5-1 Flow of the study 
 
The exclusion criteria included patients with previous knee surgery, serious valgus or 
varus deformity, any disease which was informed by the treating physician in the 
referral form and is contraindicated for treating by laser therapy, such as cancer, acute 
diseases, uncontrolled diabetes mellitus, and untreated hypertension; and finally, 
patients already on treatment with drugs that could interfere with the intensity of pain 
for more than six weeks, particularly steroids, were excluded and directed to continue 
with their medication (Gur et al., 2003; Yurtkuran et al., 2007). Patients were allowed 
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to take only analgesics as required for severe pain, due to ethical reasons, and to stop 
any other medication related to their knee pain; their physicians were consulted about 
this point. A patient information sheet (Appendix II) was read, and written informed 
consent form (Appendix III) was signed by each participant prior to participation in the 
study. 
5.3 Ethical approval and data base registration 
The Research Committee of SFH in Riyadh, Saudi Arabia, granted ethical approval for 
all procedures of this study before starting the clinical trial (Appendix IV). Furthermore, 
the current study has been registered in the following database: 
ISRCTN24010862; Doi 10.1186/ISRCTN24010862. 
5.4 Study design 
It has been reported that the most robust design should be chosen, especially in 
healthcare, in order to minimise potential bias and maximise generalisability (Eccles et 
al., 2003). Ohshiro et al. (1994) suggested some critical considerations that should be 
taken into account when conducting a study to investigate the effect of LLLT on pain. 
They stated that trials should be double-blinded and use an inactive laser as a placebo. 
Furthermore, Campbell et al. (2007) stated that it has been reported that the UK 
Medical Research Council (MRC) considers that RCTs are the “most scientifically 
rigorous, unbiased way of comparing alternative healthcare interventions”. Moreover, it 
has been reported that RCTs have been considered as the gold standard method for 
evaluation of drugs, devices, and procedures (Boutron et al., 2008).  
It is important that alternative treatments such as LLLT be subject to rigorous scientific 
study to establish that they are safe, genuine, and efficacious interventions. Moher et al. 
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(2010) reported that, in healthcare, well designed RCTs provide the most reliable 
evidence on the efficacy of interventions, unlike poorly designed studies, which are 
usually associated with biased results.  
The current study was performed using a RDBCT design to investigate the efficacy of 
LLLT on patients with KOA. It is important here to differentiate between the efficacy 
and effectiveness of intervention. According to Revicki and Frank (1999), the efficacy 
can be defined as the performance of an intervention under ideal and controlled 
circumstances, whereas effectiveness refers to its performance under ‘real-world’ 
conditions. 
Furthermore, the current study was conducted based on the Consolidated Standards of 
Reporting Trials (CONSORT) statement (Appendix V). The CONSORT statement has 
been developed by a group of scientists, epidemiologists and editors in order to improve 
the quality of reporting of RCTs. It was first published by Begg et al. (1996) and further 
meetings of the group led to the publication of the revised CONSORT statement 2001. 
Several versions of CONSORT have been updated after that (Boutron et al., 2008; 
Moher et al., 2010; Nelson and Mathiowetz, 2004).  
5.4.1 Randomisation  
Adequate randomisation reduces selection bias at study entry and is the crucial 
component of high-quality RCT studies (Moher et al., 2010). In the current study, 58 
patients were randomly assigned to one of the two study groups, the active laser group 
(n = 30) or the placebo laser group (n = 28), using software-generated randomised 
numbers; the randomisation depended on random blocks of 10 (Dallal, 2010). Appendix 
VI shows the randomisation table. 
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5.4.2 Blinding  
Blinding is an important component to the study quality. To ensure that the current 
study was conducted in a double-blind fashion, both the investigator and the patient 
were unaware of whether placebo or active treatment were utilised, and only the 
research assistant had the identifying code to determine which treatment was given 
(Figure 5.2).  
 
Figure  5-2 Blinding technique, only the research assistant determines the code of the treatment. 
 
Moreover, the laser device was placed behind both the patient and the investigator, and 
it was covered by a hard cover paper. The same laser device was used for both groups. 
The placebo emitter is identical in appearance to the active emitter, but it is inactive 
(both produce red light); no heat, sound, or vibration is detectable from either the active 
or the placebo laser. 
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5.5 Measurement tools  
Prior to the current study being conducted, the expectations were that most participants 
might be elderly patients who had low levels of education, so, valid, reliable, and simple 
measurement tools have been used to meet older patient’s capabilities.  According to 
Herr and Garand (2001), it has been reported that patients’ self-report is the most 
accurate, reliable, and well-established tool for measuring the existence of pain and its 
intensity, furthermore, a few adaptations could be applied when measuring pain with 
standard scales to meet the older person’s capabilities. In the current study, the average 
age of participants was 54 years, their mother language was Arabic language, and 61% 
of them were uneducated. For the previously mentioned reasons, an adapted Arabic 
language VAS was used in the current study (Appendix VII). Furthermore, the current 
study was conducted in Saudi Arabia, and it was applied to Saudi patients, therefore, the 
SKFS was used taking into account cultural characteristics (Appendix VIII). 
The outcome measures were the level of pain, QoL, ROM, KC, and patient satisfaction. 
The tools used to assess the outcomes were the adapted VAS (in Arabic language), the 
SKFS (total) (Appendix VIII), goniometry, a tape measure, and the percentage 
assessment of patient satisfaction (%), respectively; more details about these 
measurement tools are presented in sections 5.5.1 to 5.5.5. In the current study, all 
patients were tested by the same assessor, and they were assessed at baseline, at the 5th 
session of treatment, at the last session of treatment and at 6 weeks and 6 months after 
the last treatment session.  
5.5.1 VAS 
The primary outcome of the current study was the change in the VAS score for pain 
during movement. The VAS is the most frequently used measure of pain in clinical and 
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research settings, especially where changes in symptoms are to be recorded (Ahsin et 
al., 2009; Katz and Melzack, 1999). The VAS has been shown to be a reliable and valid 
measure of pain, and it only gives information about the intensity of the pain (Katz and 
Melzack, 1999; Pritchard, 2010). However, the VAS has been criticised because of its 
unidimensional measures, which have scaling difficulties and possible lack of 
sensitivity. In addition, the information that is provided by these scales is limited to only 
the intensity of the pain and it cannot be used to assess variations in the type of pain, 
such as burning, piercing etc. (Martinez et al., 2011). 
Furthermore, small changes in the VAS may have statistical signiﬁcance, without 
clinical meaning (Lee et al., 2003). It has been reported that failure to use the VAS 
correctly has been attributed to a variety of factors including educational level. In the 
current study, adapted Arabic language VAS was used, which consists of a 10 cm line 
anchored at each end. The right-hand anchor reads ‘no pain’ and left-hand anchor reads, 
‘worst possible pain’. The patient is asked to mark on this line how much pain is being 
experienced. The score is read in centimetres, from 0 –10 cm. 
5.5.2 SKFS 
The changes in the SKFS scores for pain, stiffness, and physical function and social and 
emotional functions were used. The SKFS contains activities especially related to 
Arabic and Muslim societies, which are not present in other commonly used indices, 
such as WOMAC index, which is widely and commonly used in similar studies. People 
in Saudi Arabia and many other Arabic and Islamic countries bend their knees 
extensively during several activities, such as during prayer (minimum  five times daily) 
(Figure 5.3), sitting on the ground during meals, at social gatherings (Figure 5.4) and 
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also for the toilet (Arabic squat style toilet) (Figure 5.5). These activities are included as 
items in the SKFS. 
 
Figure  5-3 Prayer positions (adapted from, http://www.exoticindiaart.com/article/islam/) 
 
SKFS is a reliable and valid scale, which was developed by Al-Sobayel (1997), in her 
study (Construction and Validation of the Saudi Knee Function Scale). Her study was 
submitted to the School of Rehabilitation Therapy, Queen’s University, Canada, in 
August 1997. The reason for her study was that studies of disability evaluation and 
outcome measurement of the KOA in Saudi Arabia were not available. Therefore, her 
study has contributed to filling this gap and providing information on the effect of this 
disease on Saudi people. 
 
Figure  5-4 Sitting on the ground during meals and at social gatherings 
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Figure  5-5 Arabic squat style toilet (http://johnnyvagabond.com/featured/how-to-use-a-squat-
toilet-in-5-easy-steps/) 
The SKFS index is an Arabic language validated, multidimensional, and self-
administrated questionnaire, used to assess pain, stiffness, and physical function, social 
and emotional activities for KOA (Appendix VIII). SKFS consists of a 5-dimensional 
measure of pain, stiffness, physical function, social function, and emotional function. 
The pain subscale includes 8 questions about pain, the stiffness subscale includes two 
questions about stiffness, the physical function subscale (PF subscale) includes 12 
questions about the degree of difficulty when practising specific activities, the social 
function subscale includes three questions about social activities, and finally, the 
emotional function subscale includes three questions about feelings because of knee. 
For more details see Appendix (VIII). 
Each of the 28 questions in the SKFS is graded on a 5-point Likert scale ranging from 0 
(no symptoms) to 4 (maximum symptoms). In the SKFS, the maximum total score 
possible is (112), which is calculated by the addition of the five sections (pain = 32 
maximum score; stiffness = 8 maximum score; physical function = 48 maximum score; 
social function = 12 maximum score; and emotional function = 12 maximum score) of 
this scale, indicating the worst suffering possible, and the minimum score is zero (0), 
indicating the absence of suffering.   
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5.5.3 Goniometry 
Measuring joint mobility could be used as a tool to assess disease severity and to 
document recovery after various interventions (Cleffken et al., 2007; Naylor, 2011). 
Even though a variety of instruments for measuring joint mobility have been developed, 
ranging from simple visual estimation to high-speed cinematography, the universal 
goniometer (full-circle manual goniometer) is still a crucial instrument that is used 
extensively for measuring knee ROM in orthopaedic and rehabilitation practice (Bennett 
et al., 2009; Miner et al., 2003; Naylor et al., 2011; Santos et al., 2012). It has been 
reported by Gogia et al. (1987) that goniometric measurements of the knee joint are 
both reliable and valid. However, Naylor et al. (2011) stated that the validity and 
reliability of goniometers are critical to note. Whereas, Watkins et al. (1991) reported 
that goniometric measurements for passive ROM are highly reliable when taken by the 
same therapist. Standard plastic two-arm 360° goniometer, with 30-cm movable arms, 
and a scale in 1° increments was used in the present study. The specific procedure 
adopted in this study is carefully described in section 5.8.1.5, with a description of the 
tools and practical steps.  
5.5.4 Tape measure  
One of the common symptoms associated with patients with OA is joint effusion (Cho 
et al., 2011; Majima et al., 2012). Joint effusion is an excessive accumulation of fluid 
within the joint capsule (Sturgill et al., 2009). An ordinal tape measure is the frequently 
used instrument in the assessment of effusion of the knee joint, in order to monitor and 
guide rehabilitation (Jakobsen et al., 2010). The ordinal tape measure is simple, cheap, 
fast, and easy to apply, and it is a readily available instrument to measure joint 
circumference (Nicholas et al., 1976; Sturgill et al., 2009). Furthermore, the reliability 
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of this instrument was reported to be excellent (Holm et al., 2010). In the current study, 
a non-adhesive ordinal tape measure of total length 152 centimetres was used to 
measure KC. An illustration of the tape used and the specific practical procedure is 
presented in Sectioin 5.8.1.6. 
5.5.5 Patient satisfaction (%) 
There are many outcome instruments available and used in clinical trials to assess how a 
patient feels. Patient-reported outcome, QoL, health status, psychometric, and patient 
satisfaction are examples of these instruments (Scoggins and Patrick, 2009). Patient 
satisfaction in the current study focuses on the patient’s satisfaction about the benefits 
they have had from treatment and not about the quality and type of health care services 
received. For the current study, the patient satisfaction assessment procedure is 
presented in detail on page 98, Section 5.8.1.7.  
5.6 Laser device and its parameters 
The laser device used in this study was a gallium-aluminium-arsenide (GaAlAs) 
(Endolaser 476, Enraf Nonius, Botterdam, Netherlands) with a single 30 mW diode 
probe, infrared-producing laser with a wavelength of 830 nm and an irradiation area 
0.28 cm2 (Figure 5.6). To ensure that it was working properly, the power of the probe 
was checked prior to the first treatment session of the day, using a beam tester 
incorporated in the equipment itself. For the same reason, the laser device was checked 
by a specialist from the hospital maintenance department before treatment commenced. 
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Figure  5-6 Laser device 
It is well-known that lasers with wavelengths ranging from 600 to 700 nm are used for 
treating superficial tissues, while wavelengths between 780 and 950 nm are used for 
deeper tissues (Chung et al., 2012; Hamblin and Demidova, 2006). Furthermore, laser 
beam from the diode laser, particularly the (GaAlAs, 830nm) has the highest 
penetration rate (Houreld, 2006), as in the red and NIR spectral region, haemoglobin, as 
a photo-acceptor, does not absorb in this region, and light can penetrate deep into living 
tissue. Even more, it has been reported that the GaAlAs laser (830 nm) is effective in 
accelerating the healing process of bone injuries; previous mentioned features together 
support the decision that this type of laser is one of the best to be used in the current 
study.  
5.7 Acupuncture points 
Unlike previous laser acupuncture studies for treating KOA that used only one AP, the 
current study used five APs on and around the knee joint that were irradiated by LLLT.  
The five APs used in the current study were selected by the researcher because they are 
frequently used local points for treating KOA by acupuncturists in clinical and research 
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settings (Ahsin et al., 2009; Berman et al., 2004; Foster et al., 2007; Taechaarpornkul et 
al., 2009) (Figure 5.7), and because the intention was to determine the efficacy of LLLT 
when applied to local APs around the affected knee. Furthermore, using more than one 
AP makes the current study more comparable to clinical trials involving conventional 
acupuncture. Table 5.2 shows the location, indication, and action in TCM for each of 
the five APs (Berman et al., 1999; Hecker et al., 2008). 
 
Figure  5-7 Five acupuncture points used in the study 
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Table  5-2 The APs which were irradiated in the study* 
APs Location Indication Action in TCM 
(ST-35) 
Xiyan-Lateral 
With the knee slightly 
flexed, below the patella 
and lateral to the patellar 
tendon. 
Pain, numbness, and 
motor impairment of 
the knee joint. 
Removes obstruction 
from the channel, 
reduces swelling and 
pain, and expels wind, 
dampness, and cold. 
(Ex-LE-4) 
Xiyan-Medial  
 
With the knee slightly 
flexed, below the patella 
and medial to the patellar 
tendon. 
Knee pain, weakness 
of lower extremities. 
Dispels wind-dampness, 
reduces swelling, and 
alleviates pain. 
ST-36 With the knee slightly 
flexed, roughly at the 
level of the lower border 
of the tibial tuberosity. 
Gastric pain, aching 
of the knee joint and 
leg, and emaciation 
due to general 
deficiency. 
Strengthens spleen and 
stomach, regulates the 
circulation of the blood, 
removes dampness, 
dispels exterior 
pathogenic cold, 
regulates the intestine, 
and stabilizes the mind 
and emotions.   
SP-9 On the inferior border of 
the medial condyle of the 
tibia, in the depression 
between the posterior 
border of the tibia and the 
gastrocnemiumuscle.  
Abdominal pain and 
distension, 
diarrhoea, oedema, 
jaundice, dysuria, 
and pain in the knee.  
The most important 
point for removing 
dampness and moisture; 
regulates the urinary 
tract and remove 
obstruction from the 
channel.  
SP-10 With the knee flexed, 
when placing the palm 
onto the patella with the 
thumb slightly spread, it 
lies in the front of the tip 
of the thumb. 
An important 
immune modulating 
point. 
Regulates blood, cools 
blood, circulates blood, 
removes stagnation, 
tonifies   blood, and 
regulates menstruation. 
* (Berman et al., 1999 ;  Hecker et al., 2008) 
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5.8 Procedures  
Once the patient arrived at the PTD with a physician referral, the initial information was 
taken (Screening visit), such as the knee involved, duration of symptoms, pain intensity, 
previous treatment, and other medical factors, to ensure that the patient met the 
inclusion criteria of the study.  Then, if the participant met the inclusion criteria, he or 
she would be informed that there was a study being done to evaluate the efficacy of 
LLLT in the treatment of KOA.  From the beginning, the participants were provided 
with details about the procedures and the purpose of the study, such as participation 
procedures, confidentiality safeguards, attendance requirements, assessment, treatment 
procedures, and any risk from the treatment (Appendix II, patient information sheet). 
All participants were unaware of the hypothesis of the study, and were unaware which 
type of treatment they would receive, to minimise bias from the participants (double-
blinded).  Patients were then given enough time to read the patient information sheet 
and were allowed to ask any related questions.  Each participant was then required to 
sign the informed consent form prior to participation in the study (Appendix III, consent 
form). After that, participating patients were given an appointment to start the study, 
whereas excluded patients were given an appointment with another therapist to be 
treated according to the PTD treatment strategy for these cases. When the participant 
came to his or her appointment at the PTD, baseline data were collected immediately 
prior to the first treatment session. 
5.8.1 Data collection 
5.8.1.1 Demographic information 
Demographic information was taken, such as the patient’s name, age, sex, marital 
status, level of education and occupation, knee involved, duration of symptoms, 
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previous treatment, and other medical factors. Demographic information was recorded 
on special forms previously prepared for this reason (Appendix IX). 
5.8.1.2 Weight, height, and BMI 
Height and weight, were measured using a digital scale (Health-O-meter 500KL Digital 
Medical Scale with Height Rod, capacity of 500 lbs or 227 Kg) (Figure 5.8). Each 
participant was instructed to remove shoes and any jacket or other heavy garment and 
then stand on the scale, and then readings were recorded pro-forma. Height and weight 
were measured, and BMI was calculated at the baseline only. 
 
Figure  5-8 Health-O-meter 500KL Digital Medical Scale with Height Rod. 
5.8.1.3 Pain intensity 
VAS was the main outcome tool for the current study. Prior to the first treatment 
session, the modified 10 cm VAS was used to assess the intensity of the pain, while the 
evaluation was conducted at all of the relevant study points, the last one at 6 months. In 
the current study, despite the participants having a variety of educational backgrounds, 
ranging from illiterate to higher education, the same level of illustration (same words 
and same information) was provided by the investigator for each participant to instruct 
them in how to use the VAS in order to prevent any bias.  
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The participant was asked to anchor a short vertical line on the horizontal line 
representing how much pain was being experienced. The consolidated question for all 
participants was as follows: identify how your pain is felt during the past period by 
marking a short vertical line on the horizontal line. The more you move to the left-hand 
side of the scale, the worse your pain is, and the closer you are to the right-hand side of 
the scale, the less pain you are experiencing (mirror image of the western system).  The 
score is read in centimetres (cm), starting from the right (no pain) to the left (worst 
possible pain). Appendix X shows the VAS scores of each participant throughout the 
study. 
5.8.1.4 Quality of life (QoL) 
All participants were asked to complete SKFS on their level of pain, stiffness, physical 
disability, and social and emotional problems associated with the affected knee. Similar 
to the VAS assessment, the QoL evaluation was conducted at the baseline, at the 5th 
treatment session, at the last treatment session, at 6 weeks and 6 months after the last 
treatment session.  
Despite the SKFS being a self-administrated questionnaire, in the current study, because 
61% of the participants were uneducated and some of them were illiterate and could not 
read or write, the SKFS forms were filled out by the investigator himself according to 
each patient’s assessment at the time of the consultation to reduce and keep any bias to a 
minimum. The 28 questions of the SKFS were read for each participant by the 
investigator, and then circles were marked around 0, 1, 2, 3, or 4 according to each 
patient’s assessment and request. Appendices XI and XII show the SKFS (total) and the 
SKFS subscales scores of each participant throughout the study. 
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5.8.1.5 ROM 
The degree of active knee angle flexion was assessed using a standard goniometer. 
Greater trochanter and the lateral epicondyle of the femur and lateral malleolus of the 
fibula were used as landmarks in order to maintain accurate alignment of goniometer at 
each of the measurements. To measure the ROM, each participant was asked to lie in 
the supine position with the affected knee joint clear of clothes. Then, the centre of 
goniometer body was placed on the lateral epicondyle of the participant’s femur, and the 
stationary arm of the goniometer was aligned with the midline of the femur, using the 
greater trochanter for reference. After that, the participant was asked to bend her/his 
knee as much as they could without pain; while the moving arm of the goniometer was 
aligned with the lateral malleolus of the participant. Three measurements were taken 
each time, and the mean of the three measurements was recorded. Finally, the reading 
was recorded on a pro-forma. This process was conducted at the baseline, at the 5th and 
the 9th (last) session, at 6 weeks and at 6 months after the last treatment session. 
5.8.1.6 Knee Circumference (KC) 
KC was  measured  using a  standard  tape  measure  at  the  middle  part  of  the patella 
of the affected knee. The medial malleolus of the fibula was used as the reference mark; 
the same distance from the medial malleolus to the middle part of the patella was 
marked in order to fix the measurement point of the KC assessment at each assessment. 
The measurement was performed directly on the skin from a supine position for each 
participant, and the circumferential measurements were recorded on a pro-forma. 
Similar to the ROM assessment, measurements were taken three times, and the mean of 
the three measurements was recorded. This measurement was conducted at the baseline, 
5th session, last session, and at 6 weeks and 6 months after the last treatment session. 
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5.8.1.7 Satisfaction 
The participants were asked to rate their satisfaction with the intervention received, to 
see if they felt they had gained any benefit. The assessment was performed using a 
verbal numeric scale (0% indicates no improvement or benefit, 100% indicates full 
improvement or benefit; in blocks of 5%). The consolidated question for all participants 
was “Are you satisfied with your treatment? Please, give a percentage ranging from 0% 
(no benefit) to 100% (full benefit)”. The evaluation was conducted at the 5th session, 
the last treatment session, and at 6 weeks and 6 months after the last treatment session. 
5.8.2 Treatment procedure 
A series of 9 treatment sessions was given to each patient over 3 weeks, 3 times a week. 
5.8.2.1 Laser intervention 
To ensure safety, confidentiality, and privacy of participants and others, a separate quiet 
room was used for treatment and data collection procedures. Patients were placed on a 
bed in a comfortable and safe sitting position, using a single electric adjustable bed, 
with the affected knee slightly flexed and supported by a rolled towel (Figure 5.7).  
The five APs were determined by the investigator, who was trained to locate these 
points on healthy patients and volunteers prior to the current study being conducted, 
using anatomical landmarks (Table 5.2). Furthermore, to ensure that the same points 
were treated on each occasion, the same supported rolled towel was used each time, and 
all patients have been advised to keep a circle line that was outlined by the investigator 
around each AP at the first treatment session as much as possible (see Figure 5.7).  
Because the current study was conducted in a double-blind fashion, only the research 
assistant had the identifying code to determine which treatment was given. The laser 
device was operated and programmed by the research assistant prior to each single 
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treatment session depending on the type of intervention: active or placebo treatment. 
Furthermore, the laser device was placed behind the investigator who performed the 
treatment, thus ensuring the blinding process. The same tools, materials and patient 
position were used each time in order to assure consistency in the delivery of the 
intervention. 
The investigator, the research assistant, and the patient wore protective goggles to guard 
their eyes from active laser radiation. On the affected knee, the laser probe was 
sequentially and perpendicularly placed at the five APs, which are the commonly used 
points for treating KOA (Figure 5.7 and Table 5.2). The laser probe was fully contacted 
with the skin with a firm pressure to maximise the irradiation or power density on the 
tissue surfaces (Figure 5.7). For all patients of both groups, the five APs were irradiated 
in the same order (Xiyan-Medial, Xiyan- lateral, ST36, SP10 and then SP9).  
In the active laser group, a continuous laser beam irradiated each point for 40s with a 
dose of 1.2 J/point, 6 joules per session for each patient; this dose is somewhat lower 
than that recommended by WALT for Laser Therapy for a 830 nm laser (WALT, 2010). 
The energy density was 4 J/cm2. According to Litscher and Opitz (2012), the Australian 
Medical Acupuncture College recently stated, ‘the optimal energy density for laser 
acupuncture and bio-stimulation, based on current clinical experience, is 4 J/cm2’. 
Furthermore, Huang et al. (2009) indicated that LLLT delivered at low doses may 
produce better results when compared to the same wavelength delivered in high doses. 
Additionally, previous studies showed that LLLT at energy densities up to 4 J/cm2 had 
stimulating effects. Moreover, a study done by Jia and Guo (2004), who compared 
doses ranging from 1 to 6 J/cm2, found a greater proliferation of chondrocytes at doses 
of 4–6 J/cm2. According to Azevedo et al. (2006), energy density of 2–4 J/cm2 has 
shown to be most effective at improving cell growth. These reasons, together with the 
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previously discussed parameters, have been used in the current study in order to 
stimulate APs.  
The same procedures were applied to patients in the placebo group, but this time the 
device was inactivated, only producing the visible red light. Note that the laser probe 
contains start/stop icon, where the start icon was pressed by the investigator for starting 
the treatment for 40 s, using a stop watch, the icon is pressed again to stop the treatment 
for the first AP, and then this process was applied again with the remaining APs, 
sequentially. The procedure allows the investigator to provide the treatment with no 
need to look at the device’s screens, which ensures that the treatment was done in a 
blinded fashion. The stop watch used in the current study was sufficiently accurate in 
determining the length of treatment, because it was compatible with the laser machine 
timer, which was tested prior the trial being conducted. 
5.8.2.2 Strengthening exercise 
According to Pendleton et al. (2000), these exercises directed towards increasing the 
strength of the quadriceps and/or preserving the normal mobility of the knee should be 
strongly recommended. In the current study, in both groups, patients were given an 
exercise therapy programme, with exercises to perform after each session, and advised 
to repeat them at home at least 5 times daily. The exercise program should be tailored to 
the individual patient capacity, taking into account factors such as age and co-morbidity. 
SLR exercise was chosen as the isometric quadriceps exercise. This exercise is easy to 
perform even for elderly patients (Figure 5.9).  
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Figure  5-9 Straight Leg Raises exercise (SLR), one leg is bent, and the other leg is kept as 
straight as possible and tightens muscles on the anterior aspect of thigh. Leg lifts straight 10 
inches off the bed and is held for 10 s, and then it is lowered (Adapted from 
http://www.cpmc.org/learning/documents/rg-tkr-prepare.html) 
 
5.8.2.3 Home instructions and advice  
Patients in both groups were given advice and instructions regarding their problems and 
how they should be dealing and coping with KOA.  Obese or overweight patients were 
advised to lose weight, whereas others were advised to maintain their weight within a 
normal range, and they were advised to eat healthy food. Patients were advised not to 
bend their knees excessively, to wear comfortable shoes, to use aids or support such as a 
walking stick if necessary, and to avoid heavy activities such as lifting heavy objects 
while climbing stairs. Additionally, all patients were advised to perform their exercise 
gently, slowly, and ideally as often as possible. 
5.9 Statistical analysis 
It has been reported that in data analysis, the choice between parametric and non-
parametric procedures is not easy. However, the parametric test is a more sensitive tool 
for statistical analysis, and there are certain requirements which have to be fulfilled. For 
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instance, data should be normally distributed; data must be of an interval/ratio level of 
measurement and sample size should be large enough. In the event that previous 
requirements cannot be fulfilled in a study or if there is any doubt, then a non-
parametric test should be sought (Hicks 2004; Sim and Wright, 2000).  
In the current study, if the data have fulfilled the parametric test requirements, it will be 
presented as mean (standard deviation (SD)), mean difference, and the confidence 
interval of the mean difference (95% CI). Otherwise, if the data have failed to fulfil the 
parametric test requirements and the non-parametric tests have been used, the data will 
be presented as median, interquartile range (IQR), and median difference (Olsen, 2003; 
WALT, 2006). In the current study, data was analysed using the SPSS (Statistical 
Package for the Social Sciences, Chicago) version 17.0 for Windows and Microsoft 
Excel 2010. The treatment allocation code was broken (un-blinded) after all the 
participants had completed all assessments.  
5.9.1 Sample size  
To estimate the sample size to be collected, a power analysis was done. From previous 
studies, the clinical difference was set to be 3.0 points on VAS (Lee et al., 2003), and 
SD was taken as 3.49, based on a previous study on laser acupuncture in KOA 
(Yurtkuran et al., 2007), with the Type I error rate being 0.05 and the power as 0.8. The 
estimation sample-size calculation indicated that at least 21 participants in each group 
were required (Armitage et al., 2001). Therefore, the number of participants in the 
current study, set at 26 and 23, respectively, in each group, is sufficient.    
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5.9.2 Test for normality    
Prior to the within-group and between-groups analyses, the normality of the data was 
assessed using the Shapiro-Wilk test. The Shapiro-Wilk test has been recommended for 
use with the sample-size less than 50 (Razali and Wah, 2011; Ahad et al., 2011). This 
test gives a value between 0 and 1; the closer the test statistic is to 1, the greater the 
likelihood that the distribution of the data is normal. In the case of p > 0.05, then the 
data can be assumed to be normally distributed. No normality test needs to be applied 
for nominal data (gender, affected knee, level of education, occupation) and ordinal data 
(SKFS (total), SKFS (subscales), and patient satisfaction), because this type of data 
must be analysed by non-parametric tests.  
5.9.3 Test for correlation  
In order to find out if there was a correlation between some variables, the Pearson 
correlation test has been used for numeric data, whereas Spearman's rho correlation test 
was used for non-numeric data. The strength of the correlation was based upon the table 
taken from statistical correlation - http://www.explorable.com/statistical-correlation 
(Table 5.3). However, p-value should be < 0.05 in all cases. 
Table  5-3 Strength of correlation table 
Value of r. Strength of relationship 
-1.0 to -0.5 or 1.0 to 0.5 Strong 
-0.5 to -0.3 or 0.3 to 0.5 Moderate 
-0.3 to -0.1 or 0.1 to 0.3 Weak 
-0.1 to 0.1 None or very weak 
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5.9.4 Baseline data analysis   
It has been reported that definitive conclusions of the study regarding the differences in 
response to the treatment cannot be drawn unless demographic data and initial baseline 
measures are comparable between the two groups of a research study (Thomas and 
Nelson 1990; Portney and Watkins, 2000).  
In the current study, data were compared between groups using different statistical tests 
to determine if there were any statistically significant differences in the baseline 
measures between the two groups. The independent samples t-test was applied for data 
that fulfilled the parametric test requirements, while the Mann-Whitney U test and Chi-
square test were applied for non-normal distributed, ordinal, and nominal data.  
Baseline characteristics, such as gender, affected knee, and level of education, were 
analysed using Chi-square test, and age, height, weight, BMI, VAS, and KC were 
analysed using the independent samples t-test; while, SKFS, ROM and patient 
satisfaction were analysed using the Mann-Whitney U test. In this stage, the differences 
between both groups of the study should be non-significant. Non-significance was 
expressed by a p-value greater than 0.05 (p > 0.05). 
5.9.5 Within-group analysis  
Within-group analyses were conducted to assess changes in the outcome variables 
within each group of the study separately. Where data fulfilled the parametric test 
requirements, the paired Student t-test was applied; otherwise the Wilcoxon signed-rank 
test was used.   
SKFS (total), SKFS subscales (pain, stiffness, PF, SF, and EF), ROM, and patient 
satisfaction were analysed using the Wilcoxon signed-rank test. However VAS and KC 
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were analysed using the paired Student t-test. The significance of the tests was 
expressed by a p-value less than 0.05 (p < 0.05). 
5.9.6 Between-groups analysis 
Between-groups analyses were conducted to assess differences in the outcome variables 
between the active laser group and the placebo laser group. Where data fulfilled the 
parametric requirements, the independent sample t-test was applied; otherwise, the 
Mann-Whitney U test and Chi-square test were applied.  
SKFS (total), SKFS (subtotals), ROM, and patient satisfaction were analysed using the 
Mann-Whitney U test. Nevertheless, VAS and KC were analysed using the independent 
samples t-test. The significance of the tests was expressed by a p-value less than 0.05 (p 
< 0.05). 
5.9.7 Subgroup analyses 
In the current study, analyses were undertaken to investigate if a response to the 
treatment is different across particular groups of patients. The interaction effect between 
subgroup and treatment was tested using Univariate Analysis of Variance (UAV) (see 
Section 6.5.6). 
5.10 Research operator 
The operator of the current study completed his Bachelor degree in Rehabilitation and 
Physiotherapy from King Saud University in Riyadh, Saudi Arabia; and earned a 
Master's degree in Physiotherapy from the University of Manchester, UK. He has 14 
years clinical experience in rehabilitation and physiotherapy. Prior to conducting the 
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current study, the research operator had had training and attended many courses in laser 
and acupuncture therapy. The researcher had the opportunity to learn and practice LLLT 
by attending two LLLT courses (one in London, UK, the other in Riyadh Saudi Arabia 
organized by THOR (http://www.thorlaser.com/courses/) (Appendix XVII). The 
researcher also had the opportunity to learn and practice the location and identification 
of the APs related to this study at a private clinic for acupuncture treatment at Riyadh, 
Saudi Arabia. During his Master’s and PhD study, the research operator had attended 
courses in research methodology and medical statistics. 
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Chapter 6 Results 
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6.1 Introduction  
A total of 107 patients were referred to the PTD for the initial assessment, 25 did not 
meet the inclusion criteria; 24 refused to participate; and subsequently 9 dropped out (4 
from active group and 5 from control group) prior to the start of the first treatment 
session without any reasons given and were completely excluded from the study 
without affecting the minimum required number of subjects per group as per the power 
of study (refer to Section 5.9.1). Hence, a total of 49 patients who met the inclusion 
criteria of the study were included and completed the treatment phase of 9 sessions for 3 
weeks, and the same number completed the follow-up periods. Figure 5-1 displays the 
participants’ flow through the study. All data sought were obtained, and there were no 
missing data points.   
Raw data are presented in Tables 1 and 2, which are presented in Appendix XIII. Tables 
in Appendix XII indicate the gender (F/M) of each subject in both groups of the study, 
along with the age, height, weight, BMI, affected knee, level of education, and 
occupation. Tables in Appendices XIV, XV, and XVI indicate all outcome measurement 
scores of ROM, KC, and patient satisfaction, respectively, for each subject in the both 
groups of the study, from baseline to all follow-up periods. 
6.2 Baseline data 
Of  the  49  participants  in  the  study,  26  were  randomly allocated  into  the  active 
laser  group  (G1),  and  23  into  the  placebo laser  group  (G2). Thirty-one of them 
were women (63%) and 18 were men (37%), with an average age of 54.1 and SD 10.2 
years. Demographic and baseline data from all 49 participants are presented in Table 
6.1. Age, height, weight, BMI, affected knee, level of education, VAS, SKFS, ROM, 
and KC of both groups were compared to investigate if the participants in each group 
originated from the same study population. There were no statistical differences in 
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demographic data and baseline measurements observed between groups. Table 6.2 
shows tests for distribution for numeric data. 
Table  6-1 Demographic data and baseline measurements of both groups 
Characteristics G1 
(n=26) 
G2 
(n=23) 
p-value 
Gender    
 
Female 16 (61.50%) 15 (65.2%) 0.790 ᵃ 
Male 10 (38.50%) 8 (34.8%)  
Age (years), Mean (SD) 52.31 (9.26) 56.13 (11.09) 0.195 ᵇ 
Height (cm), Mean (SD) 157.74 (7.31) 155.45 (6.35) 0.251 ᵇ 
Weight (Kg), Mean (SD) 87.24 (12.37) 84.54 (11.88) 0.441 ᵇ 
Body Mass Index (Kg/ m2), Mean 
(SD) 
37.99 (5.60) 37.07 (5.341) 0.563 ᵇ 
Affected Knee     
 
Left 16 (61.50%) 15 (65.2%) 0.790 ᵃ 
Right 10 (38.50%) 8 (34.8%)  
Level Of Education     
 
Educated 9 (34.6%) 10 (43.5%) 0.830 ᵃ 
Non-educated 17 (65.4%) 13 (56.5%)  
VAS, Mean (SD) 6.39 (1.92) 5.91 (1.78) 0.474 ᵇ 
SKFS,  Median (IQR) 61 (43.50 to 71.25) 60 (49.00 to 70.00) 0.912 ᶜ 
ROM (°),  Median (IQR) 130° (124.50 to 135.75) 130° (128.0 to 135.0) 0.921 ᶜ 
KC (cm), Mean (SD) 43.30 (4.09) 43.15 (4.89) 0.885 ᵇ 
Patient satisfaction (%),  Median 
(IQR)  
35 (20.00 to 50.00) 15 (0.00 to 50.00) - 
G1, active group; G2, control group; Values are mean (SD) (if the data is numeric and normally 
distributed) or Median (IQR) (if the data are nominal or ordinal or is not normally distributed) 
for all variables unless stated to be a number of cases (percentage). SD, standard deviation; IQR, 
interquartile range; no significant difference between groups (p > 0.05); Statistical signiﬁcance 
for the between group comparisons was tested using: a: Chi- square test, b: Independent 
Samples T-test, or c: Mann-Whitney test. 
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Table  6-2 Test for distribution at the baseline (Shapiro-Wilk test) 
 G1 
Sig. 
G2 
Sig. 
Age 0.616 0.016 
Height 0.088 0.365 
BMI 0.332 0.356 
VAS 0.145 0.162 
ROM 0.010 0.002 
KC 0.512 0.128 
G1, active group; G2, control group;  
If the significance of the Shapiro-Wilk Test is > 0.05, the data are normally distributed.  
6.3 Within-group analyses  
Within-group analyses were performed within each group of the study separately in 
order to investigate the efficacy of the treatment based on the change in the outcome 
scores during the course of the study. Changes from baseline versus each follow-up 
period were measured (i.e. baseline versus the 5th  session, baseline versus the 9th  
session, baseline versus the week 6, and finally baseline versus 6 months after the last 
treatment session). 
6.3.1 VAS 
The VAS changes from baseline to each follow-up period were measured. In the active 
laser group and at the 5th session of the treatment, there was a statistically significant 
reduction on the VAS (p < 0.001).  This improvement being statistically (p < 0.001) and 
clinically (≥ 3 scores mean difference) significant at the remaining 3 follow-up points. 
The mean total scores had decreased from 6.39 at baseline to 3.73 at the 5th session 
   122 
assessment, to 3.15 at the 9th session, to 2.96 at week 6 and finally to 3.35 after 6 
months from last treatment sessions. Previous results are presented in Table 6.3; see 
also Figure 6.1. Appendix X shows VAS scores for each participant from baseline to a 6 
month assessment.  
Table  6-3 Changes in the outcomes from baseline over time for both groups with regard 
to VAS 
 Mean (SD) Mean difference (95% CI) p-value a 
G1:    
Baseline 6.39 (1.92)    
 
5 sessions 
 
3.73 (2.12) 
 
2.65 (1.99 to 3.32) 
 
< 0.001* 
 
9 sessions 
 
3.15 (1.74) 
 
3.23 (2.66 to 3.80) ** 
 
< 0.001* 
 
6 weeks 
 
2.96 (1.64) 
 
3.42 (2.72 to 4.12) ** 
 
< 0.001* 
 
6 months 
 
3.35 (1.78) 
 
3.04 (2.15 to 3.93) ** 
 
< 0.001* 
G2:    
Baseline 5.91 (1.78)    
- 
 
5 sessions 
 
4.78 (2.34) 
 
1.13 (0.30 to 1.95) 
 
0.010* 
 
9 sessions 
 
3.78 (2.33) 
 
2.13 (1.27 to 2.98) 
 
< 0.001* 
 
6 weeks 
 
4.28 (1.99) 
 
1.63 (0.79 to 2.46) 
 
0.001* 
 
6 months 
 
5.15 (2.21) 
 
0.76 (-0.17 to 1.69) 
 
0.103 
a Paired Samples test, two-tailed.  
G1, active group; G2, control group; Values are Mean (SD); (95% CI), confidence interval of 
the difference means; All comparisons were done versus the baseline values; *, represents a 
statistical significant difference (p < 0.05); **, represent clinically significant difference. 
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In the control group, statistically significant reduction was observed on the VAS scores 
at the 1st 3 follow-up points (p < 0.05). However, VAS scores of individuals in this 
group seems to have recurred OA symptoms after 6 months of stopping the placebo 
treatment (p = 0.103), with only (0.76) mean difference from the baseline (Table 6.3).  
 
 
Figure  6-1 Change from baseline in mean scores of pain at movement which was measured by 
VAS for both groups 
6.3.2 SKFS (total) 
In the active laser group statistically significant reductions were detected in the SKFS 
scores in the post-treatment periods when compared to baseline for all comparisons (p < 
0.001) (Table 6.4 and Figure 6.2). The median total scores had decreased from 61.00 at 
baseline to 37.00 at the 5th session assessment, to 26.00 at the 9th session, to 30.50 at 
week 6 and finally to 30.50 at 6 months from the last treatment sessions. Although 
scores slightly increased at the last two follow-up point’s assessments, the improvement 
still continued reaching 50%, despite stopping the treatment by LLLT for 6 months 
(Table 6.4).  
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Table  6-4 Changes in outcomes from baseline over time for both groups with regard to 
Saudi knee functional scale (total) 
 
Similar results were found in the control group; statistically significant improvement 
was observed in the SKFS at all follow-up points (p < 0.05) (Table 6.4 and Figure 6.2). 
The median total scores had decreased from 60.00 at baseline to 45.00 at the 5th session 
assessment; to 41.00 at the 9th session; and to 40.00 after 6 weeks. However, at 6 
 Median (IQR) Median difference p-value a 
G1:    
 
Baseline 
 
61.00 (43.50 to 71.25) 
 
- 
 
- 
 
5 sessions 
 
37.00 (19.50 to 53.50) 
 
24.00 
 
< 0.001* 
 
9 sessions 
 
26.00 (13.50 to 43.00) 
 
35.00 
 
< 0.001* 
 
6 weeks 
 
30.50 (12.00 to 43.50) 
 
30.50 
 
< 0.001* 
 
6 months 
 
30.50 (19.00 to 43.25) 
 
30.50 
 
< 0.001* 
G2: 
   
 
Baseline 
 
60.00 (49.00 to 70.00) 
 
- 
 
- 
 
5 sessions 
 
45.00 (38.00 to 54.00) 
 
15.00 
 
0.001* 
 
9 sessions 
 
41.00 (29.00 to 53.00) 
 
19.00 
 
< 0.001* 
 
6 weeks 
 
40.00 (29.00 to 54.00) 
 
20.00 
 
< 0.001* 
 
6 months 
 
51.00 (33.00 to 55.00) 
 
9.00 
 
0.004* 
a Wilcoxon signed-rank test, two-tailed 
G1, active group; G2, control group; Values are Median (IQR); (IQR), interquartile range; All 
comparisons were done versus the baseline values; *, represents a significant difference (p < 
0.05). 
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months from the last treatment sessions, the median total scores had increased again to 
reach 51.00 (Table 6.4). Nevertheless, both groups showed statistically significant 
improvement in the SKFS, and the improvement was greater in the active laser group. 
For example, the improvement of KOA symptoms in the active laser group had reached 
50% at 6 months after the last session of the treatment, whereas, in the placebo laser 
group, the improvement was only 15% for the same period of the assessment. Appendix 
XI shows SKFS scores for each participant from baseline to a 6 month assessment. 
 
 
Figure  6-2 Change from baseline in median scores of SKFS for both groups 
6.3.3 SKFS subscales 
As stated previously (Section 5.5.2), the SKFS index contains five subscales (pain, 
stiffness, physical function, social function, and emotional function). The Wilcoxon 
signed-rank test was used for these analyses. Each follow-up period was analysed 
versus the baseline. In the active group, analysis indicated that there were statistically 
significant improvements (p < 0.05) for all five subscales (Tables 6.5 to 6.9). Similar 
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findings were detected regarding the control group, and the improvements were 
statistically significant for all five subscales (p < 0.05) (Tables 6.5 to 6.9), except with 
regard to the social function subscale at the 5th session and at the 9th session 
assessment period (p > 0.05) (Table 6.8). 
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Table  6-5 Changes in outcomes from baseline over time for both groups with regard to 
SKFS (Pain) subscale. 
 Median(IQR) Median difference p-value a 
G1:    
 
Baseline 
 
17.00 (13.75 to 21.25) 
 
- 
 
- 
 
5 sessions 
 
11.00(6.75 to 14.50) 
 
6.00 
 
< 0.001* 
 
9 sessions 
 
8.00 (4.75 to 12.00) 
 
9.00 
 
< 0.001* 
 
6 weeks 
 
8.50 (4.75 to 13.50) 
 
8.50 
 
< 0.001* 
 
6 months 
 
10. (6.75 to 13.00) 
 
7.00 
 
< 0.001* 
G2: 
   
 
Baseline 
 
17.00 (15.00 to 21.00) 
 
- 
 
- 
 
5 sessions 
 
11.00 (9.00 to16. 00) 
 
6.00 
 
0.001* 
 
9 sessions 
 
10.00 (9.00 to 14.00) 
 
7.00 
 
< 0.001* 
 
6 weeks 
 
13.00 (9.00 to 16.00) 
 
4.00 
 
0.002* 
 
6 months 
 
15.00 (12.00 to 18.00) 
 
2.00 
 
0.040* 
a Wilcoxon signed-rank test, two-tailed. 
G1, active group; G2, control group; Values are Median (IQR); (IQR), interquartile range; pain 
subscale (score 0 to 32); All comparisons were done versus the baseline values; *, represent a 
significant difference (p < 0.05). 
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Table  6-6 Changes in outcomes from baseline over time for both groups with regard to 
SKFS (Stiffness) subscale 
 
 Median (IQR) Median difference p-value a 
G1:    
 
Baseline 
 
5.00 (4.00 to 6.00) 
 
- 
 
- 
 
5 sessions 
 
3.00 (2.00 to 5.25) 
 
2.00 
 
0.001* 
 
9 sessions 
 
2.00 (0.00 to 3.00) 
 
3.00 
 
< 0.001* 
 
6 weeks 
 
2.00 (1.00 to 4.00) 
 
3.00 
 
< 0.001* 
 
6 months 
 
2.00 (1.00 to 4.00) 
 
3.00 
 
< 0.001* 
G2:    
 
Baseline 
 
6.00 (4.00 to 6.00) 
 
- 
 
- 
 
5 sessions 
 
4.00 (1.00 to 6.00) 
 
2.00 
 
0.002* 
 
9 sessions 
 
3.00 (1.00 to 6.00) 
 
3.00 
 
0.001* 
 
6 weeks 
 
4.00 (2.00 to 5.00) 
 
2.00 
 
0.005* 
 
6 months 
 
2.00 (1.00 to 4.00) 
 
4.00 
 
0.001* 
a Wilcoxon signed-rank test, two-tailed 
G1, active group; G2, control group; Values are Median (IQR); (IQR), interquartile range; 
stiffness subscale (score 0 to8); All comparisons were done versus the baseline values; *, 
represents a significant difference (p < 0.05). 
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Table  6-7 Changes in outcomes from baseline over time for both groups with regard to 
SKFS (Physical function) subscale 
 Median (IQR) Median difference p-value a 
G1    
 
Baseline 
 
27.00 (19.75 to 33.50) 
  
 
5 sessions 
 
16.00 (8.75 to 24.25) 
 
11.00 
 
< 0.001* 
 
9 sessions 
 
12.00 (6.75 to 19.00) 
 
15.00 
 
< 0.001* 
 
6 weeks 
 
14.00 (6.75 to 23.00) 
 
13.00 
 
< 0.001* 
 
6 months 
 
13.50 (7.75 to 18.00) 
 
13.50 
 
< 0.001* 
G2    
Baseline 27.00 (21.00 to 30.00)   
 
5 sessions 
 
21.00 (16.00 to 26.00) 
 
6.00 
 
0.003* 
 
9 sessions 
 
19.00 (14.00 to 23.00) 
 
8.00 
 
< 0.001* 
 
6 weeks 
 
19.00 (14.00 to 23.00) 
 
8.00 
 
0.001* 
 
6 months 
 
23.00 (16.00 to 27.00) 
 
4.00 
 
0.028* 
a Wilcoxon signed-rank test, two-tailed. 
G1, active group; G2, control group; Values are Median (IQR); (IQR), interquartile range; 
physical function subscale (score 0 to 48); All comparisons were done versus the baseline 
values; *, represent a significant difference (p < 0.05). 
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 Table  6-8 Changes in outcomes from baseline over time for both groups with regard to 
SKFS (Social functions) subscale 
 
 
 
 Median (IQR) Median difference 
 
p-value a 
G1:    
Baseline 6.00 (0.00 to 8.00) - - 
 
5 sessions 
 
3.00 (0.00 to 6.25) 
 
3.00 
 
0.006* 
 
9 sessions 
 
1.00 (0.00 to 6.00) 
 
5.00 
 
0.001* 
 
6 weeks 
 
0.00 (0.00 to 6.00) 
 
6.00 
 
0.001* 
 
6 months 
 
3.00 (0.75 to 4.25) 
 
3.00 
 
0.011* 
G2:    
 
Baseline 
 
6.00 (4.00 to 8.00) 
 
- 
 
- 
 
5 sessions 
 
5.00 (3.00 to 8.00) 
 
1.00 
 
0.087 
 
9 sessions 
 
3.00 (1.00 to 6.00) 
 
3.00 
 
0.058 
 
6 weeks 
 
3.00 (0.00 to 6.00) 
 
3.00 
 
0.036* 
 
6 months 
 
5.00 (0.00 to 6.00) 
 
1.00 
 
0.019* 
a Wilcoxon signed-rank test, two-tailed. 
G1, active group; G2, control group; Values are Median (IQR); (IQR), interquartile range; 
social subscale (score 0 to 12); All comparisons were done versus the baseline values; *, 
represents a significant difference (p < 0.05). 
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Table  6-9 Changes in outcomes from baseline over time for both groups with regard to  
SKFS (Emotional function) subscale 
 
 
 
 
 
 
 Median (IQR) Median difference p-value a 
G1:    
 
Baseline 
 
6.00 (2.75 to 9.00) 
 
- 
 
- 
 
5 sessions 
 
2.00 (0.00 to 6.00) 
 
4.00 
 
< 0.001* 
 
9 sessions 
 
0.00 (0.00 to 3.25) 
 
6.00 
 
< 0.001* 
 
6 weeks 
 
0.50 (0.00 to 5.00) 
 
5.50 
 
< 0.001* 
 
6 months 
 
2.00 (0.00 to 4.00) 
 
4.00 
 
0.001* 
G2:    
 
Baseline 
 
6.00 (4.00 to 9.00) 
 
- 
 
- 
 
5 sessions 
 
5.00 (0.00 to 6.00) 
1.00 0.006* 
 
9 sessions 
 
0.00 (0.00 to 3.25) 
 
6.00 
 
0.004* 
 
6 weeks 
 
1.00 (0.00 to 6.00) 
 
5.00 
 
< 0.001* 
 
6 months 
 
4.00 (2.00 to 6.00) 
 
2.00 
 
0.003* 
a Wilcoxon signed-rank test, two-tailed. 
G1, active group; G2, control group; Values are Median (IQR); (IQR), interquartile range; 
emotional function subscale (score 0 to 12); All comparisons were done versus the baseline 
values; *, represents a significant difference (p < 0.05). 
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6.3.4 ROM 
Because the data collected for the degree of active knee flexion were not normally 
distributed (Table 6.2), the Wilcoxon signed-rank test was used in the analyses. There 
was a statistically significant improvement with regards to the ROM for individuals in 
the active laser group when the baseline-versus-follow-up periods were compared (p < 
0.05) (Table 6.10). The median total scores had increased with a median difference 
(6.50) at the 5th session assessment; with a median difference (8) at the 9th session; 
with a median difference (7) at 6 weeks after; and finally with a median difference (6) at 
6 months from the last treatment sessions (Table 6.10 and Figure 6.3). That means that 
the ROM of participants remained improved in this group. Appendix XIV shows the 
ROM scores for each patient from baseline to a six month assessment. 
In the control group, statistically significant increases in the ROM were seen at the 1st 
and 2nd follow-up periods, compared to the baseline values (p < 0.05). The median total 
scores had increased with a median difference (2) at the 5th session assessment; with a 
median difference (5) at the 9th session. However, this improvement was regressed at 
week 6 to be not significant (p > 0.05), and it was back to the same level at six months 
after the last treatment session (p > 0.05) (Table 6.10 and Figure 6.3). 
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Table  6-10 Changes in outcomes from baseline over time for both groups with regard to 
ROM. 
 
 Median (IQR) Median difference p-value a 
G1:    
Baseline 130.00 (124.50 to 135.75) - - 
5 sessions 136.50 (132.75 to 140.50) 6.50 <0.001* 
9 sessions 138.00 (131.75 to 144.25) 8.00 <0.001* 
6 weeks 137.00 (130.00 to 140.00) 7.00 0.001* 
6 months 136.00 (134.25 to 140.00) 6.00 <0.001* 
G2:    
Baseline 130.00 (128.00 to 135.00) - - 
5 sessions 132.00 (130.00 to 139.00) 2.00 0.021* 
9 sessions 135.00 (130.00 to 138.00) 5.00 0.029* 
6 weeks 135.00 (125.00 to 140.00) 5.00 0.102 
6 months 130.00 (127.00 to 138.00) 0.00 0.663 
a Wilcoxon signed-rank test, two-tailed. 
G1, active group; G2, control group; Values are Median (IQR); (IQR), interquartile range; All 
comparisons were done versus the baseline values; *, represents a significant difference (p < 
0.05). 
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Figure  6-3 Change from baseline in median scores of ROM for both groups 
6.3.5 KC 
Participants in the active laser group showed no statistically significant improvement (p 
> 0.05) in the KC at any follow-up period when compared with the baseline values 
(Table 6.11 and Figure 6.4). In contrast, participants in the control group showed 
statistically significant improvement at the 9th session assessment and at the 6 month 
assessment (p < 0.05). At the 5th week and 6 week follow-up assessment, there was no 
statistically significant improvement (p > 0.05) (Table 6.11 and Figure 6.4). Appendix 
XV shows KC scores for each patient from baseline to a 6 month assessment. 
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Table  6-11 Changes in outcomes from baseline over time for both groups with regard to 
KC. 
 
 
 Mean (SD) Mean difference (95% CI) p-value a 
G1:    
Baseline 43.34 (4.09)  - 
5 sessions 43.12 (4.16) -0.22 (-0.49 to 0.05) 0.102 
9 sessions 43.06 (4.10) -0.28 (-0.78 to 0.21) 0.254 
6 weeks 43.27 (4.09) -0.06 (-0.49 to 0.35) 0.737 
6 months 43.21 (4.33) -0.13 (-0.64 to 0.39) 0.614 
G2:    
Baseline 43.15 (4.89)  - 
5 sessions 42.78 (4.72) -0.37 (-0.78 to 0.04) 0.074 
9 sessions 42.59 (4.61) -0.57 (-0.91 to 0.23 ) 0.002* 
6 weeks 42.91 (4.79) -0.24 (-0.65 to 0.18 ) 0.241 
6 months 42.51 (4.79) -0.64 (-1.26 to 0.02 ) 0.043* 
a Paired Student T-test, two-tailed. 
G1, active group; G2, control group; Values are Mean (SD); (95% CI), confidence interval of 
the difference means; All comparisons were done versus the baseline values; *, represents a 
significant difference (p < 0.05). 
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Figure  6-4 Change from baseline in median scores of KC for both groups. 
6.3.6 Patient satisfaction  
Patients in both groups of the study were asked to rate their satisfaction with the 
intervention that they received. Patient satisfaction was analysed by comparing the 
value of the 5th session assessment period versus the remaining three follow-up periods. 
In the active laser group, statistically significant differences have been noted at all 
assessment periods (p < 0.05) (Table 6.12 and Figure 6.5). An average patient 
satisfaction of individuals in the active laser group was 36% at the 5th assessment 
period, which increased to 46.50% at the 9th session assessment, 50% at 6 weeks 
assessment, and 53% at 6 months after the last treatment session by active LLLT (Table 
6.12 and Figure 6.5).  
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 Table  6-12 Changes in outcomes from baseline over time for both groups with regard to 
patient satisfaction. 
 
Regarding the control group, the average patient satisfaction was 23% at the 5th 
assessment period, which was increased to 37% at the 9th session assessment (p < 0.05), 
and up to 38% (p < 0.05) at week 6 of the assessment. However, the satisfaction 
decreased to 25% at six months after the last treatment session, and the result became 
statistically non-significant (p > 0.05). For more details, see Table 6.12 and Figure 6.5. 
Appendix XVI shows patient satisfaction scores for each patient from baseline to a 6 
month assessment. 
 
 Median (IQR) Median difference p-value a 
G1:    
5 sessions 35.00 (20.00 to 50.00) - - 
9 sessions 50.00 (23.75 to 65.00) 15.00 0.003* 
6 weeks 47.50 (30.00 to 70.00) 12.50 0.004* 
6 months 50.00 (30.00 to 76.25) 15.00 0.003* 
G2:    
5 sessions 15.00 (00.00 to 50.00) - - 
9 sessions 40.00 (10.00 to 60.00) 25.00 0.001* 
6 weeks 45.00 (15.00 to 50.00) 30.00 0.001* 
6 months 20.00 (10.00 to 30.00) 05.00 0.678 
a Wilcoxon signed-rank test, two-tailed. 
G1, active group; G2, control group; Values are Median (IQR); (IQR), interquartile range; All 
comparisons were done versus the baseline values (5 sessions, assumed to be the baseline); *, 
represents a significant difference (p < 0.05). 
**Table presents percentage satisfaction.  
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Figure  6-5 Change from baseline (5th session) in median scores of patient satisfaction for both 
groups. 
6.4 Between-groups analyses 
Between-groups analyses were performed between the two groups of the study, Group 1 
and Group 2, in order to investigate if there were any statistical differences between the 
two groups. Then, if there were significant differences between them, the superiority of 
the treatment type (active laser or placebo laser) would be investigated. The Mann-
Whitney U test was applied as a non-parametric test for data that failed to fulfil the 
requirements of the parametric test, and the independent samples t-test was applied to 
data that fulfilled the parametric test requirements. As stated previously in this chapter 
(Section 6.2), there was no difference between the two groups in the baseline data with 
regards to all of the baseline outcome measurements. In addition to the baseline 
comparisons, the change in each of the outcome variables at the 5th session, at the 9th 
session, at week 6, and after six months of the last treatment session of both groups was 
compared between groups.  
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6.4.1 VAS 
Comparisons between the mean VAS scores of the two groups are displayed below in 
Table 6.13; the result is expressed as mean (SD) and mean difference (95% CI). 
Statistically significant differences were detected between groups in the VAS after 6 
weeks and after 6 months of the end of treatment (p < 0.05) in favour of the active laser 
group. The between-groups analyses showed no statistically significant difference 
between the two groups in the VAS scores at the 5th session and at the 9th session (p > 
0.05). 
Table  6-13 Changes in the outcomes between both groups with regard to the VAS 
 G1 
Mean (SD) 
G2 
Mean (SD) 
Mean difference  (95% CI) p-value a 
Baseline 6.39 (1.92) 5.91 (1.78) 0.47 (-0.58 to 1.52) 0.372 
5 sessions 3.73 (2.12) 4.78 (2.34) -1.05 (-2.34 to 0.23) 0.106 
9 sessions 3.15 (1.74) 3.78 (2.34) -0.63 (-1.80 to 0.55) 0.287 
6 weeks 2.96 (1.64) 4.28 (1.99) -1.32 (-2.37 to -0.27) 0.014* 
6 months 3.35 (1.78) 5.15 (2.21) -1.80 (-2.95 to -0.66) 0.003* 
a Independent Samples Test, two-tailed.  
G1, active group; G2, control group; Values are Mean (SD); (95% CI), confidence interval of 
the difference means; *, represents a significant difference (p <0.05). 
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6.4.2 SKFS (total) 
Comparison of the two groups showed significant statistical reduction in the SKFS 
scores in the active laser group compared to the placebo laser group at the 9th session (p 
= 0.035). This significant improvement was increased at 6 months after the last 
treatment session (p = 0.006). No significant difference between the two groups was 
noted when comparing the change at the 5th session and at week 6 (p > 0.05) (Table 
6.14). 
Table  6-14 Changes in the outcomes between both groups with regard to the SKFS (total) 
SKFS 
(total) 
G1 
Median (IQR) 
G2 
Median (IQR) 
Median 
difference 
p-value a 
Baseline 61.00 (43.50 to 71.25) 60.00 (49.00 to 70.00) 1.00 0.912 
5 sessions 37.00 (19.50 to 53.50) 45.00 (38.00 to 54.00) -8.00  0.141 
9 sessions 26.00 (13.50 to 43.00) 41.00 (29.00 to 53.00) -15.00  0.035* 
6 weeks 30.50 (12.00 to 43.50) 40.00 (29.00 to 54.00) - 09.50  0.054 
6 months 30.50 (19.00 to 43.25) 51.00 (33.00 to 55.00) - 20.50  0.006* 
a Mann-Whitney U test, two-tailed. 
G1, active group; G2, control group; Values are Median (IQR); (IQR), interquartile range; *, 
represents a significant difference (p <0.05). 
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6.4.3 SKFS subscales 
Comparisons between the median scores of the two groups with respect to subscales of 
the SKFS are displayed below in Tables 6.15–6.19. Comparison of the two groups 
showed a statistically significant difference in the pain subscale favouring the active 
laser group at the week 6 assessment and after 6 months (p < 0.05). Otherwise, no 
statistically significant differences were detected between the two groups for the other 
periods (p > 0.05) (Table 6.15). 
Table  6-15 Changes in the outcomes between both groups with regard to the SKFS  
(Pain) subscale 
SKFS  
(Pain) 
G1 
Median (IQR) 
G2 
Median (IQR) 
Median 
difference 
p-value a 
Baseline 17.00 (13.75 to 21.25) 17.00 (15.00 to 21.00) 0.00 0.794 
5 sessions 11.00 (6.75 to 14.5) 11.00 (9.00 to16. 00) 0.00 0.451 
9 sessions 8.00 (4.75 to 12.00) 10.00 (9.00 to 14.00) -2.00 0.082 
6 weeks 8.50 (4.75 to 13.50) 13.00 (9.00 to 16.00) -4.50 0.035* 
6 months 10.00 (6.75 to 13.00) 15.00 (12.00 to 18.00) -5.00 0.001* 
a  Mann-Whitney U test two-tailed. 
G1, active group; G2, control group; Values are Median (IQR); (IQR), interquartile range; pain 
subscale (score 0 to 32); *, represents a significant difference (p < 0.05). 
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The stiffness subscale between-groups analyses showed statistically significant 
difference favouring the active laser group at the 9th session and at week 6 (p < 0.05); 
all other comparisons for the remaining assessment periods showed no statistical 
significant difference between the groups (p > 0.05) (Table 6.16).  
Table  6-16 Changes in the outcomes between both groups with regard to the SKFS  
(Stiffness) subscale. 
SKFS  
(Stiffness) 
G1 
Median (IQR) 
G2 
Median (IQR) 
Median 
difference 
p-value a 
Baseline 5.00 (4.00 to 6.00) 6.00 (4.00 to 6.00) -1.00 0.792 
5 sessions 3.00 (2.00 to 5.25) 4.00 (1.00 to 6.00) -1.00 0.823 
9 sessions 2.00 (0.00 to 3.00) 3.00 (1.00 to 6.00) -1.00 0.041* 
6 weeks 2.00 (1.00 to 4.00) 4.00 (2.00 to 5.00) -2.00 0.048* 
6 months 2.00 (1.00 to 4.00) 2.00 (1.00 to 4.00) 0.00 0.399 
a  Mann-Whitney U test two-tailed. 
G1, active group; G2, control group; Values are Median (IQR); (IQR), interquartile range; 
stiffness subscale (score 0 to 8); *, represents a significant difference (p < 0.05). 
 
The active laser group showed statistically significant, differences in median scores of 
the physical function subscale were identified between the two groups at the 9th session 
assessment period (p = 0.022). This significant difference continued until the next 
assessment period, week 6, with a slight decrease (p = 0.043). However, this significant 
difference considerably increased after 6 months of the last treatment session (p = 
0.001).  No statistically significant differences between the groups (p > 0.05) were 
found for the rest of the comparison periods (Table 6.17).   
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Table  6-17 Changes in the outcomes between both groups with regard to the SKFS  
(Physical function) subscale. 
SKFS  
(Physical 
function) 
G1 
Median (IQR) 
G2 
Median (IQR) 
Median 
difference 
p-value a 
Baseline 27.00 (19.75 to 33.50) 27.00 (21.00 to 30.00) 0.00 0.817 
5 sessions 16.00 (8.75 to 24.25) 21.00 (16.00 to 26.00) - 5.00 0.111 
9 sessions 12.00 (6.75 to 19.00) 19.00 (14.00 to 23.00) -7.00 0.022* 
6 weeks 14.00 (6.75 to 23.00) 19.00 (14.00 to 23.00) -5.00 0.043* 
6 months 13.50 (7.75 to 18.00) 23.00 (16.00 to 27.00) -9.50 0.001* 
a  Mann-Whitney U test two-tailed. 
G1, active group; G2, control group; Values are Median (IQR); (IQR), interquartile range; 
physical function subscale (score 0 to 48); *, represents a significant difference (p < 0.05). 
 
With respect to social function subscale, the result showed no statistically significant 
difference between the groups at any time during follow-up (p > 0.05); although the 
result came close to being significant at the week-6 assessment period (p = 0.053) 
(Table 6.18). A similar result has been found with regards to the emotional function 
subscale, where no statistically significant difference between the groups was found in 
any of the follow-up assessment periods (p > 0.05) (Table 6.19). 
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Table  6-18 Changes in the outcomes between both groups with regard to the SKFS  
(Social function) subscale. 
SKFS  
(Social 
function) 
G1 
Median (IQR) 
G2 
Median (IQR) 
Median 
difference 
p-value a 
Baseline 6.00 (0.00 to 8.00) 6.00 (4.00 to 8.00) 0.00 0.737 
5 sessions 3.00 (0.00 to 6.25) 5.00 (3.00 to 8.00) -2.00 0.162 
9 sessions 1.00 (0.00 to 6.00) 3.00 (1.00 to 6.00) -2.00 0.086 
6 weeks 0.00 (0.00 to 6.00) 3.00 (0.00 to 6.00) -3.00 0.053 
6 months 3.00 (0.75 to 4.25) 5.00 (0.00 to 6.00) -2.00 0.202 
a  Mann-Whitney U test two-tailed. 
G1, active group; G2, control group; Values are Median (IQR); (IQR), interquartile range; 
social subscale (score 0 to 12); *, represents a significant difference (p < 0.05). 
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Table  6-19 Changes in the outcomes between both groups with regard to the SKFS 
(Emotional function) subscale. 
SKFS  
(Emotional 
function) 
G1 
Median (IQR) 
G2 
Median (IQR) 
Median 
difference 
p-value a 
Baseline 6.00 (2.75 to 9.00) 6.00 (4.00 to 9.00) 0.00 0.784 
5 sessions 6.00 (0.00 to 6.00) 5.00 (0.00 to 6.00) 1.00 0.279 
9 sessions 0.00 (0.00 to 3.25) 2.00 (0.00 to 7.00) -2.00 0.101 
6 weeks 0.50 (0.00 to 5.00) 1.00 (0.00 to 6.00) -0.50 0.681 
6 months 2.00 (0.00 to 4.00) 4.00 (2.00 to 6.00) -2.00 0.164 
a  Mann-Whitney U test two-tailed. 
G1, active group; G2, control group; Values are Median (IQR); (IQR), interquartile range; 
emotional function subscale (score 0 to 12); *, represents a significant difference (p < 0.05). 
6.4.4 ROM 
There was no statistically significant difference between the two groups with regards to 
ROM at all follow-up assessment periods (p > 0.05), except at 6 months after the last 
treatment session which showed statistically significant improvement in favour of the 
active laser group (p < 0.05) (Table 6.20). 
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Table  6-20 Change in the outcomes between groups with regard to ROM. 
 G1 
Median (IQR) 
G2 
Median (IQR) 
Median 
difference 
p-value a 
Baseline 130.00 (124.50 to 135.75) 130.00 (128.00 to 135.00) 0.00 0.848 
5 sessions 136.50 (132.75 to 140.50) 132.00 (130.00 to 139.00) 4.50 0.112 
9 sessions 138.00 (131.75 to 144.25) 135.00 (130.00 to 138.00) 3.00 0.101 
6 weeks 137.00 (130.00 to 140.00) 135.00 (125.00 to 140.00) 2.00 0.308 
6 months 136.00 (134.25 to 140.00) 130.00 (127.00 to 138.00) 6.00 0.019* 
a  Mann-Whitney U test two-tailed. 
G1, active group; G2, control group; Values are Median (IQR); (IQR), interquartile range; *, 
represents a significant difference (p < 0.05). 
6.4.5 KC 
The between-groups analyses showed that there was no statistically significant 
difference (p > 0.05) between the two groups of the study with respect to KC at all 4 
follow-up assessment periods (Table  6.21 and Figure 6.4) . 
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Table  6-21 Changes in the outcomes between both groups with regard to KC 
 G1 
Mean (SD) 
G2 
Mean (SD) 
Mean difference  (95% CI) p-value a 
Baseline 43.34 (4.09) 43.15 (4.89) 0.19 (-2.39 to 2.77) 0.885 
5 sessions 43.12 (4.16) 42.78 (4.72) 0.33 (-2.22 to 2.88) 0.794 
9 sessions 43.06 (4.10) 42.59 (4.61) 0.47 (-2.04 to 2.98) 0.708 
6 weeks 43.27 (4.09) 42.91 (4.79) 0.36 (-2.19 to 2.91) 0.780 
6 months 43.21 (4.33) 42.51 (4.79) 0.70 (-1.91 to 3.33) 0.592 
a Independent t-test, two-tailed. 
G1, active group; G2, control group; Values are Mean (SD); (95% CI), confidence interval of 
the difference means; *, represents a significant difference (p <0.05). 
6.4.6 Patient satisfaction 
After the first 4 sessions, more specifically, at the 5th session assessment period, each 
patient was asked about her/his satisfaction with the benefit they have gained from the 
treatment provided. Comparisons between groups for this period showed statistically 
significant difference between the two groups (p < 0.05) in favour of the active laser 
group (Table 6.22). Although the active laser group showed more consistent increases 
in their satisfaction, the results showed no statistically significant between the two 
groups at the 9th session assessment period and at week 6 of the assessment (p > 0.05). 
However, at six months after the last treatment session, participants in the active laser 
group showed considerably greater satisfaction than those in the placebo laser group did 
(p < 0.001) (Table 6.22). 
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Table  6-22 Changes in the outcomes between both groups with regard to patient 
satisfaction. 
 G1 
Median (IQR) 
G2 
Median (IQR) 
Median 
difference 
p-value a 
5 sessions 35.00 (20.00 to 50.00) 15.00 (00.00 to 50.00) 20.00 0.033* 
9 sessions 50.00 (23.75 to 65.00) 40.00 (10.00 to 60.00) 10.00 0.184 
6 weeks 47.50 (30.00 to 70.00) 45.00 (15.00 to 50.00) 2.50 0.167 
6 months 50.00 (30.00 to 76.25) 20.00 (10.00 to 30.00) 30.00 <0.001* 
a Mann-Whitney U test two-tailed. 
G1, active group; G2, control group; Values are Median (IQR); (IQR), interquartile range; *, 
represents a significant difference (p < 0.05). 
**Table presents percentage satisfaction.  
6.5 Assessment of possible Correlation and 
relationships between variables 
The following section describes the investigation of possible correlations between 
different variables, such as age, BMI, patient satisfaction, ROM, KC, VAS, and SKFS. 
The analysis has been used to assess whether variables had a relationship and if so, to 
quantify the strength of the relationship between variables if required. The Pearson 
correlation test has been used for numeric data, whereas Spearman’s rho correlation test 
was used for non-numeric data. If there is no significant correlation or weak correlation 
between some variables, it is still relevant to test them, the reasons for which will be 
discussed in Chapter 7 (Section 7.3). 
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6.5.1 Correlation between different variables and VAS 
Table 6.23 below shows that there was no significant correlation between any variables 
and the VAS at any time in both groups of the study. 
Table  6-23 Correlation table between age, BMI and VAS for both groups of the study 
 Correlation a Baseline 5 
Sessions 
Last 
Session 
6 
Weeks 
6 
Months 
G1       
Age  r. 0.186 0.125 0.091 0.371 0.196 
 Sig. 0.362 0.542 0.657 0.062 0.338 
BMI r. -0.166 -0.068 0.035 -0.366 -0.139 
 Sig. 0.418 0.742 0.866 0.066 0.498 
G2       
Age  r. 0.017 0.146 0.276 0.244 0.128 
 Sig. 0.937 0.505 0.202 0.261 0.561 
BMI r. 0.261 0.072 -0.078 -0.067 -0.217 
 Sig. 0.229 0.743 0.725 0.76 0.32 
a Pearson correlation test; r, correlation coefficient; Sig., significant; G1, active group; G2, 
control group. 
6.5.2 Correlation between different variables and SKFS 
Table 6.24 below shows that, in the active laser group, there was only a moderate 
significant positive correlation between age and SKFS at the last session assessment 
period. With regard to the control group, there was no significant correlation between 
any variables and the SKFS at any time. 
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Table  6-24 Correlation table between age, BMI and SKFS for both groups of the study, 
significant correlations are bolded. 
 Correlation a Baseline 5 
Sessions 
Last 
Session 
6 
Weeks 
6 
Months 
G1       
Age  r. 
 
0.184 
 
0.318 
 
0.413* 
 
0.388 
 
0.214 
 Sig. 0.368 0.114 0.036 0.05 0.294 
BMI r. 0.063 0.02 0.094 -0.008 0.244 
 Sig. 0.76 0.922 0.648 0.968 0.229 
G2       
 
Age  
 
r. 
 
0.105 
 
0.255 
 
0.31 
 
0.251 
 
0.376 
 Sig. 0.635 0.24 0.15 0.247 0.077 
BMI r. 0.352 0.33 0.116 0.027 -0.149 
 Sig. 0.1 0.124 0.599 0.902 0.497 
a Spearman's rho correlation test; r, correlation coefficient; Sig., significant;*, significant 
correlation; G1, active group; G2, control group. 
6.5.3  Correlation between different variables and ROM 
In the active laser group, there was no significant correlation between ROM and age, 
and BMI at any time of the assessment (Table 6.25). However, with regard to the 
control group, a moderate significant negative correlation was noted between BMI and 
the ROM at baseline, last treatment session, and at week 6 assessment periods (Table 
6.25). 
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Table  6-25 Correlation table between age, BMI, and ROM for both groups of the study, 
significant correlations are bolded. 
 Correlation a Baseline 
 
5 
Sessions Last Session 
6 
Weeks 
6 
Months 
G1       
Age r. -0.08 -0.004 -0.033 -0.121 -0.244 
 Sig. 0.699 0.986 0.873 0.556 0.23 
BMI r. -0.07 -0.255 -0.202 -0.095 -0.163 
 Sig. 0.735 0.208 0.322 0.644 0.425 
 
G2 
      
Age r. 0.01 -0.019 0.025 0.049 0.067 
 Sig. 0.963 0.931 0.909 0.823 0.76 
BMI r. -0.470* -0.343 -0.456* -0.433* -0.269 
 Sig. 0.024 0.11 0.029 0.039 0.214 
a Spearman's rho correlation test;  r,  correlation coefficient; Sig., significant; *, significant 
correlation. 
G1, active group; G2, control group. 
6.5.4 Correlation between different variables and KC 
Table 6.26 below shows that, in the active laser group, there was a moderate significant 
positive correlation between BMI and KC at the baseline, last treatment session, and at 
6 months assessment periods. With regard to the control group, there was a strong 
significant positive correlation between BMI and KC at all assessment periods. 
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Table  6-26 Correlation table between age, BMI and KC for both groups of the study, 
significant correlations are bolded 
 Correlation a Baseline 
 
5 
Sessions Last Session 
6 
Weeks 
6 
Months 
G1       
Age r. -0.069 -0.064 -0.12 -0.075 -0.094 
 Sig. 0.739 0.755 0.558 0.716 0.648 
BMI r. 0.395* 0.38 0.459* 0.38 0.409* 
 Sig. 0.046 0.056 0.018 0.055 0.038 
 
G2 
      
Age r. -0.143 -0.122 -0.126 -0.176 -0.159 
 Sig. 0.514 0.579 0.566 0.422 0.469 
BMI r. 0.537** 0.533** 0.519* 0.506* 0.520* 
 Sig. 0.008 0.009 0.011 0.014 0.011 
a Pearson correlation test; r,  correlation coefficient; Sig., significant;  *, significant correlation; 
**, strong significant correlation; G1, active group; G2, control group, 
6.5.5 Correlation between different variables and patient 
satisfaction 
In the active laser group, there was a strong significant negative correlation between age 
and patient satisfaction at six month assessment period (Table 6.27). In the control 
group, a moderate significant positive correlation was noted between BMI and patient 
satisfaction at the six month assessment (Table 6.27).    
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 Table  6-27 Correlation table between age, BMI and patient satisfaction for both groups 
of the study, significant correlations are bolded. 
 Correlation a 5 
Sessions Last Session 
6 
Weeks 
6 
Months 
G1      
Age r. -0.008 -0.068 -0.086 -0.525** 
 Sig. 0.967 0.74 0.676 0.006 
BMI r. -0.2 -0.304 -0.033 -0.023 
 Sig. 0.326 0.131 0.872 0.912 
 
G2 
     
Age r. -0.309 -0.313 -0.285 0.05 
 Sig. 0.151 0.146 0.188 0.82 
BMI r. -0.017 0.261 0.294 0.478* 
 Sig. 0.94 0.229 0.173 0.021 
a Spearman's rho correlation test; r,  correlation coefficient; Sig., significant; *, significant 
correlation; **, strong significant correlation; G1, active group; G2, control group. 
6.5.6 Subgroup analyses 
In the current study, the subgroup analyses were undertaken after the results of the study 
had been compiled. They were not based on a primary study outcome, therefore it has 
not been powered to detect subgroup effects. In the current study, analyses were 
undertaken to investigate if a response to the treatment is different across particular 
groups of patients. The interaction effect between subgroup and treatment was tested 
using UAV test. The independent variables for the UAV were age, gender, BMI, and 
level of education. The two dependent variables were VAS and SKFS scores.  At each 
time point two models were fitted: one with main effects of treatment and the 
independent variables and a second including interactions between treatment and these 
variables.  
Brookes et al. (2001) reported that subgroup testing requires the data to be split and 
these smaller datasets will have reduced power to detect a similar treatment which 
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might lead to a number of erroneous conclusions. In the current study, for age subgroup 
the cut-off point was age 55 years old. This point was used because age 55 has been 
used in many earlier studies as the cut-off for younger patients (Julin et al., 2010). 
Furthermore, the age of 55 years has been used in many earlier studies as the cut-off for 
eligibility for TKR (Keenan et al., 2012,). For gender subgroup, patients were 
distributed according to their gender, males or females. Regarding BMI subgroups, the 
cut-off points were overweight (25–29.9 Kg/m2), obese (30–39.9Kg/m2), and severely 
obese (≥ 40 Kg/m2) according to the BMI classification of the UK National Health 
Service (NHS, 2010); this classification is applied in the KSA. Finally, for level of 
education, patients were divided into educated or uneducated; patients who have 
secondary school and higher categorised to be educated and who have less than 
secondary school have lower levels of education (uneducated). Table 6.28 shows 
subgroups distribution for both groups. 
Table  6-28 subgroup distribution 
 Age groups BMI Gender Education level 
 35-54 55-74 Overweight 
(25–29.9 
Kg/m2) 
Obese  
(30-39.9 
Kg/m2) 
Morbidity 
obese 
(≥40 Kg/m2) 
F M Educated Uneducated 
Active 
group 
15 11 3 21 2 16 10 11 15 
Control 
group 
9 14 4 15 4 15 8 8 15 
 
With regard to VAS as a dependent variable, the UAV showed that there was evidence 
that the active group showed better improvement than the control group after 6 weeks 
and 6 months of the last treatment session (p < 0.05) (Table 6.29). Furthermore, there 
was evidence that BMI is an influential factor at 6 weeks assessment periods (p < 0.05) 
(Table 6.29), however, due to heterogeneity of patient numbers in the subgroups, it is 
difficult to make any reliable conclusion. 
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Table  6-29 Univariate Analysis of Variance - (VAS): 95% CI and P-value for main effects 
in linear model applied separately at each time. 
  
However, the UAV showed that there was no evidence of any interaction between the 
treatment and the other variables at any time of evaluation (Table 6.30). 
 5 sessions 
95% CI 
P-value 
9 sessions 
95% CI 
P-value 
6 Weeks 
95% CI 
P-value 
6 Months 
95% CI 
P-value 
Treatment 
Groups 
(-2.22 to 0.43) 
0.18 
(-1.68 to 0.81) 
0.48 
(-2.11 to 0.05) 
0.04* 
(-2.78 to -0.40) 
0.010* 
Age     (-1.87 to 0. 94) 
0.51 
(-1.62 to1. 02) 
0.65 
(-1.88 to 0.30) 
0.15 
(-1.40 to 1.14) 
0.85 
Gender (-1.49to 1.71) 
0.99 
(-1.81 to 1.19) 
0.68 
(-0.53 to 1.95) 
0.25 
(-2.15 to 0.73) 
0.32 
BMI ** (-1.16 to 4.08) 
0.27 
(-1.29 to 2.74) 
0.47 
(-1.63 to 3. 29) 
0.50 
(-2.18 to 1.6.9) 
0.83 
(0.38 to 4.44) 
0.02* 
(-1.15 to 2.17) 
0.53 
(-1.85 to 2.86) 
0.67 
(2.75 to 0.86) 
0.29 
Level of 
education 
(-0.24 to 2.77) 
0.09 
(-0.52 to 2.32) 
0.21 
(-1.11 to 1.24) 
0.91 
(-0.74 to 1. 97) 
0.37 
*, p < 0.05 
**, As BMI has three categories there should be two parameter estimates. 
Comparisons were done aginst variables of both groups of the study. 
   156 
 Table  6-30 Univariate Analysis of Variance (interaction) - (VAS): P values for interaction of 
treatment with other covariated. 
VAS 5 sessions 
P-value 
9 sessions 
P-value 
6 Weeks 
P-value 
6 Months 
P-value 
Treatment 
groups * age 
0.59 0.82 0.55 0.68 
Treatment 
groups * 
gender 
0.97 0.58 0.37 0.47 
Treatment 
groups *BMI 
0.63 0.62 0.21 0.35 
Treatment 
groups * Level 
of education 
0.20 0.20 0.96 0.37 
 
With regard to SKFS as a dependent variable, the UAV showed that there was evidence 
that the active group showed better improvement than the control group after 6 months 
of the last treatment session (p < 0.05) (Table 6.31), otherwise, there was no evidence of 
any significant relationship or interaction between the variables (p> 0.05) (Tables 6.31 
and 6.32). 
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Table  6-31: Univariate Analysis of Variance - (SKFS): 95% CI and P-value for main effects 
in linear model applied separately at each time. 
 5 sessions 
95% CI 
P-value 
9 sessions 
95% CI 
P-value 
6 Weeks 
95% CI 
P-value 
6 Months 
95% CI 
P-value 
Treatment 
groups 
(-16.12 to 6.82) 
0.42 
(-20.63 to 0.97) 
0.73 
(-20.22 to 2.38) 
0.11 
(-23.03 to -2.52) 
0.02* 
Age (-23.98 to 0.34) 
0.06 
(-22.67to 0.23) 
0.55 
(-21.00 to 2.95) 
0.14 
(-15.10 to 5.84) 
0.36 
Gender (-3.60to 24.09) 
0.14 
(-5.90 to 20.18) 
0.28 
(-8.53 to 18.75) 
0.45 
(-17.66 to 7.09) 
0.39 
BMI** (-32.36 to 12.99) 
0.39 
(-21.18 to 13.77) 
0.67 
(-29.80 to 12.90) 
0.43 
(- 17.39 to 15.46) 
0.91 
(-18.36 to 26.30) 
0.72 
(-14.40 to 19.94) 
0.75 
(-29.50 to 11.02) 
0.36 
(-24.48 to 6.70) 
0.26 
Level of 
education 
(-10.39to 15.80) 
0.68 
(-6.63to 18.03) 
0.36 
(-10.91 to 14.89) 
0.76 
(-5.31 to 18.09) 
0.28 
*, p < 0.05 
**, As BMI has three categories there should be two parameter estimates. 
 
Table  6-32 Univariate Analysis of Variance (interaction) - (SKFS): P values for interaction of 
treatment with other covariated. 
 5 sessions 
P-value 
9 sessions 
P-value 
6 Weeks 
P-value 
6 Months 
P-value 
Treatment 
groups * age 
0.20 0.16 0.41 0.50 
Treatment 
groups * gender 
0.43 0.74 0.86 0.50 
Treatment 
groups *BMI 
0.90 0.66 0.82 0.32 
Treatment 
groups * Level 
of education 
0.87 0.63 0.89 0.66 
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Chapter 7 Discussion 
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7.1 Introduction  
The results of this study showed that the active LLLT applied to specific APs around 
the knee, in combination with quadriceps strengthening exercises and advice, effectively 
reduces pain and improves knee joint function, with an improvement in the VAS and 
SKFS measurements noticed in the treatment group up to the last time point in the study 
at six months post-treatment compared with the placebo group. The effect of the 
additional treatment of exercise and advice might also be beneficial to patients with 
KOA, as demonstrated by the improvements of most outcomes in virtually all patients 
involved in this study. Of course, there may have been a contribution from the placebo 
effect and indeed ‘trial participation effect’ (participants may experience improved 
clinical outcomes simply by participation in a clinical trial itself), but these would be 
expected to be equally distributed in both groups. 
7.2 Changes in the outcome measurements through the 
study 
The primary outcome of the current study was the change in the VAS score for pain 
during movement. Lee et al. (2003) stated that small changes in the VAS may have 
statistical signiﬁcance, without clinical meaning. They suggested that a 3 cm mean 
reduction in VAS represents a clinically relevant difference in pain severity. 
In the current study, the within-group analysis showed that OA symptoms had 
significantly improved in the active laser group at the 5th session of the treatment, as 
measured by a reduced VAS score for knee pain. Interestingly, this improvement 
became clinically and statistically significant at the remaining three periods of 
assessment, respectively (Table 6.3 and Figure 6.1). This implies that there is a residual 
positive effect of the treatment (active laser, quadriceps exercise, and advice) until six 
months post-treatment, even though the active treatment had stopped at 3 weeks (9 
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sessions).   The placebo group (placebo laser, quadriceps exercise, and advice) failed to 
display such effect, although it was also found to reduce the VAS scores statistically 
(but not clinically) at the 1st 3 follow-up periods. This improvement deteriorated and 
was not detected at six months, and the differences between the placebo and treatment 
groups increased (Table 6.3 and Figure 6.1). 
The between-groups analysis showed statistically (but not clinically) significant 
difference in the VAS scores after 6 weeks and after 6 months of the end of treatment in 
favour of the active laser group (Table 6.13). However, there was no significant clinical 
difference found between the two groups in the VAS score. 
SKFS was the most important secondary assessment tool for the current study. Similar 
to the VAS, the within-group analysis showed that OA symptoms had significantly 
improved in both groups at all assessment periods, as measured by a reduction in total 
SKFS scores and in SKFS subscales (pain, stiffness, physical function, social function, 
and emotional function) (Table 6.4 to Table 6.9; and Figure 6.2). However, the 
between-groups comparisons showed that OA symptoms of participants in the active 
laser group had significantly improved at the last session of the treatment and at the 
week-6 assessment measured by a reduced SKFS score (Table 6.14).   
Regarding subscales of the SKFS, the between-groups analysis showed that patients in 
the active laser group experienced significant improvement in pain at week 6 and 6-
month assessment (Table 6.15), stiffness at the last session and week-6 assessment 
(Table 6.16), and physical function at week 6 and 6-month assessment (Table 6.17) 
compared with those in the control group by a reduced SKFS score for knee pain, 
stiffness, and physical activities.  Obviously, this finding supports the previous 
discussion of the VAS findings.  
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With respect to social function and emotional function subscales, in spite of the 
statistically significant difference within both groups (Tables 6.8 and 6.9), the between-
groups comparisons showed no difference at any time of assessment (Tables 6.18 and 
6.19). This finding could be attributed to the religious background of most of the 
participants in both groups, who believe that this disease has come from God and that it 
will not affect them socially or emotionally, according to their answers in this particular 
section.  
ROM, as a secondary assessment tool for the current study, showed a significant 
improvement at all assessment periods for the participants in the active laser group, 
whereas this improvement in the control group was only at the 5th and 9th session 
assessment periods (Table 6.10 and Figure 6.3). Nevertheless, between-groups 
comparisons showed statistically significant improvement in favour of the active laser 
group at the 6-month assessment period only (Table 6.20 and Figure 6.3). The previous 
result was logical because patients in the active laser group and those in the control 
group recorded relatively acceptable ROM at the baseline assessment with a mean ROM 
of 128.9° and 129° respectively. The short- and long-term improvements in the ROM 
and in the other outcomes of the active laser group participants can be attributed to the 
treatment provided (active laser, quadriceps exercise, and advice).  
However, the short-term improvement shown by the participants in the control group 
could be related to the quadriceps exercise and advice provided, in addition to the 
placebo effect.  Maintained improvement in the ROM and the other outcomes among 
participants in the active laser group and the relapse among participant in the control 
group implies that the positive effect of LLLT is sustained at least until 6 months after 
the treatment ceased.  
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Previous findings of the sustained positive effect of LLLT are supported by the 
continued patient satisfaction of participants in the active laser group, even at 6 months 
after discontinuing the treatment (Table 6.12). A statistically significant difference of 
patient satisfaction within the control group was seen in all follow-up assessments, 
except after 6 months (Table 6.12).   This could be attributed to the quadriceps exercise 
and advice provided, in addition to the placebo effect, in that participants might believe 
they had received a treatment that could improve their situation during that period. 
The KC assessment did not indicate a significant change between groups at any 
assessment period (Table 6.21), even though the within-group analysis showed a 
significant improvement within the control group at the 9th session and at the 6-months 
assessment (Table 6.11). This result could be because the majority of participants in 
both groups had no significant swelling in their joints, or it could be because the LLLT 
type and/or its parameters used in the current study had no effect on the joint swelling. 
In summary, the most significant improvements have been found in the active laser 
group, compared to the control group, in almost all outcome measurements after 6 
months treatment cessation, which suggests that there was a sustained therapeutic effect 
of active LLLT that was not seen in the placebo group.  
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7.3 Correlation and relationship between variables 
In the current study, a correlation analysis has been done to test the degree of 
association between variables. Pearson correlation coefficients reported in Table 6.23 
suggested that age and BMI does not correlate significantly with the changes in the 
VAS scores through all assessment periods. This was the case regarding the SKFS, 
although a moderate significant positive correlation was seen at the last treatment 
session (Table 6.24). A moderate significant negative correlation was noted between 
BMI and ROM in the control group at baseline, last treatment session, and at week 6 
assessment periods (Table 6.25). However, the significant negative correlation was 
expected to be seen in both groups, because it is logical that ROM increases as BMI 
decreases, but it was not the case in the active laser group (Table 6.25). A moderate to 
strong significant positive correlation was noted in both groups between BMI and KC 
(Table 6.26), which is a logical and expected result.  
Nevertheless, in the active group and at the endpoint assessment, there was a strong 
significant negative correlation between age and patient satisfaction, which implies that 
older patients might need a special consideration and another dose of the treatment 
might need to be re-applied earlier than in a younger patient (Table 6.27). Also, in the 
control group, there was a moderate significant positive correlation between BMI and 
satisfaction, which could be attributed to the strengthening exercises and advice, which 
was provided, in addition to the placebo effect. In general, for patients with KOA, the 
greater the BMI, the more knee pain and activity limitations, therefore, their satisfaction 
might be increased with a slight improvement more than the others did.  
In the current study, data have been analysed to investigate the effects of different 
variables and their interaction with treatment. In effect, subgroup analyses were 
undertaken to investigate if the effects of treatment are different across particular groups 
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of patients by using the UAV test. The result showed that there was no interaction 
between the variables and treatment at any time evaluation with regard to the VAS 
(Table 6-29). However, because of the heterogeneity of the number of patients in the 
subgroups (overweight group= 7, obese group= 36, and morbidly obese group = 6), it is 
difficult to make a reliable conclusion. However, this might be taken into account in 
future studies. Regarding the SKFS, the subgroup analysis showed that there was no 
evidence of any significant relationship or interaction between the variables and 
treatment (Tables 6-31 and 6-32). This implies that there was no evidence of a 
differential response to the treatme, regardless of the other variables. 
7.4 The observed results and the current literature. 
Corroborating the findings of Alfredo et al. (2011), improvements seen in the active 
laser group might be attributed to the anti-inﬂammatory properties of the LLLT applied 
onto speciﬁc points on the articular capsule. Analgesia induced by LLLT resulted in 
improved exercise performance, and this combination resulted in maintaining benefits 
up to 6 months, even after laser therapy was discontinued.  
Tascioglu et al. (2012) reported that several studies show that LLLT has anti-
inﬂammatory, anti-oedema effects, and plays a role in pain reduction without side 
effects. Although LLLT is clinically used to relieve pain, the mechanism by which it 
reduces pain is still not clear. However, pain relief can be as an inhibition of nociceptive 
signals at peripheral nerves. Furthermore, it has also been demonstrated that the LLLT 
induces analgesia by increasing endorphin and serotonin release (Abrisham et al., 2011; 
Fulop et al., 2010), see Section (3.8.2) for more details. Nevertheless, this improvement 
can be attributed to the ability of LLLT to stimulate reparative properties in human 
cartilage and to improve bone tissue healing (Bouvet-Gerbettaz et al., 2009; de Paula 
Eduardo et al., 2010; da Rosa et al., 2012). 
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On the other hand, analgesia sustained among participants in the active laser group can 
be considered as a result of stimulating specific APs. The  five APs used in the current 
study (ST35, Ex-LE4, ST36, SP9, and SP10) are commonly used in clinical trials of AP 
in order to treat patients with KOA (Ahsin et al., 2009; Berman et al., 2004; Foster et 
al., 2007; Taechaarpornkul et al., 2009; Tsang et al., 2007 ). It has been stated that 
LLLT appears to exert equivalent effects to needle AP, whereas LLLT can act at the 
skin level through an inhibitory mechanism through a neural blockade. Furthermore, it 
has been reported that LLLT, when applied to APs, has been shown to be a highly 
effective therapeutic technique for pain (Silberstein, 2013). 
However, in the current study, sustained improvement in the active laser group up to six 
months after the last treatment session could be attributed to the combined positive 
effects of LLLT with strengthening exercises and education (advice). Patients with 
KOA have a significant decrease in knee muscle strength, especially the quadriceps 
muscle, which increases knee pain; however, there is strong evidence suggesting that 
exercises can reduce pain and improve function in patients with OA (Conroy et al., 
2012; Iwamoto et al., 2011; Pisters et al., 2007). Therefore, exercise is a core 
recommendation in all international guidelines as a first-line management method for 
patients suffering KOA (Stemberger and Kerschan-Schindl, 2013).  
The average weight of participants in the current study was 86 kg; obese and overweight 
participants were advised to lose weight, whereas the others were advised to maintain 
their weight in a normal range. Interestingly, it has been shown that a loss of 5 Kg may 
be associated with a 50% reduction in the possibility of developing symptomatic KOA, 
and reduction in the severity of joint pain. In contrast, the risk for KOA is increased by 
36% for every 5 Kg of weight gain (Felson, 1996; March and Bagga, 2004; McGoey et 
al., 1990). Furthermore, it has been reported that for each kilogram of body weight lost, 
there is a 4 Kg reduction in load on the knee joint per step (Messier et al., 2005). 
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Patients in the current study were advised not to bend their knees excessively, to wear 
comfortable shoes, to use an aid or support such as walking stick if necessary, and to 
avoid activities such as lifting heavy objects while climbing stairs. Additionally, all 
patients were advised to perform their exercise gently, slowly, and in small amounts and 
often. Joint protection plays a major role in preventing further damage of the joint 
structures. By eliminating the influences that can potentially affect or damage the joint 
components, the development of OA can be prevented or at least slowed down (Michael 
et al., 2010). Therefore, education and self-help programmes can reduce symptoms and 
improve QoL in many patients with KOA (Zhang et al., 2009). 
Naturally, the fact that all patients in both groups of the current study exercised 
regularly and were better-educated about their condition played a major role in the 
improvement seen in participants of both groups. However, the sustained improvement 
in the active group and the reducing improvement in the control group after 6 weeks and 
after 6 months from the last treatment session in terms of significant difference found 
between groups in the primary outcome VAS, SKFS, ROM, and patient satisfaction 
have many interpretations. First, the combination of the positive effects of strengthening 
exercises and advice with LLLT is superior to the strengthening exercises and the 
advice alone. Second, it can be assumed that participants in both groups had stopped the 
exercises and the advice given. As a result, the positive effect of the strengthening 
exercise and advice and even the placebo effect deteriorated; however, a positive effect 
of LLLT on participants in the active group was sustained. Previous interpretations 
could be supported by the deterioration in patient satisfaction within the control group at 
the 6-month assessment period in addition to the patient satisfaction being superior in 
the active laser group compared to the placebo during this period. 
Interestingly, the average of the knee ROM of participants in the current study was 129° 
at baseline evaluation, which was greater than that of similar studies (Alfredo et al., 
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2011; Gur et al., 2003a; Hegedus et al., 2009) at their post-treatment periods. Therefore, 
in the current study, no significant improvement was possible between both groups at 
any time throughout the study, except at the 6-month assessment (p = 0.046). This 
supports what has been previously found by Szabo et al. (2000), that Arabians with 
KOA who follow the Muslim faith have an average ROM of 139.5°, in comparison with 
non-Arabic patients who are not of Muslim faith, who have an average of 102.8°. 
Previous findings could be attributed to the lifestyle practiced by Arab and Muslim 
societies, in which the traditional Arabic way of sitting and the Muslim way of praying 
force their knees into deep ﬂexion for longer periods during the day (Section 5.5.2).  
7.5 Comparison between the current study and other 
studies with similar objectives. 
The current RDBCT was conducted to evaluate the efficacy of LLLT applied to five 
specific APs in combination with exercises and advice on pain, function, and QoL in 
patients with KOA. Shen et al. (2009) conducted a pilot RSBCT to assess the efficacy 
and safety of two combined types of laser irradiation in patients with KOA when AP 
Dubi (ST35) is irradiated. Patients were treated by a 650 nm semiconductor laser and 
10.6 μ m CO2 laser in a total of 12 sessions, with irradiation time of 20 minutes for each 
patient in each session.  Primary outcome measurement was the WOMAC index and the 
secondary was the global patient assessment. All patients were evaluated at baseline and 
week 2.  
However, in comparison with the current study, Shen et al. (2009) used a different laser 
device with different parameters for irradiating only one AP and for a longer irradiation 
time. The current study appears to be more rigorous than the Shen et al. (2009) study 
for many reasons. Shen et al. (2009) provided no information about whether the study 
was powered or not. Furthermore, their study was designed as a single RCT, and the 
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authors of the study were forced to cancel the 4 week assessment as a result of high a 
dropout rate.  Despite that, both studies showed statistically significant improvement in 
pain, stiffness, and function of patients in the laser group when compared with the 
placebo group. Nevertheless, due to the small sample size and the high dropout rate of 
patients in the placebo group of Shen et al. (2009), the authors could not conclude 
whether the positive result of their study was due to the therapeutic effect or to a 
placebo effect. 
Yurtkuran et al. (2007) conducted a RDBCT to investigate the efficacy of  LLLT (GaAs 
infrared laser 904 nm with 10 mW/cm2 power density, 4 mW output power, 0.4 cm2 
spot size, 0.48 J dose per session, and 120s treatment time) in patients with KOA when 
AP SP-9 was irradiated. Similar to the current study, knee exercise was added to the 
treatment regime. All participants received a total of 10 treatment sessions and were 
evaluated at baseline, after the treatment, and at the 12th week. The main outcome 
measures were WOMAC, VAS, 50-foot walking time, KC, and medial tenderness 
score, and the secondary outcome was the Nottingham Health Profile.  
In comparison with the current study, a different laser type was used with different 
parameters; a lower dose (0.48 J/point) was applied in the Yurtkuran et al. (2007) study 
for longer irradiation time on only one AP. Both studies used VAS and KC among their 
outcome measures and both added advice and exercise to the treatment program. While 
the current study showed a statistically significant decrease in VAS scores as a primary 
outcome of the endpoint assessment (6 months) in favour of the active laser group 
compared with the placebo group (mean difference = -1.8 and p < 0.05), Yurtkuran et 
al. (2007) showed no statistically significant decrease in the VAS at any time of 
assessment (endpoint, p = 0.502). The statistically significant decrease in the VAS 
scores in the current study could be attributed to the irradiated five APs instead of one 
AP as in Yurtkuran et al. (2007). 
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However, Yurtkuran et al. (2007) found that active treatment was not superior to 
placebo treatment, except in KC, which was superior in the laser group at the second 
week. In contrast, this study showed that improvements in the active laser group were 
statistically superior to those of the placebo laser group in most outcome measures but 
not in the KC. Corroborating these finding, Hegedus et al. (2007) reported that the lack 
of the effect of LLLT on KC is expected, and it has not been demonstrated with other 
therapies. However, in the Yurtkuran et al. (2007) study, the improvement in the KC 
could be attributed to the stimulation of AP SP9, which was irradiated for 20 minutes 
each session for 10 days. In TCM, AP SP9 is a main point for eliminating 
accumulations of water and moisture, especially in the lower half of the body (Hecker et 
al., 2008).  
Furthermore, the improvement could be attributed to the type of laser and its parameters 
used in their study, whereas it has been reported that different lasers may have different 
effectiveness (Tascioglu et al., 2012). According to Azevedo et al. (2006), previous 
studies have suggested that LLLT at energy densities up to 4 J/cm2 has stimulating 
effects, whereas higher energy fluencies have rather inhibitory characteristics.  
Currently, there are two ongoing studies that use laser acupuncture for treating patients 
with KOA. The first study is being conducted by Hinman et al. (2012), which has a 
two-stage Zelen design RCT to investigate the efficacy of needle and laser acupuncture 
in patients with chronic knee pain and to evaluate maintenance of effects over the long-
term. In comparison with the current study, Hinman et al. (2012) is an ongoing trial, so 
there are no results as yet.  In terms of methodology, it is a much bigger trial where 
authors of the study have potentially better control of the trial design, given the 
experience of the steering group, however, the nature of their design, such as multi-
centric and size of the trial makes it much more difficult to control for flaws in the 
implementation of the design. Hinman and his colleagues are aware of this and tried to 
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control by requiring specific training for all participating operators. Whereas, the 
current study by comparison is small, but also had a robust design and is certainly an 
improvement in relation to existing literature, in the sense that it is already concluded 
and provides new relevant data. Furthermore, the current study was controlled for all the 
variables that proved problematic in previous studies such as Shen at al. (2007) and 
Yurtkuran et al. (2007). The single operator design has advantages and disadvantages, 
for instance, it certainly introduces a consistency of technique that is impossible to 
obtain with multi-operators. Hinman's design is very complicated and the complication 
sometime makes it difficult to exclude bias sources, as statistical corrections are limited 
in their ability to correct practical problems and will in their own right introduce a 
further bias that is difficult to detect, since the statistical corrections are by necessity 
based on unproven or untested assumptions. Moreover, primary and secondary 
outcomes used by Hinman and his colleagues are collected via a self-report 
questionnaire and mailed back to the investigators, howevere authors did not add any 
objective measurements to add more support for their result.  Despite these criticisms, 
the Hinman et al. (2012) study is still a well-designed trial and will have a longer term 
assessment; furthermore, interestingly, it is the first study to compare laser acupuncture 
with needle acupuncture in treating patients with KOA.  More details on comparisons 
between the current study and Hinman et al. (2012) are presented in Appendix (XVII). 
The other ongoing study was designed by Ress (2012) as a RDBCT to evaluate the 
effectiveness of laser acupuncture on patients with KOA. Sixty participants are being 
recruited and randomised into two groups, intervention and placebo. Treatment is being 
administered 3 times per week for 4 weeks (12 treatments) and the whole treatment time 
is about 45 minutes. Outcome measures are being administered before and after the 12 
treatments and at two months follow-up. According to the study authors so far 30 
participants have taken part in this study and preliminary results indicate the use of laser 
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acupuncture to treat KOA could be positive. However, it is difficult to compare the 
current study with the Ress (2012) study due to the dearth of available information 
derived from the study, which is currently only appears to be published as an abstract 
from the Laser Helsinki 2012 International Congress. 
Many other studies have been conducted to investigate the efficacy of LLLT on patients 
with KOA when applied to different areas, rather than on APs. Alfredo et al. (2011) 
conducted a RDBCT to estimate the effects of LLLT in combination with a programme 
of exercises on patients with KOA. Although the current study showed a significant 
difference in VAS at endpoint assessment in active laser over placebo, Alfredo et al. 
(2011) did not (mean difference -0.31, p= 0.120). However, both studies suggest that 
LLLT when associated with exercises is effective in reducing pain and improving 
function and activity in patients with KOA.  
 Hegedus et al. (2009) conducted a RDBCT to investigate the effect of LLLT in pain 
and possible microcirculatory changes in patients with KOA. They used almost 
identical laser parameters as in the current study, but the dose was 6 J/point compared to 
the current study of 1.20 J/point. Nevertheless, both studies showed a significant 
reduction in VAS scores in the active laser group, as compared with the placebo group 
at the endpoint assessment (p <0.05). Tascioglu et al. (2004) conducted a RSBCT to 
investigate the analgesic efficacy of LLLT in patients with KOA. They suggested that 
LLLT has no effect on pain in patients with KOA. Almost identical results were found 
by Bulow et al. (1994), who carried out a RDBCT to investigate the effect of LLLT on 
patients with chronic KOA with periarticular tender points. They failed to find 
significant differences in any effect variables when comparing an active laser group 
with a placebo group.  
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In contrast, a RDBCT done by Gur et al. (2003), results showed that applications of 
LLLT in different doses and duration have not affected results and both therapy regimes 
were a safe and effective method in treatment of KOA. In a partially RDBCT done by 
Stelian et al. (1992), it was found that LLLT is effective in relieving pain and disability 
in patients with KOA. However, Trelles et al. (1991) conducted a non-randomised and 
non-controlled study to investigate the efficacy of LLLT in patients with KOA and 
concluded that this treatment is a safe, effective, and non-invasive alternative to 
conventional surgical and medical treatment modalities for patients with degenerative 
KOA.   
Nevertheless, studies done by  Shen et al. (2009) and Yurtkuran et al. (2007) used only 
one AP  irradiated by LLLT, in the current study, five APs were irradiated, making it 
more comparable to clinical trials involving conventional acupuncture. Ahsin et al. 
(2009) carried out a RSBCT to investigate the effect of EA on pain intensity and plasma 
levels of endorphin and cortisol. They stimulated six APs, three of which were used in 
the current study (ST35, ST36, and SP10). Their study suggests that EA is effective for 
relieving pain, stiffness and functional disability with an increase in plasma-endorphin, 
and a decrease in plasma cortisol, as compared with sham acupuncture in patients with 
primary KOA. However, the reduction in the VAS pain score showed a similar trend 
with the sham group, showing no reduction in median score. 
Taechaarpornkul et al. (2009) conducted a comparative randomised trial to compare the 
effectiveness of six and two APs in the treatment of KOA using EA. Five of these six 
APs were used in the current study (ST35, EX-LE4, ST36, SP9, and SP10). The result 
of their study pointed out that acupuncture at both six and two APs was associated with 
a significant improvement; however, there was a non-statistically signiﬁcant 
improvement in pain in subjects who received both two and six APs. Therefore, the 
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authors of the study suggested that EA applied to two local points may be sufficient to 
treat KOA. 
Jubb et al. (2008) in their RCT to compare electro acupuncture and manual acupuncture 
with sham acupuncture, all five APs used in the current study were among the ten APs 
that were irradiated by Jubb and his team. The result of their study showed that 
acupuncture is significantly superior to non-penetrating sham acupuncture for patients 
with KOA.  A multicentre RCT was carried out by Foster et al. (2007) to investigate the 
benefit of adding acupuncture to an exercise and advice program for pain reduction in 
patients with KOA in older adults. This study is identical to the current study in that all 
participants received an exercise and advice program.  The five APs used in the current 
study (ST35, EX-LE4, ST36, SP9, and SP10) were stimulated in addition to another ten 
APs irradiated by Foster and his colleagues. However, in contrast to the current study 
results, they clarified that the addition of acupuncture to a course of advice and exercise 
for KOA provided no additional improvement in pain scores.   
Berman et al. (2004) conducted an RCT to determine the efficacy of true acupuncture 
compared with sham acupuncture or education in patients with KOA. Of 9 APs used in 
their study, 4 APs ST35, Xiyan, ST36, and SP9 of the current study were used. The 
authors concluded that acupuncture seems to provide improvement in function and pain 
relief as an adjunctive therapy for KOA, in comparison with credible sham acupuncture 
and education control groups. A prospective controlled trial was done by Tillu et al. 
(2002) comparing acupuncture with no treatment in patients with advanced KOA 
awaiting TKR. The APs SP9, SP10, and ST36 used in the current study were among the 
five APs used in their study. The result showed that the acupuncture group improved in 
all parameters, whereas the control group deteriorated.  
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Finally, Suarez-Almazor et al. (2010) conducted an RCT in patients with KOA to 
compare the efficacy of traditional acupuncture with sham acupuncture. Only one AP 
(SP9) of those used in the current study was among APs used in the study by Suarez-
Almazor and his colleagues. Their results showed that traditional acupuncture was not 
superior to sham acupuncture, and the needling of meridian points was no more 
effective than the use of sham points. 
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7.6 Problems and limitations of the study 
During the planning stage of this study, there was difficulty in finding published studies 
related to the use of LLLT in treating KOA. Furthermore, studies concerning laser 
acupuncture are rare. To the best knowledge of the author, to date, only two studies 
have been published for testing the efficacy of LLLT when applied on APs in patients 
with KOA; moreover, only one AP has been stimulated in each study (Shen et al., 2009; 
Yurtkuran et al., 2007). Despite the dearth of published studies on the use of laser 
therapy in KOA, many problems and limitations were found, including the lack of 
standard protocols for inclusion and exclusion criteria. In addition, LLLT studies have 
been criticised because the laser devices, experimental designs, parameters, and 
techniques used in the literature are highly variable. Therefore, it is important for one to 
be careful when reviewing and comparing these studies. 
VAS as a primary outcome for the current study has been shown to be influenced by 
many factors, including age, mental condition, impaired sensation, and the subject’s 
psychological condition (Lu et al., 2010). Furthermore, the SKFS used as a secondary 
outcome for the current study, such as other pain and functional outcome measurement 
scales used in similar studies, is influenced by some diseases other than KOA. Older 
patients with KOA frequently present several co-morbidities, including low back pain, 
fibromyalgia, rheumatoid arthritis, depression, and fatigue. Therefore, care should be 
taken when using such assessment tools to assess the efficacy of treatment. To fill this 
gap, objective and precise assessment tools are necessary, e.g. three-dimensional gait 
analysis (Lu et al., 2010).  
The use of scales, such as VAS and SKFS, in their concept of evaluation, is still new to 
Saudi patients, who may be influenced greatly by educational level, as the illiteracy rate 
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among the participants in the current study is relatively high. It has been reported that 
highly educated patients show a better outcome and response (Hmamouchi et al., 2012). 
Another limitation, which has already been found in most similar studies, is that the 
study samples included more female than male participants; for example, in the current 
study, 63.5% of the participants were female. Therefore, representativeness of the 
sample for both genders may be influenced.  
An additional limitation is that more than 61% of the participants in the current study 
were uneducated. Educated patients are expected to have the ability to apply the 
instruction in a better manner and to express their feedback in a better way than 
uneducated patients can. Especially in subjective assessment scales, such as VAS and 
SKFS, information obtained from educated patients is likely to be more accurate and 
hence could be an important factor in determining the outcome of a study.  
 
 
 
 
 
 
 
 
 
 
   177 
 
 
Chapter 8 Conclusion 
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8.1 Conclusion 
LLLT is one of the most recent pain management modalities in the field of 
physiotherapy. Recent studies have clearly shown that laser light can be successfully 
used as an alternative to metal needles (Laser acupuncture) for effective AP treatment. 
Furthermore, LLLT is safer and it requires less time than needle AP; hence patients can 
avoid the pain and psychological fear associated with traditional AP. 
This study appears to be the first RDBCT to investigate the efficacy of LLLT when 
applied to more than one AP in patients with KOA: five APs were irradiated. 
Furthermore, it is the first RDBCT study conducted in the Arabic world using LLLT for 
treating patients with KOA and the first study to use the SKFS as an outcome measure 
for KOA. 
A reasonable sample-size and follow-up period was employed in the current study, in 
comparison with similar studies of LLLT for treating KOA. The results of our study 
demonstrated that short-period application of LLLT (three sessions weekly for three 
weeks, for a total of nine sessions) on specific APs on patients with KOA, in 
conjunction with exercise and advice, has a beneficial positive effect on pain reduction 
and improvement in knee joint function, with an improvement in all outcomes except 
KC Despite the current study showed that there was statistically significant difference 
(but not clinically difference) between groups of the study, both groups of the study 
showed relative improvement over the study period, but the patients receiving active 
laser acupuncture had a significantly greater improvement at the end point evaluation. 
Although the current study indicated that active laser is superior to the placebo, the 
placebo effect is also clearly beneficial to patients with KOA, as demonstrated by the 
improvements of most outcomes in virtually all patients involved in this study.  
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According to Ernst (1994) no clinical research can be without flaws. Therefore, despite 
the aforementioned limitations and problems encountered during the completion of the 
current thesis (Section 7.6), it has provided evidence to add to the scientific basis 
around the use of LLLT in treating patients with KOA. The findings of this study are 
important, especially for those patients who seek non-pharmacological analgesia 
without side effects and for patients who are not candidates for, or refuse, surgery. 
Additionally, the results of the study showed that LLLT might make a contribution as 
an adjunct to other forms of interventions for KOA.  
Because of the lack of a standard regimen for treating patients with KOA compared to 
other physiotherapy interventions, which usually require a longer time, it is fair to say 
that LLLT is time-and-effort saving for both patients and practitioners. Therefore, 
LLLT can help in minimising the long waiting lists for patients with KOA and give 
them an equal chance for receiving an appropriate treatment. The greater pain relief and 
the improvement in the QoL obtained from LLLT might encourage patients to practise 
their strengthening exercises with less discomfort and less pain and to become more 
mobile.     
8.2 Summary and Implications for Future Research 
This study appears to be the first RDBCT to investigate the efficacy of LLLT when 
applied to more than one AP in patients with KOA. It is the first RDBCT conducted in 
the Arabic world using LLLT for treating patients with KOA and the first study to use 
the SKFS as an outcome measure for KOA. The results of this study demonstrate that 
short-period application of LLLT (GaAlAs infrared LLLT at 830nm wavelengths with a 
continuous mode, delivering an energy density of 4 J/cm2, with 40 s of irradiation time 
and a dose of 1.20 J/point per session repeated 3 times a week for 3 weeks) on specific 
APs in conjunction with exercise, education, and advice are effective in reducing pain 
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and improving the QoL in patients with KOA. However, the results of this study 
support LLLT, at the parameters used in the trial, as an important adjunct intervention 
in the treatment of KOA and possibly for other joints. This modality may be especially 
relevant for patients who do not respond to medical therapy, for whom other physical 
modalities are contraindicated, those who suffer adverse side effects of drug therapy, or 
those who are not candidates for surgery.  
As the current study is the first study that used more than one AP for testing the efficacy 
of LLL in treating KOA, it provides a model for further research.  Further well-designed 
RCTs with longer term findings are required, not only to establish the efficacy of LLLT 
applied to APs but also to identify important factors including wavelength, treatment 
duration, dosage, and site of application that signiﬁcantly increase the heterogeneity of 
the literature and thus dilute the applicability of the results. In addition, further RDBCTs 
are needed to investigate a positive effective of LLLT on APs, if any, as a result of 
stimulating APs directly or as a result of biological effect from surrounding tissues or 
both. Further studies are required to stimulate the same and/or different APs related to 
the KOA according to acupuncture regimen, in order to provide scientific evidence 
about its prospective efficacy.     
Laser acupuncture seems to work well when added to an exercise and advice regimen. 
For more scientific evidence, there is a need for future RCTs to compare LLLT when 
applied to APs with commonly used non-pharmacological or even pharmacological 
agents. As aforementioned, the VAS, the primary measurement tool of the current 
study, in addition to the SKFS, the secondary measurement tool, are subjective tools, 
which are influenced by many factors, which have been mentioned earlier. Further 
studies using objective and precise assessment tools are necessary; for example, three-
dimensional gait analysis and/or MRI. Furthermore, VAS and SKFS may be influenced 
greatly by the educational level of the patient; the uneducated patients and the illiteracy 
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rate among the participants in the current study were relatively high. Therefore, the 
effect of the educational level on responses may need further study, especially in 
communities with diverse educational levels. 
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APPENDIX I: Search strategy 
 
 
Keywords for Search Strategy 
Databases 
searched* 
Osteoarthritis Low-Level Laser 
Therapy 
Acupuncture 
AMED, Biosis, 
Cinahl, Cochrane 
Library, Embase, 
Google Scholar, 
Medline, NHS 
Library, Pub 
Med, Scirus, 
Scopus, 
University of 
Dundee Library 
catalogue, Web 
of the Knowledge 
and Zetoc, The  
Physiotherapy  
Evidence 
Database 
(PEDro). 
Osteoarthritis, 
Osteoarthritis of 
knee. OA Knee, 
Knee OA, 
Osteoarthrosis, 
Osteoarthritis 
AND knee, 
Osteoarthritis OR 
knee, 
Degenerative 
changes, Knee 
pain.  
Low-Level Laser 
Therapy (LLLT), Low 
Energy Laser Therapy 
(LELT), Low-Intensity 
Laser Therapy (LILT), 
Low Energy Photon 
Therapy (LEPT), Diode 
laser therapy, Infrared 
laser therapy, Laser 
therapy, Light therapy, 
Soft laser therapy, Cold 
laser therapy, Visible 
laser therapy, 
Semiconductor, Bio-
stimulation, 
Photobiostimulation, 
Photobioactivation, 
Photobiomodulation, 
Phototherapy, Gallium-
Aluminium-Arsenide 
(GaAlAs), Gallium-
Arsenide  (GaAs),  830 
nm, 904 nm. 
Acupuncture 
treatment, 
Acupuncture 
for knee joint, 
Traditional 
Chinese 
Medicine (TC
M) 
*, restricted to English language papers 
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APPENDIX II (A): Patient Information Sheet 
(English version) 
 
 
The efficacy of low-level laser therapy applied at acupuncture points in knee 
osteoarthritis: a randomised double-blind controlled trial 
Introduction: 
Osteoarthritis of the knee is a common disorder in our community which is usually 
associated with pain, swelling and stiffness of the knee joint. This study is designed to 
evaluate the effectiveness of laser therapy when applied on chosen acupuncture points 
in relieving the pain caused by Osteoarthritis of the knee. Laser therapy is widely used 
as a medical treatment modality. It is considered to be non-invasive, painless and safe. 
We are doing a study to investigate the effectiveness of laser therapy when applied to 
specific acupuncture points at the knee joint in patients with knee Osteoarthritis.  
Methods of the study:  
The study will be conducted in a double-blind fashion. Patients and investigator will be 
unaware of which treatment the patients received, known only to the research assistant. 
In this study, participants will be randomly assigned to either active or placebo laser 
group based on a sequence of computer generated random numbers. If you wish to 
participate in the study you will receive a standard physiotherapy assessment of your 
knee to ensure you are suitable for the study. If you are fit, you will be allocated to one 
of two groups. That means you will have an equal chance of being included in either the 
laser group (you will receive active laser + knee exercises and home instructions) or 
control group (you will receive placebo laser + knee exercises and home instructions). 
The laser machine that will be used in this study for both active and placebo groups is 
the same machine. The placebo emitter is like the active emitter in appearance, but is 
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inactive (both produce red light); no heat or vibration is detectable from either the active 
or placebo laser. 
You will be asked to record your level of pain and functional disability on standard 
questionnaires before the first session and after the last one. You will be required to 
attend physiotherapy department three times weekly for three weeks. 
If the participants in the laser group show an increased benefit all the participants will 
be receiving a laser treatment later on, otherwise a standard physiotherapy treatment 
will be given. 
Treatment: 
Laser treatment will be applied to chosen acupuncture points in your lower limb by an 
experienced physiotherapist in laser treatment. 15 minutes for each session are required 
to have this treatment three times a week for 3 weeks (9 treatment sessions). In addition, 
30 minutes are required to be added to the assessment sessions (baseline, at the 5th 
session, at the 9 th (last) session, 6 weeks and 6 months after the last session). 
Risk from participating in the study: 
Laser therapy used in physiotherapy is usually safe and non-invasive treatment. You 
will never feel any heat, but you will see a red light. The only possible risk when there 
is direct laser on your eyes. So, you and the physiotherapist will be provided with 
special goggles to provide full protection. Also, laser therapy is contraindicated in some 
cases such as patients with active carcinoma. Laser therapy should be avoided on areas 
of haemorrhage. Treatment of infected tissue, especially infected open wounds should 
be avoided as the laser may stimulate the bacteria.  Care must be taken for patients with 
a history of photosensitivity (adverse reactions to sunlight). Direct irradiation over the 
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pregnant uterus should be avoided as well. So, if you have any of the previous cases, 
please don’t hesitate to inform the researcher.  
Benefits from participating in the study: 
Laser therapy has been shown in some previous studies to be a successful treatment in 
relieving the pain of Osteoarthritis. The information gathered from this study will help 
to increase our knowledge of the effectiveness of laser therapy in treating patients 
suffering from knee pain as a result of Osteoarthritis like yourself and the others. At the 
end of the study if you have not shown any improvement you will receive the 
appropriate treatment. 
Inability to participate in the study: 
Participating in this study is voluntary. So, if you do not wish to participate in the study, 
your normal (standard) treatment will be given to you in the normal way. If you take 
part, but later you change your mind, at any time you can withdraw from the trial and 
there is no need to give any explanation and you will be treated in the normal way.  
Confidentially:  
Any information or results that may be gathered from you will be kept confidential. 
Records will be referred to you as a number rather than name. So, no one can link your 
results.   
If you need any query about this study, please don’t hesitate to contact:  
Abdullah S. AL-Rashoud 
Security Forces Hospital 
Physiotherapy department 
Tel/ 01 4754561 
Mobile: 0555487703 
E-mail: joud55@yahoo.com  
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  ﻣﻌﻠﻮﻣﺎت ﺗﮭﻢ اﻟﻤﺮﯾﺾ ﺣﻮل اﻟﺪراﺳﺔ
اﺳﺘﺨﺪام اﻟﻠﯿﺰر ﻟﻌﻼج ﻣﺮﺿﻰ روﻣﺎﺗﯿﺰم اﻟﺮﻛﺒﺔ ﻋﻨﺪ ﺗﺴﻠﯿﻄﮫ ﻋﻠﻰ ﻧﻘﺎط ﻣﺨﺘﺎرة ﻣﻦ ﻧﻘﺎط اﻟﻮﺧﺰ : ﻋﻨﻮان اﻟﺪراﺳﺔ
 ﺑﺎﻹﺑﺮ اﻟﺼﯿﻨﯿﺔ
 : ﺪﻣﺔﻣﻘ
ﺗﻢ ﺗﺼﻤﯿﻢ . روﻣﺎﺗﯿﺰم اﻟﺮﻛﺒﺔ ھﻮ اﺿﻄﺮاب ﺷﺎﺋﻊ ﻓﻲ ﻣﺠﺘﻤﻌﻨﺎ اﻟﺬي ﯾﺮﺗﺒﻂ ﻋﺎدة ﺑﺄﻟﻢ وﺗﻮرم وﺗﯿﺒﺲ ﻓﻲ ﻣﻔﺼﻞ اﻟﺮﻛﺒﺔ
ھﺬه اﻟﺪراﺳﺔ ﻟﺘﻘﯿﯿﻢ ﻓﻌﺎﻟﯿﺔ اﻟﻌﻼج ﺑﺎﻟﻠﯿﺰر ﻋﻨﺪ ﺗﻄﺒﯿﻘﮫ ﻋﻠﻰ ﻧﻘﺎط ﻣﺨﺘﺎرة ﻣﻦ ﻧﻘﺎط اﻟﻮﺧﺰ ﺑﺎﻹﺑﺮ اﻟﺼﯿﻨﯿﺔ ﻓﻲ ﺗﺨﻔﯿﻒ 
وھﻮ ﯾﻌﺘﺒﺮ ﻋﻼج . ﺪم اﻟﻌﻼج ﺑﺎﻟﻠﯿﺰر ﻋﻠﻰ ﻧﻄﺎق واﺳﻊ ﻛﻌﻼج طﺒﻲوﯾﺴﺘﺨ. اﻷﻟﻢ اﻟﻨﺎﺟﻢ ﻋﻦ اﻟﺘﮭﺎب ﻓﻲ ﻋﻈﺎم اﻟﺮﻛﺒﺔ
 .ﻏﯿﺮ ﻣﺆﻟﻢ وآﻣﻦ
ﻧﺤﻦ ﺑﺼﺪد إﺟﺮاء دراﺳﺔ ﻟﻠﺘﺤﻘﻖ ﻣﻦ ﻓﻌﺎﻟﯿﺔ اﻟﻌﻼج ﺑﺎﻟﻠﯿﺰر ﻋﻨﺪ ﺗﺴﻠﯿﻄﮫ ﻋﻠﻰ ﻧﻘﺎط ﻣﺨﺘﺎرة وﻣﺤﺪده ﻣﻦ ﻧﻘﺎط اﻟﻮﺧﺰ 
 .ﺑﺎﻹﺑﺮ اﻟﺼﯿﻨﯿﺔ ﻋﻠﻰ وﺣﻮل ﻣﻔﺼﻞ اﻟﺮﻛﺒﺔ ﻟﻠﻤﺮﺿﻰ اﻟﺬﯾﻦ ﯾﻌﺎﻧﻮن ﻣﻦ اﻟﺘﮭﺎب ﻣﻔﺎﺻﻞ اﻟﺮﻛﺒﺔ
 : ق اﻟﺪراﺳﺔطﺮ
اﻟﻤﺠﻤﻮﻋﺔ اﻷوﻟﻰ . ﺳﻮف ﯾﺘﻢ ﺗﻮزﯾﻊ اﻟﻤﺸﺎرﻛﯿﻦ ﻓﻲ ھﺬه اﻟﺪراﺳﺔ ﻋﺸﻮاﺋﯿﺎ إﻟﻰ ﻣﺠﻤﻮﻋﺘﯿﻦ وذﻟﻚ ﺑﻮاﺳﻄﺔ اﻟﻜﻤﺒﯿﻮﺗﺮ
ﺳﺘﺠﺮى ھﺬه اﻟﺪراﺳﺔ  . ﺳﻮف ﺗﻌﺎﻟﺞ ﺑﻮاﺳﻄﺔ ﻟﯿﺰر ﻧﺸﻂ ﺑﯿﻨﻤﺎ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺜﺎﻧﯿﺔ ﺳﻮف ﺗﻌﺎﻟﺞ ﺑﻮاﺳﻄﺔ ﻟﯿﺰر ﻏﯿﺮ ﻧﺸﻂ
ﻋﻠﻢ ﻣﺴﺒﻖ ﺑﻨﻮﻋﯿﺔ اﻟﻌﻼج ( أﺧﺼﺎﺋﻲ اﻟﻌﻼج اﻟﻄﺒﯿﻌﻲ )ﻓﻲ ظﺮوف ﺧﺎﺻﺔ ﺑﺤﯿﺚ ﻟﻦ ﯾﻜﻮن ﻟﺪى اﻟﻤﺮﯾﺾ واﻟﺒﺎﺣﺚ 
 .اﻟﻤﺴﺘﺨﺪم، ﻓﻘﻂ ﻣﺴﺎﻋﺪ اﻟﺒﺎﺣﺚ ھﻮ ﻣﻦ ﯾﻌﺮف ﻧﻮﻋﯿﺔ اﻟﻌﻼج اﻟﻤﻘﺪم ﻟﻠﻤﺮﯾﺾ
أﺧﺼﺎﺋﻲ اﻟﻌﻼج )إذا ﻛﻨﺖ ﺗﺮﻏﺐ ﻓﻲ اﻟﻤﺸﺎرﻛﺔ ﻓﻲ ھﺬه اﻟﺪراﺳﺔ ﻓﺎﻧﮫ ﺳﻮف ﯾﺘﻢ ﺗﻘﯿﯿﻤﻚ ﺑﻮاﺳﻄﺔ اﻟﺒﺎﺣﺚ اﻟﺮﺋﯿﺲ 
ً ًإذا ﻛﻨﺖ ﻣﻨﺎﺳﺒﺎ ،ﺳﯿﺘﻢ ﺗﻮزﯾﻌﻚ ﻋﺸﻮاﺋﯿﺎ إﻟﻰ واﺣﺪة ﻣﻦ . ء اﻟﺪراﺳﺔﻟﮭﺬه اﻟﺪراﺳﺔ ﻟﻠﺘﺄﻛﺪ ﻣﻦ أﻧﻚ ﻣﻨﺎﺳﺐ ﻹﺟﺮا( اﻟﻄﺒﯿﻌﻲ
وھﺬا ﯾﻌﻨﻲ أﻧﮫ ﺳﯿﻜﻮن ﻟﺪﯾﻚ ﻓﺮﺻﺔ ﻣﺘﺴﺎوﯾﺔ ﻟﯿﺘﻢ ﺿﻤﻚ ﺿﻤﻦ ﻣﺠﻤﻮﻋﺔ اﻟﻠﯿﺰر اﻟﻨﺸﻂ أو إﻟﻰ . اﻟﻤﺠﻤﻮﻋﺘﯿﻦ اﻟﺴﺎﺑﻘﺘﯿﻦ 
  .ﻣﺠﻤﻮﻋﺔ اﻟﻠﯿﺰر ﻏﯿﺮ اﻟﻨﺸﻂ
ﺑﺎﻋﺚ اﻟﻠﯿﺰر ﻏﯿﺮ ﻧﺸﻂ ھﻮ ﻧﻔﺲ . ﻟﺠﮭﺎزﺟﮭﺎز اﻟﻠﯿﺰر اﻟﺬي ﺳﻮف ﯾﺴﺘﺨﺪم ﻓﻲ ھﺬه اﻟﺪراﺳﺔ ﻟﻜﻼ اﻟﻤﺠﻤﻮﻋﺘﯿﻦ ھﻮ ﻧﻔﺲ ا
ﻋﻠﻤﺎ ﺑﺎن ﺑﺎﻋﺚ اﻟﻠﯿﺰر ﻓﻲ ﺣﺎﻟﺔ . ﺑﺎﻋﺚ اﻟﻠﯿﺰر اﻟﻨﺸﻂ وﻟﻜﻦ اﻟﺠﮭﺎز ﻓﻲ ھﺬه اﻷﺛﻨﺎء ﺳﻮف ﯾﻜﻮن ﻓﻲ وﺿﻊ اﻟﺴﻜﻮن
 .اﻟﺴﻜﻮن وﻓﻲ ﺣﺎﻟﺔ اﻟﻮﺿﻊ اﻟﻨﺸﻂ ﯾﺒﻌﺚ ﻟﻮﻧﺎ أﺣﻤﺮا وﻟﻜﻨﮫ ﻻ ﯾﺒﻌﺚ ﺣﺮارة أو ﺻﻮﺗﺎ أو اھﺘﺰازا
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اﻟﻮظﯿﻔﻲ اﻟﺬي ﺗﻌﺎﻧﻲ ﻣﻨﮫ وذﻟﻚ ﻣﻦ ﺧﻼل ﺗﻌﺒﺌﺔ اﺳﺘﺒﯿﺎﻧﺎت ﻣﻌﯿﺎرﯾﺔ ﺳﻮف ﯾﻄﻠﺐ ﻣﻨﻚ أن ﺗﺴﺠﻞ ﻣﺴﺘﻮى اﻷﻟﻢ واﻟﻌﺠﺰ 
ﻣﺒﺎﺷﺮة ﻗﺒﻞ اﻟﺠﻠﺴﺔ اﻷوﻟﻰ ﻣﻦ اﻟﻌﻼج وﺑﻌﺪ اﻟﺠﻠﺴﺔ اﻟﺨﺎﻣﺴﺔ ﺛﻢ ﺑﻌﺪ اﻟﺠﻠﺴﺔ اﻟﺘﺎﺳﻌﺔ واﻷﺧﯿﺮة ﺛﻢ ﺳﻮف ﺗﻌﻄﻰ ﻣﻮﻋﺪا 
 ﺳﺘﻜﻮن ھﻨﺎك .ﻟﻠﻤﺘﺎﺑﻌﺔ ﺑﻌﺪ أرﺑﻌﺔ أﺳﺎﺑﯿﻊ ﺣﯿﺚ ﺳﻮف ﯾﻄﻠﺐ ﻣﻨﻚ أﯾﻀﺎ ﺗﻌﺒﺌﺔ ﻧﻔﺲ اﻻﺳﺘﺒﯿﺎﻧﺎت وﺑﻨﻔﺲ اﻟﻄﺮﯾﻘﺔ اﻟﺴﺎﺑﻘﺔ
 .ﺣﺎﺟﺔ ﻟﺤﻀﻮرك ﻗﺴﻢ اﻟﻌﻼج اﻟﻄﺒﯿﻌﻲ ﺛﻼث ﻣﺮات أﺳﺒﻮﻋﯿﺎ ﻟﻤﺪة ﺛﻼﺛﺔ أﺳﺎﺑﯿﻊ
إذا أﺿﮭﺮ اﻟﻤﺸﺎرﻛﻮن ﻓﻲ ﻣﺠﻤﻮﻋﺔ اﻟﻠﯿﺰر اﻟﻨﺸﻂ  ﺗﺤﺴﻨﺎ ﻗﯿﺎﺳﯿﺎ ﻣﻠﺤﻮظﺎ ﯾﻔﻮق اﻟﻤﺸﺎرﻛﯿﻦ ﻓﻲ ﻣﺠﻤﻮﻋﺔ اﻟﻠﯿﺰرﻏﯿﺮ 
 ﻛﺎﻧﺖ اﻟﻨﺘﺎﺋﺞ ﻏﯿﺮ ذﻟﻚ ﻓﺎﻧﮫ وإذا. ﻧﺸﻂ ﻓﺎﻧﮫ ﺳﻮف ﯾﺘﻢ ﻋﻼج ھﺆﻻء ﺑﺎﻟﻠﯿﺰر اﻟﻨﺸﻂ ﺑﻨﻔﺲ اﻟﻄﺮﯾﻘﺔ وﺑﻨﻔﺲ ﻋﺪد اﻟﺠﻠﺴﺎت
 .ﺳﯿﺘﻢ ﻋﻼج اﻟﺠﻤﯿﻊ ﺑﺎﻟﻄﺮق اﻟﻔﯿﺰﯾﺎﺋﯿﺔ اﻷﺧﺮى اﻟﻤﺘﻮﻓﺮة ﻓﻲ ﻗﺴﻢ اﻟﻌﻼج اﻟﻄﺒﯿﻌﻲ
 :اﻟﻌﻼج
ﺳﯿﺘﻢ وﺿﻊ ﺑﺎﻋﺚ اﻟﻠﯿﺰر ﻋﻠﻰ ﺧﻤﺲ ﻧﻘﺎط ﻣﻮﺟﻮدة ﻋﻠﻰ ﻣﻔﺼﻞ اﻟﺮﻛﺒﺔ اﻟﻤﺼﺎﺑﺔ ﻟﺪﯾﻚ وﺣﻮﻟﮭﺎ ﻟﻤﺪة دﻗﯿﻘﺔ ﻟﻜﻞ ﻧﻘﻄﺔ، 
ﺧﻤﺲ ﻋﺸﺮ دﻗﯿﻘﺔ إﻟﻰ ﻋﺸﺮﯾﻦ دﻗﯿﻘﺔ ھﻲ ﻣﺪة . ج ﺑﺎﻟﻠﯿﺰروﺳﻮف ﯾﻘﻮم ﺑﺎﻟﻌﻼج أﺧﺼﺎﺋﻲ ﻋﻼج طﺒﯿﻌﻲ ذو ﺧﺒﺮة ﺑﺎﻟﻌﻼ
اﻟﺠﻠﺴﺔ اﻟﻌﻼﺟﯿﺔ اﻟﻮاﺣﺪة وﺗﺸﻤﻞ اﻟﻌﻼج ﺑﺎﻟﻠﯿﺰر وﺗﻤﺎرﯾﻦ اﻟﺘﻘﻮﯾﺔ واﻟﺘﻌﻠﯿﻤﺎت واﻟﻨﺼﺎﺋﺢ، أﻣﺎ ﺟﻠﺴﺎت اﻟﺘﻘﯿﯿﻢ واﻟﻌﻼج 
ﻠﺴﺔ ﻣﺒﺎﺷﺮة ﻗﺒﻞ أول ﺟﻠﺴﺔ ﻋﻼج، ﻣﺒﺎﺷﺮة ﻗﺒﻞ اﻟﺠﻠﺴﺔ اﻟﺨﺎﻣﺴﺔ، ﻣﺒﺎﺷﺮة ﻗﺒﻞ اﻟﺠ) ﻓﻘﺪ ﺗﺴﺘﻐﺮق ﺧﻤﺴﺔ وارﺑﻌﻮن دﻗﯿﻘﺔ 
ھﺬا ﯾﺘﻄﻠﺐ ﻣﻨﻚ اﻟﺤﻀﻮر إﻟﻰ ﻗﺴﻢ (.، ﺛﻢ ﺑﻌﺪ ﺳﺘﺔ اﺳﺎﺑﯿﻊ وﺑﻌﺪ ﺳﺘﺔ أﺷﮭﺮ ﻣﻦ اﺧﺮ ﺟﻠﺴﺔ ﻋﻼﺟﯿﺔ(اﻟﺘﺎﺳﻌﺔ)اﻻﺧﯿﺮة 
  (تﺟﻠﺴﺎ٩) أﺳﺎﺑﯿﻊ ٣اﻟﻌﻼج اﻟﻄﺒﯿﻌﻲ ﺛﻼث ﻣﺮات ﻓﻲ اﻷﺳﺒﻮع ﻟﻤﺪة 
 :اﻷﺧﻄﺎر واﻹﺿﺮار اﻟﻤﺤﺘﻤﻠﺔ ﻣﻦ اﻟﻤﺸﺎرﻛﺔ ﻓﻲ ھﺬه اﻟﺪراﺳﺔ
اﻧﻚ ﻟﻦ ﺗﺸﻌﺮ ﺑﺄي ﺣﺮارة وﻟﻜﻦ ﺳﺘﺮى . ﻌﻲ ﻋﺎدة ﻣﺎ ﯾﻜﻮن آﻣﻦ وﻏﯿﺮ ﻣﺆذاﻟﻌﻼج ﺑﺎﻟﻠﯿﺰر اﻟﻤﺴﺘﺨﺪم ﻓﻲ اﻟﻌﻼج اﻟﻄﺒﯿ
ﻟﺬﻟﻚ ﻓﺎن اﻟﻤﺮﯾﺾ وأﺧﺼﺎﺋﻲ . اﻟﺨﻄﺮ اﻟﻮﺣﯿﺪ اﻟﻤﻤﻜﻦ ﻋﻨﺪﻣﺎ ﯾﺴﻠﻂ ﺿﻮء اﻟﻠﯿﺰر ﻣﺒﺎﺷﺮة ﻋﻠﻰ ﻋﯿﻨﯿﻚ. ﺿﻮء أﺣﻤﺮ
أﯾﻀﺎ، ﯾﻤﻨﻊ اﺳﺘﺨﺪام اﻟﻌﻼج . اﻟﻌﻼج اﻟﻄﺒﯿﻌﻲ ﺳﻮف ﯾﻀﻌﻮن ﻧﻈﺎرات ﺧﺎﺻﺔ ﻋﻠﻰ أﻋﯿﻨﮭﻢ ﻟﺘﻮﻓﯿﺮ اﻟﺤﻤﺎﯾﺔ اﻟﻜﺎﻣﻠﺔ
ﻛﺬﻟﻚ ﯾﺠﺐ ﺗﺠﻨﺐ اﻟﻌﻼج ﺑﺎﻟﻠﯿﺰر ﻋﻠﻰ ﻣﻨﺎطﻖ اﻟﻨﺰف . ﻟﻠﯿﺰر ﻓﻲ ﺑﻌﺾ اﻟﺤﺎﻻت ﻣﺜﻞ ﻣﺮﺿﻰ اﻟﺴﺮطﺎﻧﺎت اﻟﻨﺸﻄﺔﺑﺎ
وﯾﺠﺐ ﺗﻮﺧﻲ اﻟﺤﺬر ﺑﺎﻟﻨﺴﺒﺔ ﻟﻠﻤﺮﺿﻰ . وﺧﺎﺻﺔ اﻟﺠﺮوح اﻟﻤﻔﺘﻮﺣﺔ واﻟﻤﻠﻮﺛﺔ ﻷن اﻟﻠﯿﺰر ﯾﻤﻜﻦ أن ﯾﺤﻔﺰ ﻋﻤﻞ اﻟﺒﻜﺘﯿﺮﯾﺎ
وﯾﻨﺒﻐﻲ ﺗﺠﻨﺐ اﻹﺷﻌﺎع اﻟﻤﺒﺎﺷﺮ (. ﻌﺔ اﻟﺸﻤﺲردود اﻟﻔﻌﻞ اﻟﺴﻠﺒﯿﺔ ﻷﺷ)اﻟﺬﯾﻦ ﻟﺪﯾﮭﻢ ﺗﺎرﯾﺦ ﻣﻦ اﻟﺤﺴﺎﺳﯿﺔ ﻣﻦ اﻟﻀﻮء 
 .ﻟﺬا، إذا ﻛﺎن ﻟﺪﯾﻚ أي ﻣﻦ اﻟﺤﺎﻻت اﻟﺴﺎﺑﻘﺔ، ﻣﻦ ﻓﻀﻠﻚ ﻻ ﺗﺘﺮدد ﻓﻲ إﺑﻼغ اﻟﺒﺎﺣﺚ. ﻋﻠﻰ رﺣﻢ اﻟﻤﺮأة اﻟﺤﺎﻣﻞ
 :ﻓﻮاﺋﺪ اﻟﻤﺸﺎرﻛﺔ ﻓﻲ اﻟﺪراﺳﺔ
إن اﻟﻤﻌﻠﻮﻣﺎت . ﺑﯿﻨﺖ ﺑﻌﺾ اﻟﺪراﺳﺎت اﻟﺴﺎﺑﻘﺔ أن اﻟﻌﻼج ﺑﺎﻟﻠﯿﺰر ﯾﻌﺘﺒﺮ ﻋﻼﺟﺎ ﻧﺎﺟﺤﺎ ﻓﻲ ﺗﺨﻔﯿﻒ آﻻم اﻟﺘﮭﺎب اﻟﻤﻔﺎﺻﻞ
اﻟﺘﻲ ﺳﯿﺘﻢ ﺟﻤﻌﮭﺎ ﻣﻦ ھﺬه اﻟﺪراﺳﺔ ﺳﻮف ﺗﺴﺎﻋﺪ ﻋﻠﻰ زﯾﺎدة ﻣﻌﺮﻓﺘﻨﺎ ﻟﻔﻌﺎﻟﯿﺔ اﻟﻌﻼج ﺑﺎﻟﻠﯿﺰر ﻓﻲ ﻋﻼج اﻟﻤﺮﺿﻰ اﻟﺬﯾﻦ 
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ﻓﻲ ﻧﮭﺎﯾﺔ . ﯾﻌﺎﻧﻮن ﻣﻦ آﻻم ﻓﻲ اﻟﺮﻛﺒﺔ ﻧﺘﯿﺠﺔ ﻻﻟﺘﮭﺎب ﻋﻈﺎم اﻟﻤﻔﺎﺻﻞ ﻣﺜﻞ ﻣﺎ ﺣﺪث ﻣﻌﻚ وﻣﺜﻞ ﻣﺎﯾﺤﺪث ﻣﻊ اﻵﺧﺮﯾﻦ
 .أﺧﺮى ﻣﻦ اﻟﻌﻼج ﻣﺘﻮﻓﺮة ﻓﻲ ﻗﺴﻢ اﻟﻌﻼج اﻟﻄﺒﯿﻌﻲ" ﻘﻰ طﺮﻗﺎاﻟﺪراﺳﺔ إذا ﻟﻢ ﯾﻈﮭﺮ ﻟﺪﯾﻚ أي ﺗﺤﺴﻦ ﺳﻮف ﺗﺘﻠ
 :ﻋﺪم اﻟﻘﺪرة ﻋﻠﻰ اﻟﻤﺸﺎرﻛﺔ ﻓﻲ اﻟﺪراﺳﺔ
ﻟﺬا، إذا ﻛﻨﺖ ﻻ ﺗﺮﻏﺐ ﻓﻲ اﻟﻤﺸﺎرﻛﺔ ﻓﻲ اﻟﺪراﺳﺔ، ﺳﻮف ﯾﺘﻢ اﻟﺘﻌﺎﻣﻞ ﻣﻌﻚ . اﻟﻤﺸﺎرﻛﺔ ﻓﻲ ھﺬه اﻟﺪراﺳﺔ ھﻮ طﻮﻋﻲ
 ﻓﻲ وﻗﺖ ﻻﺣﻖ وأردت اﻻﻧﺴﺤﺎب ﻓﻠﻚ إذا ﺷﺎرﻛﺖ ﻓﻲ اﻟﺪراﺳﺔ ﺛﻢ ﻏﯿﺮت رأﯾﻚ. ﺑﺎﻟﻄﺮﯾﻘﺔ اﻟﻤﺘﺒﻌﺔ ﻓﻲ اﻟﻮﺿﻊ اﻟﻄﺒﯿﻌﻲ
اﻟﺤﻖ ﻓﻲ ذﻟﻚ  ﻓﻲ أي وﻗﺖ ﺗﺸﺎء دون اﻟﺤﺎﺟﺔ ﻹﻋﻄﺎء أي ﺗﻔﺴﯿﺮ أو ﺗﺒﺮﯾﺮ، وﺳﯿﺘﻢ اﻟﺘﻌﺎﻣﻞ ﻣﻌﻚ ﺑﻌﺪ ذﻟﻚ ﺑﺎﻟﻄﺮﯾﻘﺔ 
 .اﻟﻌﺎدﯾﺔ اﻟﻤﺘﺒﻌﺔ ﻣﻊ اﻟﻤﺮﺿﻰ اﻻﺧﺮﯾﻦ
 :اﻟﺴﺮﯾﺔ
ﻞ اﻟﻮﺛﺎﺋﻖ اﻟﺨﺎﺻﺔ ﺑﮭﺎ وﺳﻮف ﺗﺴﺠ. ﺳﯿﺘﻢ اﻟﺤﻔﺎظ ﻋﻠﻰ ﻛﺎﻓﺔ اﻟﻤﻌﻠﻮﻣﺎت أو اﻟﻨﺘﺎﺋﺞ اﻟﺘﻲ ﺗﻢ ﺟﻤﻌﮭﺎ ﻋﻨﻜﻢ ﺑﺴﺮﯾﺔ ﺗﺎﻣﺔ
 .ﻟﺬا، ﻻ ﯾﻤﻜﻦ ﻷﺣﺪ اﻻطﻼع أو اﻻﺳﺘﻔﺎدة ﻣﻦ اﻟﻨﺘﺎﺋﺞ واﻟﻤﻌﻠﻮﻣﺎت. ﻛﺮﻗﻢ ﺑﺪﻻ ﻣﻦ اﺳﻢ
 : إذا ﻛﻨﺖ ﺑﺤﺎﺟﺔ إﻟﻰ أي اﺳﺘﻔﺴﺎر ﻋﻦ ھﺬه اﻟﺪراﺳﺔ، ﻣﻦ ﻓﻀﻠﻚ ﻻ ﺗﺘﺮدد ﻓﻲ اﻻﺗﺼﺎل ب
 ﻋﺒﺪا Ϳ اﻟﺮﺷﻮد :اﻟﺒﺎﺣﺚ
 ﻣﺴﺘﺸﻔﻰ ﻗﻮى اﻷﻣﻦ
 ﻗﺴﻢ اﻟﻌﻼج اﻟﻄﺒﯿﻌﻲ
 ٣٠٧٧٨٤٥٥٥٠: ﺟﻮال 
 : 55@oohay.moc duojﺑﺮﯾﺪ اﻟﻜﺘﺮوﻧﻲ
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APPENDIX III (A): Consent form 
(English version) 
 
 
I,…………………................................, freely and voluntarily agree to participate in this 
research study that conducted at Security Forces Hospital in Physiotherapy department. 
I understand that I am free to withdraw from the study at any time I wish and there is no 
need to give any explanation, then I will be treated in the normal way. I further 
understand that my confidentiality will be preserved. 
 I have read and understood the information sheet given to me and all questions have 
been answered to my complete satisfaction. 
Signature                …………………………                          Date……………… 
 
Participant Name ………………………….                           Phone No. …………… 
 
For investigator use:  
I confirm that I have explained the clinical trial and supplied the participant with an 
information sheet, which, in my opinion, is easy to read and understand by the 
participant.   
Investigator Name…………………………                           Date…………………….. 
 
Signature:             ………………………… 
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 )ﻧﻤﻮذج ﻣﻮاﻓﻘﺔ(
 
، ﺑﺤﺮﯾﺔ وطﻮاﻋﯿﺔ أواﻓﻖ ﻋﻠﻰ اﻟﻤﺸﺎرﻛﺔ ﻓﻲ ھﺬه اﻟﺪراﺳﺔ اﻟﺘﻲ .....................................................ﻧﻌﻢ أﻧﺎ
أﻓﮭﻤﺖ ﺑﺄﻧﻨﻲ ﺣﺮ ﻓﻲ اﻻﻧﺴﺤﺎب ﻣﻦ اﻟﺪراﺳﺔ ﻓﻲ (. ﻗﺴﻢ اﻟﻌﻼج اﻟﻄﺒﯿﻌﻲ) ﺳﻮف ﺗﻘﺎم ﻓﻲ ﻣﺴﺘﺸﻔﻰ ﻗﻮى اﻷﻣﻦ ﺑﺎﻟﺮﯾﺎض
ﻨﺎك ﺣﺎﺟﺔ ﻹﻋﻄﺎء أي ﺗﻔﺴﯿﺮ أو ﻣﺒﺮر، وﻣﻦ ﺛﻢ ﺳﯿﺘﻢ اﻟﺘﻌﺎﻣﻞ ﻣﻌﻲ ﺑﺎﻟﻄﺮق اﻟﻌﺎدﯾﺔ أي وﻗﺖ ﺧﻼل اﻟﺪراﺳﺔ وﻟﯿﺲ ھ
 .ﻛﺬﻟﻚ أﻓﮭﻤﺖ ﺑﺄﻧﮫ ﺳﻮف ﯾﺘﻢ اﻟﺘﻌﺎﻣﻞ ﺑﺎﻟﻤﻌﻠﻮﻣﺎت اﻟﺨﺎﺻﺔ ﺑﻲ ﺑﺴﺮﯾﺔ ﺗﺎﻣﺔ. اﻟﻤﺘﺒﻌﺔ ﻟﺪى اﻟﻘﺴﻢ
 .ﻟﻘﺪ ﻗﺮأت وﻓﮭﻤﺖ ورﻗﺔ اﻟﻤﻌﻠﻮﻣﺎت اﻟﺘﻲ أﻋﻄﯿﺖ ﻟﻲ وﻟﻘﺪ ﺗﻤﺖ اﻹﺟﺎﺑﺔ ﻋﻠﻰ ﺟﻤﯿﻊ أﺳﺌﻠﺘﻲ ﺑﺎﻟﻜﺎﻣﻞ 
 
 ..................ﺗﺎرﯾﺦ...........................                         ...اﻻﺳﻢ   
 
 ...............رﻗﻢ اﻟﮭﺎﺗﻒ...............................                        اﻟﺘﻮﻗﯿﻊ 
 
 :ﻻﺳﺘﺨﺪام اﻟﺒﺎﺣﺚ
ﻲ ﻓﻲ رأﯾﻲ أﻧﮫ ﻣﻦ اﻟﺴﮭﻞ ﻗﺮاءﺗﮭﺎ أؤﻛﺪ ﺑﺄﻧﻨﻲ أوﺿﺤﺖ اﻟﺘﺠﺎرب اﻟﺴﺮﯾﺮﯾﺔ وﺗﺰوﯾﺪ اﻟﻤﺸﺎرﻛﯿﻦ ﺑﻮرﻗﺔ اﻟﻤﻌﻠﻮﻣﺎت، واﻟﺘ
 .وﻓﮭﻤﮭﺎ ﻣﻦ ﻗﺒﻞ اﻟﻤﺸﺎرﻛﯿﻦ
 
 .......................اﻟﺘﺎرﯾﺦ.................................                           اﻻﺳﻢ
 
 ..............................: اﻟﺘﻮﻗﯿﻊ
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APPENDIX IV: Ethical approval 
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APPENDIX V: CONSORT 
 
Checklist of Items for Reporting Trials of Non-pharmacologic Treatments 
 
Section Item Standard CONSORT Description 
Extension for Non-
pharmacologic Trials 
Title and abstract 1 
 
How participants were allocated to 
interventions (e.g., “random 
allocation,” “randomised,” or 
“randomly assigned”) 
In the abstract, description of the 
experimental treatment, 
comparator, care providers, 
centres, and blinding status 
Introduction    
Background 2 Scientific background and 
explanation of rationale 
 
Methods    
Participants 3 Eligibility criteria for participants 
and the settings and locations where 
the data were collected 
When applicable, eligibility 
criteria for centres and those 
performing the interventions 
Interventions 4 Precise details of the interventions 
intended for each group and how and 
when they were actually 
administered 
Precise details of both the 
experimental treatment and 
comparator  
 4A  Description of the different 
components of the interventions 
and, when applicable, descriptions 
of the procedure for tailoring the 
interventions to individual 
participants 
 4B  Details of how the interventions 
were standardized 
 4C  Details of how adherence of care 
providers with the protocol was 
assessed or enhanced 
Objectives 5 Specific objectives and hypotheses  
Outcomes 6 Clearly defined primary and 
secondary outcome measures and, 
when applicable, any methods used 
to enhance the quality of 
measurements (e.g., multiple 
observations, training of assessors) 
 
Sample size 7 How sample size was determined 
and, when applicable, explanation of 
any interim analyses and stopping 
rules 
When applicable, details of 
whether and how the clustering by 
care providers or centres was 
addressed 
Randomisation– 
sequence 
generation 
8 Method used to generate the random 
allocation sequence, including details 
of any restriction (e.g., blocking, 
stratification) 
When applicable, how care 
providers were allocated to each 
trial group 
Allocation 
concealment 
9 Method used to implement the 
random allocation sequence (e.g., 
numbered containers or central 
telephone), clarifying whether the 
sequence was concealed until 
interventions were assigned 
 
Implementation 10 Who generated the allocation 
sequence, who enrolled participants, 
and who assigned participants to 
their groups 
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Blinding (masking) 11A 
 
Whether or not participants, those 
administering the interventions, and 
those assessing the outcomes were 
blinded to group assignment 
Whether or not those 
administering co-interventions 
were blinded to group assignment 
 11B  If blinded, method of blinding and 
description of the similarity of 
interventions† 
Statistical methods 12 Statistical methods used to compare 
groups for primary outcome (s); 
methods for additional analyses, such 
as subgroup analyses and adjusted 
analyses 
When applicable, details of 
whether and how the clustering by 
care providers or centres was 
addressed 
Results    
Participant flow 13 Flow of participants through each 
stage (a diagram is strongly 
recommended) ---specifically, for 
each group, report the numbers of 
participants randomly assigned, 
receiving intended treatment, 
completing the study protocol, and 
analysed for the primary outcome; 
describe deviations from study as 
planned, together with reasons 
The number of care providers or 
centres performing the 
intervention in each group and the 
number of patients treated by each 
care provider or in each centre 
Implementation of 
intervention† 
New 
item 
 Details of the experimental 
treatment and comparator as they 
were implemented 
Recruitment 14 Dates defining the periods of 
recruitment and follow-up 
 
Baseline data 15 Baseline demographic and clinical 
characteristics of each group 
 
When applicable, a description of 
care providers (case volume, 
qualification, expertise, etc.) and 
centres (volume) in each group 
Numbers analysed 16 Number of participants 
(denominator) in each group 
included in each analysis and 
whether analysis was by “intention-
to-treat”; state the results in absolute 
numbers when feasible (e.g., 10/20, 
not 50%) 
 
Outcomes and 
estimation 
17 For each primary and secondary 
outcome, a summary of results for 
each group and the estimated effect 
size and its precision (e.g., 95% 
confidence interval)  
 
Ancillary analyses 18 Address multiplicity by reporting 
any other analyses performed, 
including subgroup analyses and 
adjusted analyses, indicating those 
prespecified and those exploratory 
 
Adverse events 19 All important adverse events or side 
effects in each intervention group 
 
Discussion    
Interpretation 20 Interpretation of the results, taking 
into account study hypotheses, 
sources of potential bias or 
imprecision, and the dangers 
associated with multiplicity of 
analyses and outcomes 
In addition, take into account the 
choice of the comparator, lack of 
or partial blinding, and unequal 
expertise of care providers or 
centres in each group 
   218 
Generalizability 21 Generalizability (external validity) of 
the trial findings 
Generalizability (external 
validity) of the trial findings 
according to the intervention, 
comparators, patients, and care 
providers and centres involved in 
the trial 
Overall evidence 22 General interpretation of the results 
in the context of current evidence 
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APPENDIX VI: Randomisation table 
 
Groups 
A: Active; C: control Random blocks Randomisation numbers 
A 1 0.07 
A 1 0.09 
C 1 0.15 
C 1 0.19 
C 1 0.23 
A 1 0.31 
A 1 0.42 
A 1 0.45 
C 1 0.59 
C 1 0.68 
C 2 0.02 
A 2 0.31 
C 2 0.41 
A 2 0.42 
A 2 0.48 
A 2 0.58 
C 2 0.69 
C 2 0.77 
C 2 0.78 
A 2 0.92 
C 3 0.01 
C 3 0.09 
A 3 0.11 
C 3 0.19 
A 3 0.43 
C 3 0.44 
A 3 0.51 
A 3 0.66 
A 3 0.91 
C 3 0.93 
C 4 0.12 
C 4 0.32 
A 4 0.36 
C 4 0.46 
   220 
A 4 0.51 
C 4 0.53 
A 4 0.55 
C 4 0.55 
A 4 0.62 
A 4 0.87 
A 5 0.04 
A 5 0.31 
C 5 0.36 
A 5 0.41 
C 5 0.42 
A 5 0.48 
A 5 0.53 
C 5 0.79 
C 5 0.84 
C 5 0.84 
A 6 0.12 
C 6 0.15 
A 6 0.2 
A 6 0.37 
A 6 0.42 
A 6 0.43 
C 6 0.51 
C 6 0.55 
C 6 0.77 
C 6 0.88 
A 7 0.23 
C 7 0.31 
C 7 0.41 
A 7 0.41 
A 7 0.45 
A 7 0.49 
C 7 0.55 
C 7 0.72 
A 7 0.77 
C 7 0.81 
A 8 0.05 
A 8 0.24 
   221 
C 8 0.26 
C 8 0.26 
C 8 0.29 
C 8 0.39 
C 8 0.42 
A 8 0.73 
A 8 0.87 
A 8 0.91 
C 9 0.22 
A 9 0.22 
C 9 0.31 
C 9 0.4 
C 9 0.51 
A 9 0.52 
A 9 0.61 
A 9 0.8 
A 9 0.81 
C 9 0.93 
C 10 0.08 
A 10 0.1 
A 10 0.11 
C 10 0.17 
A 10 0.25 
A 10 0.65 
A 10 0.68 
C 10 0.73 
C 10 0.74 
C 10 0.85 
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SKFS
I~-------------------------------Today Date =
The Saudi Knee Function Scale
A Knee Osteoarthritis Index
Instructions
In each of the five sections in the following questionnaire you will be asked to rate the
amount of Pain, Stiffness (slowness or limitation of movement), Difficulty, and Social
and Emotional dysfunction, on a scale as follows:
1. If you choose '0' the face on the left hand side then you are indicating that you
have no pain
2. If you choose '4' the face on the right hand side then you are indicating that
you have extreme pain.
The further to the left you go the less pain, stiffness, difficulty, or dysfunction you are
experiencing, and the further to the right the more pain, stiffness, difficulty, or
dysfunction you are experiencing.
SKFS
A. Pain
Please indicate the amount of pain experienced in your knee with the following activities over the last
three days:
1. At night disturbing sleep, or at rest during the day 0 Z 3 4
2. Getting on or off the floor 0 2 3 4
3. Getting on or off a (regular) chair 0 1 2 3 4
4. Walking on a flat surface ( short distance approx. 50m) 0 1 2 3 4
5. Going up and down the stairs (one flight) 0 2 3 4
6. Standing in prayers (or short time < 5 min 0 2 3 4
7. Bowing, prostrating, or sitting in prayers 0 2 3 4
8. Squatting (like when using an Arabic toilet) 0 2 3 4
B. Stiffness
In the following questions you are asked to rate the amount of stiffness (slowness & limitation in
movement, not pain) you are experiencing at the knee over the last three days:
1. How severe is your stiffness after first waking in the morning 0 2 3 4
2. How severe is your stiffness after prolonged 0 2 3 4
sitting on the floor or on a chair
C. Physical Function
Please indicate the degree of difficulty you are having because of your knee with the following
activities over the last three days:
1. Walking on a flat surface 0 1 2 3 4
2. Getting on or off the floor 0 1 2 3 4
3. Getting on or off a (regular) chair 0 1 2 3 4
4. Going up the stairs (one flight) 0 1 2 3 4
5. Going down the stairs (one flight) 0 1 2 3 4
6. Standing in prayers (or for short time, less than 5 min) 0 1 Z 3 4
7. Bending to the floor (Bowing) 0 1 2 3 4
8. Prostrating in prayers 0 1 2 3 4
9. Kneeling in prayers 0 1 2 3 4
10. Squatting 0 1 2 3 4
11. Getting into or out of the car 0 1 2 3 4
12. Lifting or carrying heavy objects 0 2 3 4
SKFS
D. Social function
Please indicate how much does your knee problem affects the following social activities
1. Visiting (friends or relatives) 0 2 3 4
2. Attending social events (weddings, etc.) 0 2 3 4
3. Having guests 0 2 3 4
E. Emotional function
Please indicate how much you have been bothered by the following feelings because of your knee
problem
1. Feeling low, lacking enthusiasm
2. Nervous, anxious
3. Easily annoyed, irritated
o
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APPENDIX IX: Demographical information  
 
Today’s Date ______/______/______                               Patient No: .............. 
 
Physician's name: ............................ 
 
 
Patient’s Name:...................................................................,   Initial Ms Mr Mrs  
 
 
Birth Date        /      /                           Age ()                      Sex F ()   M () 
 
 
Weight: .............                                 Height: ....... 
 
 
Marital Status:                                    Single ()                   Married ()                                    
 
 
Street Address... ..........................    City:.........................Post Code:...................... 
 
 
Phone Number:.......................                                      May We Leave a Message?  
                                                                                                    Yes () No () 
 
 
Occupation: Student ()    Employer ().............................  Retired (),   
 
Previous job........................ 
 
Employer Phone Number: ... 
 
 
Onset disease: ............................. 
 
 
Have you or an immediate family member ever been told you have the following: 
 
                                                                                       Self                                 Family 
 
Osteoarthritis                                                                  Y N                                    Y N 
 
Cancer                                                                            Y N                                    Y N 
 
History of photosensitivity                                            Y N                                    Y N  
(Adverse reactions to sunlight) 
 
Diabetes                                                                         Y N                                    Y N 
 
High Blood Pressure                                                      Y N                                    Y N 
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Heart Disease                                                                 Y N                                    Y N 
 
Are you pregnant?    Y ()    N ()   
 
 
Are your symptoms?        ()  Better                () Worse                 () Same 
 
 
Do you currently have problems with the following? 
 
 
()  Driving   () Walking   () Standing   () Bending   () Lifting   () Up from Chair or the 
floor 
 
Days per week you exercise: 0 1 2 3 4 5 6 7 
 
 
How are you sleeping at night?  Intermittent because of pain ()   Normal () 
 
 
Are you now under medications?  No ()    Yes   ()................................................. 
 
 
Please list any major surgery and hospitalisations: ................................................... 
 
 
Have you ever had an X-ray for your knee?         Yes () No () Result: ..........................  
 
 
Have you ever had an MRI/CT scan for your knee?    Yes ()   No ()  
Result: .......................... 
 
 
Have you ever been treated by Physical Therapist?   Yes ()   No () 
 
If Yes, When?   ................................. 
 
 
What were you treated for?    ............................................................... 
 
 
What was the result? ............................................................... 
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APPENDIX X: Visual analogue scale scores 
Table1 VAS scores for each participant in the active group for all study periods 
 
Subject 
ID Baseline 5 sessions 9 sessions 
After Six 
Weeks 
After Six 
Months 
1 9 5 7 6 7 
2 9.5 4.5 5 4 2 
3 9.5 9.5 6 6 5 
4 9 3 1.5 3.5 3 
5 7 5 3 4 6 
6 5 1.5 4 1.5 5 
7 9 6 5 3 5 
8 5 3 2.5 1.5 1 
9 6 3 3.5 5 3 
10 5 3 2.5 3 5 
11 5.5 2 2 2 1 
12 6 1 0.5 0.5 2 
13 8 8 4.5 5 4 
14 4 3 1.5 5 2 
15 6.5 3 2 1 2 
16 8 5 5 3.5 3 
17 7 2.5 2 1 2 
18 4.5 1.5 2 2 2 
19 3 1 1 1 1 
20 5 2.5 2 4 4.5 
21 8 5 5 3 5 
22 3.5 3 1 0.5 6 
23 5 4 3 3.5 3 
24 5.5 1 1.5 2 0.5 
25 7.5 6 5 3.5 3 
26 5 5 4 2 4 
Total/260 166 97 82 77 87 
Total VAS = 10 Scores, 26 subjects x 10 = 260 scores 
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Table 2 VAS scores for each participant in the control group for all study periods 
Subject 
 ID  Baseline 5 sessions 9 sessions 
After Six 
Weeks 
After Six 
Months 
1 9 9.5 9 8 8.5 
2 3.5 1.5 1 2 1.5 
3 5.5 7 7 3.5 4 
4 5 5.5 2 4 2 
5 7 4 3.5 3.5 6 
6 4.5 4 4 6 6 
7 6 2.5 2.5 ٥ 6 
8 4 3.5 3 3 5 
9 3.5 3 3 5 7 
10 6 7 1.5 ٤ 2 
11 6 3 2 5 4 
12 4 4 1.5 3 4 
13 7 3 1 3 4 
14 6 5 5 5 7 
15 6.5 7 7 8 6 
16 9.5 9.5 9 9 8.5 
17 8.5 3 3 2 4.5 
18 3.5 2.5 3 3 6 
19 6 7 5 5 2.5 
20 8 8 5 5 8 
21 5 5 4 2.5 3 
22 6 3 3 2 4 
23 6 2.5 2 2 9 
Total/230 136 110 87 9٨.5 118.5 
Total VAS = 10 Scores, 23subjects x 10 = 230 scores 
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APPENDIX XI: Saudi knee functional scale (total) 
Table1 SKFS (total) for each participant in the active group for all study periods 
Subject 
 ID  Baseline 5 sessions 9 sessions 
After Six 
Weeks 
After Six 
Months 
1 94 63 6٧ 6٤ 72 
2 89 55 29 24 19 
3 60 55 49 58 41 
4 85 40 26 30 22 
5 81 76 43 3٧ 51 
6 62 37 27 24 43 
7 92 56 50 68 61 
8 60 18 18 7 5 
9 68 35 21 51 19 
10 34 21 14 7 21 
11 44 8 4 10 8 
12 45 14 2 4 14 
13 81 82 52 63 43 
14 63 37 37 55 23 
15 57 31 21 10 21 
16 64 44 26 31 44 
17 66 39 23 31 34 
18 24 13 10 14 27 
19 23 10 7 12 9 
20 55 35 39 35 38 
21 63 47 43 41 59 
22 40 20 12 12 44 
23 42 39 38 35 35 
24 13 14 6 14 2 
25 65 53 51 33 26 
26 58 35 21 17 36 
Total/2912 1528 977 73٦ 7٨٧ 817 
A total of the 5 SKFS subscales = 112 scores,  
26 subjects x 112 = 2912 scores 
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Table 2 SKFS (total) for each participant in the control group for all study periods 
Subject 
ID Baseline 5 sessions 9 sessions 
After Six 
Weeks 
After Six 
Months 
1 85 88 88 80 84 
2 28 15 14 18 19 
3 84 74 76 63 55 
4 65 65 46 40 21 
5 78 46 57 32 53 
6 46 45 34 58 59 
7 49 15 19 ٢٣ 33 
8 49 47 45 43 40 
9 58 33 36 49 55 
10 66 62 26 39 32 
11 70 43 41 50 51 
12 70 44 31 40 46 
13 74 38 29 35 51 
14 37 39 49 55 53 
15 48 52 43 51 54 
16 58 54 53 47 56 
17 71 39 36 29 42 
18 27 15 1 17 51 
19 64 71 49 32 31 
20 63 51 60 54 65 
21 57 50 59 55 35 
22 51 9 11 5 21 
23 60 40 30 28 57 
Total/2576 1358 1035 933 9٤٣ 1064 
A total of the 5 SKFS subscales = 112 scores,  
23 subjects x 112 = 2576 scores 
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APPENDIX XII: Saudi knee functional scale 
(subscales) 
Section A - Pain 
 
Table1 Pain scores for each participant in the active group for all study periods 
Subject 
 ID  Baseline 5 sessions 9 sessions 
After Six 
Weeks 
After Six 
Months 
1 27 20 24 22 18 
2 28 16 8 7 7 
3 17 17 12 16 11 
4 26 13 6 10 8 
5 20 20 14 13 18 
6 19 9 12 9 13 
7 23 14 13 15 15 
8 16 8 8 3 2 
9 19 7 7 16 8 
10 11 6 4 3 10 
11 14 3 1 5 3 
12 15 5 0 1 6 
13 21 20 12 18 12 
14 16 11 8 15 8 
15 17 11 7 3 5 
16 22 13 9 10 13 
17 18 11 9 8 13 
18 10 6 5 7 10 
19 9 5 4 6 3 
20 15 10 12 10 12 
21 22 19 14 13 18 
22 13 8 5 3 14 
23 13 13 12 11 10 
24 2 4 4 5 0 
25 19 13 13 8 8 
26 15 8 4 4 11 
Total/832 447 290 227 241 256 
Pain subscale contains 8 questions of pain, total scores= 32 scores,  
26 subjects x 32 = 832 scores 
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Table 2 Pain scores for each participant in the control group for all study periods 
Subject 
 ID  Baseline 5 sessions 9 sessions 
After Six 
Weeks 
After Six 
Months 
1 22 24 22 21 21 
2 9 5 4 5 9 
3 24 20 19 16 15 
4 15 17 12 13 5 
5 22 11 13 9 16 
6 15 16 12 19 18 
7 15 5 7 10 15 
8 14 12 13 13 15 
9 17 7 9 13 16 
10 21 19 9 12 12 
11 20 10 9 11 12 
12 17 9 9 14 14 
13 21 12 10 9 19 
14 11 10 16 20 18 
15 12 14 11 14 13 
16 16 15 14 17 18 
17 21 11 9 8 11 
18 8 5 1 6 15 
19 20 24 16 11 13 
20 19 15 16 17 19 
21 15 11 9 13 10 
22 15 5 2 2 9 
23 17 11 10 12 17 
Total/736 386 288 252 285 330 
Pain subscale contains 8 questions of pain, total scores= 32 scores,  
23 subjects x 32 = 736 scores 
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Section B - Stiffness  
 
Table 3 Stiffness scores for each participant in the active group for all study periods 
Subject 
 ID  Baseline 5 sessions 9 sessions 
After Six 
Weeks 
After Six 
Months 
1 8 4 ٢ ٣ 5 
2 8 2 0 1 1 
3 6 6 4 4 3 
4 6 2 0 2 1 
5 6 6 6 ٤ 4 
6 2 3 3 2 4 
7 6 4 2 6 4 
8 6 2 0 0 0 
9 4 6 3 3 0 
10 4 4 1 0 2 
11 6 0 0 2 1 
12 5 2 1 1 1 
13 8 6 4 5 4 
14 4 2 2 4 2 
15 6 4 2 0 0 
16 5 5 2 4 5 
17 6 2 2 4 3 
18 0 0 0 0 1 
19 4 2 0 1 1 
20 4 6 2 2 2 
21 6 0 0 2 5 
22 4 4 1 2 4 
23 4 3 4 4 3 
24 4 0 0 1 0 
25 5 6 6 2 2 
26 4 2 2 2 3 
Total/208 131 83 ٤٩ 6١ 61 
Stiffness subscale contains 2 questions of stiffness, total scores= 8 scores,  
26 subjects x 8 = 208 scores 
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Table 4 Stiffness scores for each participant in the control group for all study periods 
Subject 
 ID  Baseline 5 Sessions 9 Sessions 
After Six 
Weeks 
After Six 
Months 
1 7 8 8 8 8 
2 1 0 0 2 0 
3 6 4 6 4 3 
4 6 4 4 6 3 
5 6 1 4 0 2 
6 4 3 2 5 4 
7 5 2 2 ٥ 2 
8 4 1 1 2 1 
9 4 4 3 6 4 
10 6 6 2 4 1 
11 5 1 1 1 1 
12 4 2 0 2 2 
13 6 0 2 3 2 
14 6 5 6 6 6 
15 5 6 4 6 3 
16 4 6 6 4 5 
17 6 6 4 4 2 
18 2 0 0 2 4 
19 6 6 4 2 1 
20 5 4 6 4 5 
21 6 3 6 4 2 
22 6 1 1 0 0 
23 6 5 2 1 6 
Total/184 116 78 74 ٨١ 67 
 
Stiffness subscale contains 2 questions of stiffness, total scores= 8 scores,  
23 subjects x 8 = 184 scores 
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Section C - Physical Function 
 
Table 5 Physical Function scores for each participant in the active group for all study 
periods 
Subject 
 ID  Baseline 5 Sessions 9 Sessions 
After Six 
Weeks 
After Six 
Months 
1 44 30 30 29 31 
2 36 24 14 15 7 
3 35 32 29 27 18 
4 39 14 12 15 13 
5 35 33 17 14 18 
6 27 16 12 13 16 
7 40 25 19 29 26 
8 27 7 10 4 3 
9 27 12 7 23 8 
10 15 11 9 4 9 
11 22 5 3 3 4 
12 19 7 1 2 6 
13 33 34 22 23 15 
14 26 17 15 25 10 
15 28 16 12 7 10 
16 25 17 12 13 21 
17 30 17 10 14 14 
18 14 4 5 7 11 
19 6 3 3 4 3 
20 25 13 19 17 16 
21 29 28 26 26 32 
22 20 8 6 7 21 
23 19 18 17 14 14 
24 7 10 2 8 2 
25 29 22 23 15 11 
26 22 9 9 6 14 
Total/1248 679 432 344 364 353 
Physical Function subscale contains 12 questions of physical activities, total scores = 48 scores, 
26 subjects x 48 = 1248 scores 
 
 
 
 
 
   241 
Table 6 Physical Function scores for each participant in the control group for all study 
periods 
Subject 
 ID  Baseline 5 Sessions 9 Sessions 
After Six 
Weeks 
After Six 
Months 
1 33 33 35 33 37 
2 16 10 10 11 10 
3 37 35 34 26 25 
4 29 29 19 18 13 
5 37 21 27 14 23 
6 23 26 18 28 30 
7 19 8 9 8 16 
8 21 23 20 19 20 
9 27 18 18 19 24 
10 27 24 11 15 17 
11 30 18 19 23 27 
12 32 23 19 21 23 
13 30 18 17 19 24 
14 14 15 19 24 17 
15 21 22 17 26 27 
16 27 27 21 22 27 
17 30 19 20 16 18 
18 14 4 0 9 23 
19 29 32 26 17 15 
20 24 18 25 20 28 
21 20 22 23 23 16 
22 24 3 8 3 10 
23 26 16 14 14 24 
Total/1104 590 464 429 428 494 
Physical Function subscale contains 12 questions of physical activities, total scores = 48 scores, 
23 subjects x 48 = 1104 scores 
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Section D - Social Function 
 
Table 7 Social Function scores for each participant in the active group for all study 
periods 
Subject 
 ID  Baseline 5 Sessions 9 Sessions 
After Six 
Weeks 
After Six 
Months 
1 10 8 7 6 9 
2 8 7 7 1 4 
3 1 0 2 6 6 
4 8 6 5 3 0 
5 11 8 0 0 5 
6 6 6 0 0 6 
7 11 7 8 9 7 
8 7 0 0 0 0 
9 9 5 3 0 1 
10 0 0 0 0 0 
11 0 0 0 0 0 
12 0 0 0 0 0 
13 10 11 8 9 6 
14 8 3 6 7 3 
15 6 0 0 0 3 
16 3 3 3 2 3 
17 3 3 0 0 1 
18 0 3 0 0 3 
19 0 0 0 0 1 
20 7 6 6 6 4 
21 6 0 3 0 4 
22 0 0 0 0 2 
23 0 0 0 0 3 
24 0 0 0 0 0 
25 6 6 6 6 3 
26 8 7 3 3 4 
Total/312 128 89 67 58 78 
Social Function subscale contains 3 questions of social activities, total scores = 12 scores, 
26 subjects x 12 = 312 scores 
 
 
 
 
 
   243 
Table 8 Social Function scores for each participant in the control group for all study 
periods 
Subject 
 ID  Baseline 5 Sessions 9 Sessions 
After Six 
Weeks 
After Six 
Months 
1 11 11 11 9 9 
2 0 0 0 0 0 
3 9 8 8 8 6 
4 11 9 4 3 0 
5 8 8 6 3 6 
6 4 0 2 6 3 
7 6 0 0 0 0 
8 6 7 6 5 1 
9 6 3 6 9 6 
10 5 8 3 7 0 
11 6 8 8 9 5 
12 8 6 1 3 5 
13 8 3 0 4 6 
14 0 3 3 2 6 
15 6 5 6 5 5 
16 6 6 6 3 6 
17 8 3 3 0 6 
18 0 0 0 0 6 
19 3 3 3 1 0 
20 6 6 6 6 6 
21 7 8 12 6 3 
22 0 0 0 0 0 
23 6 3 3 0 5 
Total/276 130 108 97 89 90 
Social Function subscale contains  three questions of social activities, total scores = 12 scores,  
23 subjects x 12 = 276 scores 
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Section E- Emotional function  
 
Table 9 Emotional function scores for each participant in the active group for all study 
periods 
Subject 
 ID  Baseline 5 Sessions 9 Sessions 
After Six 
Weeks 
After Six 
Months 
1 5 1 4 4 9 
2 9 6 0 0 0 
3 1 0 2 5 3 
4 6 5 3 0 0 
5 9 9 6 6 6 
6 8 3 0 0 4 
7 12 6 8 9 9 
8 4 1 0 0 0 
9 9 5 1 9 2 
10 4 0 0 0 0 
11 2 0 0 0 0 
12 6 0 0 0 1 
13 9 11 6 8 6 
14 9 4 6 4 0 
15 0 0 0 0 3 
16 9 6 0 2 2 
17 9 6 2 5 3 
18 0 0 0 0 2 
19 4 0 0 1 1 
20 4 0 0 0 4 
21 0 0 0 0 0 
22 3 0 0 0 3 
23 6 5 5 6 5 
24 0 0 0 0 0 
25 6 6 3 2 2 
26 9 9 3 2 4 
Total/312 143 83 49 63 69 
Emotional function subscale contains  three questions about the Psychological status, total 
scores = 12 scores, 26 subjects x 12 =312 scores 
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Table 10 Emotional function scores for each participant in the control group for all 
study periods 
Subject 
 ID  Baseline 5 Sessions 9 Sessions 
After Six 
Weeks 
After Six 
Months 
1 12 12 12 9 9 
2 2 0 0 0 0 
3 8 7 9 9 6 
4 4 6 7 0 0 
5 5 5 7 6 6 
6 0 0 0 0 4 
7 4 0 1 0 0 
8 4 4 5 4 3 
9 4 1 0 2 5 
10 7 5 1 1 2 
11 9 6 4 6 6 
12 9 4 2 0 2 
13 9 5 0 0 0 
14 6 6 5 3 6 
15 4 5 5 0 6 
16 5 0 6 1 0 
17 6 0 0 1 5 
18 3 6 0 0 3 
19 6 6 0 1 2 
20 9 8 7 7 7 
21 9 6 9 9 4 
22 6 0 0 0 2 
23 5 5 1 1 5 
Total/276 136 97 81 60 83 
Emotional function subscale contains  three questions about the Psychological status, total 
scores = 12 scores, 23 subjects x 12 =276 scores 
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APPENDIX XIII: Raw data 
 
 
Table1 Raw data for the active group 
ID Sex Age Height Wight BMI 
Affected 
knee 
Level of 
Education Occupation 
Start 
Symptoms 
1 M 60 164 90 39 Lt Educated Retired 4 
2 F 56 152 88.7 38.3 Lt Uneducated Housewife 5 
3 M 65 153.5 67 30 Lt Uneducated Retired 3 
4 F 55 148 66.6 30.4 Rt Uneducated Housewife 5 
5 F 48 158 87.6 35 Lt Uneducated Housewife 5 
6 F 51 151 91.6 40.1 Rt Educated Retired 2 
7 M 56 163.5 90.2 40 Lt Uneducated Work 5 
8 F 37 161 103.3 45.9 Lt Educated Housewife 1 
9 F 46 148 65.6 29 Rt Educated Work 1 
10 M 55 156 64.5 28.3 Lt Educated Retired 2 
11 M 43 179.5 113.7 50.5 Lt Uneducated Work 2 
12 M 38 158.5 89 39.5 Lt Educated Work 4 
13 F 42 148.8 81.5 38.8 Rt Educated Housewife 4 
14 F 71 157.2 87.4 35.3 Lt Uneducated Housewife 3 
15 F 65 157.5 87.7 35.3 Lt Uneducated Housewife 4 
16 F 49 158.2 87.8 35.1 Rt Uneducated Housewife 6 
17 M 61 162.5 90.2 40 Lt Uneducated Retired 3 
18 F 43 155.2 79.5 35.3 Lt Uneducated Housewife 4 
19 M 49 163 89.5 38 Lt Educated Work 4 
20 F 69 157 87.2 35.1 Rt Uneducated Housewife 4 
21 F 52 151.3 102.9 45.7 Lt Uneducated Work 3 
22 M 51 167.5 89.1 39.6 Rt Educated Work 2 
23 F 55 168 105.1 46.7 Lt Uneducated Work 2 
24 F 54 152 76.5 34 Rt Educated Work 3 
25 F 51 149.5 84.4 37.5 Rt Uneducated Housewife 5 
26 M 38 160.5 101.7 45.2 Rt Educated Work 3 
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Table 2 Raw data for the control group 
ID Sex Age Height Wight BMI 
Affected 
knee 
Level of 
Education Occupation 
Start 
Symptoms 
1 F 46 148.5 81.1 38.5 Rt Uneducated Housewife 2 
2 M 44 160 89 39.3 Rt Educated Work 3 
3 F 70 157 87.2 35.1 Lt Uneducated Housewife 3 
4 F 63 157.5 87.7 35.3 Lt Educated Retired 3 
5 F 65 156 73.1 32.4 Lt Uneducated Housewife 6 
6 M 65 157 64.5 28.6 Lt Educated Retired 2 
7 F 42 165.2 80.5 34.3 Lt Uneducated Housewife 4 
8 M 62 150.3 78.5 34.7 Lt Educated Retired 2 
9 M 65 158.5 77.6 34.4 Lt Educated  Retired 2 
10 F 37 160.1 93.9 41.7 Lt Uneducated Housewife 3 
11 F 54 145.3 89.3 39.6 Lt Educated Work 2 
12 F 57 149.1 84.3 37.3 Lt Uneducated Housewife 2 
13 F 62 150.6 88.2 39.2 Rt Uneducated Housewife 3 
14 F 48 158 87.6 35 Lt Uneducated Housewife 5 
15 M 68 171 109.5 48.6 Rt Educated Retired 4 
16 M 66 153 66.5 29.5 Lt Uneducated Retired 4 
17 M 67 164 107.7 47.8 Lt Uneducated Retired 4 
18 M 67 157 64.5 28.6 Lt Educated Retired 3 
19 F 62 148 98.6 43.8 Rt Uneducated Housewife 3 
20 F 58 149.5 84.6 37.6 Rt Uneducated Housewife 1 
21 F 45 154.5 79.5 35.3 Lt Uneducated Housewife 2 
22 F 34 157.8 76.1 33.8 Rt Uneducated Housewife 2 
23 F 44 147.5 95 42.2 Rt Uneducated Housewife 2 
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APPENDIX XIV: Range of motion 
 
Table1 ROM for each participant in the active group for all study periods 
 
Subject 
 ID  Baseline 5 sessions 9 sessions 
After Six 
Weeks 
After Six 
Months 
1 135 138 140 140 136 
2 138 142 145 140 145 
3 138 143 144 138 140 
4 130 142 145 140 137 
5 128 140 140 135 135 
6 133 135 135 133 135 
7 122 132 133 130 130 
8 130 139 136 136 140 
9 130 140 138 130 138 
10 145 145 145 145 145 
11 138 140 145 145 145 
12 130 138 140 140 140 
13 128 129 131 134 140 
14 123 135 130 120 135 
15 125 133 135 135 132 
16 126 130 132 140 140 
17 138 145 145 145 140 
18 130 138 138 138 135 
19 145 145 145 145 145 
20 120 130 125 128 130 
21 120 133 125 122 115 
22 132 135 140 140 135 
23 112 105 110 100 115 
24 130 135 140 138 136 
25 95 100 110 110 115 
26 130 135 138 135 135 
Total 3351 3502 3530 3482 3514 
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Table 2 ROM for each participant in the control group for all study periods 
Subject 
 ID  Baseline 5 sessions 9 sessions 
After Six 
Weeks 
After Six 
Months 
1 132 132 135 128 130 
2 143 144 143 143 143 
3 122 128 125 125 129 
4 135 138 137 125 130 
5 128 130 133 140 135 
6 130 129 130 130 125 
7 132 139 138 135 130 
8 130 135 138 135 130 
9 135 138 140 135 130 
10 128 95 103 110 110 
11 125 133 132 125 130 
12 133 140 142 140 140 
13 132 140 138 143 140 
14 128 130 132 130 127 
15 128 132 132 138 138 
16 138 142 142 140 140 
17 122 122 122 125 125 
18 145 145 145 145 138 
19 115 110 106 115 110 
20 135 130 135 130 127 
21 130 135 130 135 135 
22 130 132 135 140 138 
23 95 130 130 130 93 
Total 2971 3029 3043 3042 2973 
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APPENDIX XV: Knee circumference 
 
Table1 KC for each participant in the active group for all study periods 
Subject 
 ID  Baseline 5 sessions 9 sessions 
After Six 
Weeks 
After Six 
Months 
1 41.5 40 39.5 40 39 
2 40 40 40 40.5 41 
3 38 38 38 38 38 
4 40 40 38.5 40.5 40 
5 48 48 46 48 47.5 
6 46.5 48 49 48.5 49.5 
7 39.5 39 39.5 38.5 38 
8 46.5 46 46.5 46 46.5 
9 41 40 39.5 39.5 39 
10 34.5 34 35 35 35 
11 43.5 43.5 44 44 44 
12 42 42 41.5 42 43 
13 49.5 49.5 50 49.5 49.5 
14 46.5 46.5 47.5 47.5 47 
15 50 49.5 46 47 47.5 
16 47.5 48 48 48.5 49 
17 42.3 42.5 42 42.5 42 
18 40 39 39.5 39.5 39 
19 38 38 38 38 38 
20 45.5 45.5 45 46.5 47 
21 50 48 49.5 48.5 48.5 
22 40.5 40 40 40 40 
23 44.5 44.5 44.5 44 45 
24 41 41.5 42 42 40 
25 45.5 45 45 45.5 45 
26 45 45 45.5 45.5 45.5 
Total 1126.8 1121 1119.5 1125 1123.5 
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Table 2 KC for each participant in the control group for all study periods 
Subject 
 ID  Baseline 5 sessions 9 sessions 
After Six 
Weeks 
After Six 
Months 
1 50 50 50 50 51.5 
2 41.5 41.5 41.5 41.5 38 
3 49 47.5 47.5 47 46 
4 48 48.5 48.5 50 49 
5 39.5 39.5 39.5 39.5 39 
6 37 38 37.5 38 36.5 
7 40 39.5 40 40 39.3 
8 40.5 39.5 40 39 39.3 
9 39.5 39.5 39.5 39 39 
10 51 49.5 49 49.5 47.5 
11 37 37.5 37.5 37 37 
12 34.5 34.5 34 35 35.5 
13 46.5 46.5 46.5 46.5 45.3 
14 48 47.5 47.5 48 47 
15 47.5 45 46 45.5 45 
16 38.5 37.5 38 38 38 
17 47 46.5 46 47 47 
18 37.5 37 36.5 37 36.8 
19 43.5 45.5 43.5 43 44 
20 46.5 46.5 45 45.5 45 
21 42.5 41 40.5 43 43 
22 40 39 39.5 39.5 40 
23 47.5 47 46 48.5 49 
Total 992.5 984 979.5 987 977.7 
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APPENDIX XVI: Patient Satisfaction 
 
Table1 Patient Satisfaction for each participant in the active group for all study 
periods. 
Subject 
 ID  5 sessions 9 sessions After Six Weeks 
After Six 
Months 
1 15 30 35 10 
2 50 70 75 80 
3 0 0 0 30 
4 60 65 70 50 
5 0 65 35 50 
6 50 60 65 30 
7 30 30 45 30 
8 15 55 40 100 
9 50 85 70 80 
10 40 60 70 40 
11 40 25 0 55 
12 70 90 90 90 
13 20 20 20 30 
14 30 45 40 30 
15 80 80 80 50 
16 30 30 30 75 
17 15 20 30 20 
18 50 40 50 50 
19 70 75 70 80 
20 50 60 40 50 
21 30 50 70 30 
22 40 50 80 50 
23 20 20 30 60 
24 40 50 20 90 
25 20 15 70 50 
26 20 20 70 70 
Total 935 1210 1295 1380 
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Table 2 Patient Satisfaction for each participant in the control group for all study 
periods 
Subject 
 ID  5 sessions 9 sessions After Six Weeks 
After Six 
Months 
1 10 10 0 10 
2 30 55 45 50 
3 0 15 20 30 
4 50 50 50 70 
5 30 35 45 30 
6 0 0 10 0 
7 60 60 40 0 
8 0 20 20 10 
9 0 0 0 10 
10 20 60 45 60 
11 50 85 75 30 
12 10 15 40 10 
13 30 80 50 20 
14 15 50 30 10 
15 0 0 0 40 
16 0 0 0 10 
17 60 80 90 30 
18 60 70 50 10 
19 0 50 50 75 
20 10 10 15 10 
21 25 20 50 30 
22 50 50 70 30 
23 10 40 70 0 
Total 520 855 865 575 
   254 
APPENDIX XVII: Comparison between the current study 
and Hinman et al. (2012) 
 Hinman et al. (2012) The current study 
Design A two-stage Zelen* design RCT  
(ongoing trial) 
DBRCT, (completed) 
Purpose  To investigate the efficacy of needle and 
laser acupuncture in people with chronic 
knee pain and to evaluate maintenance 
of effects over the long-term. Also 
evaluate the cost-effectiveness of the 
needle and laser acupuncture and 
explore whether psychosocial measures 
are associated with changes in pain, 
physical function and health-related 
quality of life following acupuncture 
treatment. 
To evaluate the efficacy of LLLT 
when it is applied to specific 
acupuncture points (APs) at the 
knee joint in combination with 
exercises and advice in patients 
with KOA 
Quality  CONSORT; STRICTA guidelines for 
acupuncture studies 
CONSORT, World Association 
for Laser Therapy (WALT) 
recommendation 
Participants 
and groups 
282 men and women  
A: no treatment 
B: Needle acupuncture 
C: Laser acupuncture 
D: placebo laser acupuncture 
49 men and women completed the 
study  
A: 26 received active laser, 
exercise and advice 
B: 23 received placebo laser, 
exercise and advice 
Location  Melbourne and regional Victoria, 
Australia; multicentre 
Security Forces Hospital, Riyadh, 
Saudi Arabia 
Recruitment 
strategy 
A number of recruitment strategies were 
used. 
One strategy was used 
Inclusion and 
exclusion 
criteria  
Rigorous  Rigorous 
Ethical 
approval 
Granted  Granted 
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Written 
informed 
consent 
Provided Provided 
Randomisation More than once  Direct 
Assessments  Baseline, 12 weeks and 12 months Baseline, 5 sessions, last session, 6 
weeks, and 6 months 
Blinding  Partial blinding, 
*The trial laser machine had a small red 
non-laser light source arising from inside 
the probe tip that lit up when the probe 
was in both treatment mode and sham 
mode (no output). 
Full blinding, 
* same  
Primary 
outcomes 
1- Pain via an 11-point numeric rating 
scale (NRS) 
2- Self-reported physical function via 
WOMAC. 
1- Pain via VAS 
Secondary 
outcomes 
Quality of life, global rating of change 
scores and additional measures of pain 
(other NRS and WOMAC subscale) and 
physical function (NRS). 
 
*All outcomes are collected via self-
report questionnaire and mailed back to 
the investigators. 
1- Quality of life via SKFS 
2-ROM via goniometry  
3-KC via measure tape 
4-patient satisfaction (%) 
 
Power 
calculation  
Yes  Yes  
Research 
operators 
experience  
Described Described 
Irradiation 
area  
Mixed of local points (SP9, SP10, ST34, 
ST35, ST36,  LR7, LR8, LR 9, KI10 
BL39, BL40, BL 57, GB34, GB35, 
GB36; Distal points, Segmental points, 
Non-segmental and general points 
Five APs (ST 35, Xiyan, ST 36, 
SP9, and SP10) on the affected 
knee 
Treatment 
duration   
Acupuncture treatments (approximately 
20 minutes in duration) were 
A series of 9 treatment sessions 
was given to each patient over 3 
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administered once or twice weekly (at 
the GP’s discretion) in the GP’s rooms 
for 12 weeks, with a minimum of 8 and a 
maximum of 12 treatments delivered. 
weeks, 3 times a week. In the 
active laser group, an active 
continuous laser beam irradiated 
each point for 40s with a dose of 
1.2 J/point. 
Laser 
parameters 
Output power: 10 mW 
Dose: 0.2 J per acupuncture point 
Type and wavelength:  GaAlAs, 
830nm 
-Continued wave 
Output power: 30 mW 
Dose: 1.2 J/point X 40 s 
Spot area: 0.28 cm2 
-Contact technique  
Result  Ongoing  A statistically significant 
improvement in the laser group 
compared to the placebo group in 
the primary outcome VAS and all 
other outcomes at endpoint 
assessment except KC. 
Conclusion  The findings of this study will help 
determine whether laser and/or needle 
acupuncture are efficacious in relieving 
knee pain and/or improving physical 
function. It will also determine whether 
effects of acupuncture can be maintained 
over the longer term, and whether 
psychosocial factors influence treatment 
outcomes. Importantly, the use of the 
Zelen design will minimise the bias 
typically encountered in traditionally 
designed RCTs where participant 
expectations may influence study 
outcomes. 
The results demonstrate that the 
short-period application of LLLT 
on specific APs associated with 
exercises and advice is effective in 
reducing pain and improving the 
QoL in patients with KOA. 
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APPENDIX XVII: Publications, conferences, and 
courses 
1- Al Rashoud AS, Abboud RJ, Wang W, Wigderowitz C (2014). Efficacy of low-
level laser therapy applied at acupuncture points in knee osteoarthritis: a 
randomised double-blind comparative trial. Physiotherapy, in press, available 
online 15 November 2013. http://dx.doi.org/10.1016/j.physio.2013.09.007 
2- Al Rashoud AS, Abboud RJ, Wang W, Wigderowitz C (2012). The efficacy of 
low level laser therapy (LLLT) in the treatment of osteoarthritis of the knee, 
poster presented at the 15TH world congress of pain clinicians, Granada, Spain, 
27 – 30 June 2012.  
3- Participation in the international symposium on laser surgery held at the Security 
Forces Hospital, Riyadh, kingdom of Saudi Arabia, 5 – 7 October 2010. 
4- Attending a low level laser therapy workshop held at the Security Forces 
Hospital, Riyadh, Kingdom of Saudi Arabia, January 3, 2011. 
5- Attending a  THOR laser therapy  course on  the application of LLLT and LED 
therapy, the physiological mechanisms, clinical applications, dosage, treatment 
techniques, safety and contraindications, London, UK, 18th  July, 2010. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
